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Summary  
Multiple myeloma (MM) is characterised by destructive bone disease, mediated by an 
increase in osteoclastic bone resorption and impaired osteoblastic bone formation (Boise, 
Kaufman et al. 2014) The canonical Wingless-type (Wnt) and bone morphogenic protein 
(BMP) signalling pathways have both been implicated in the osteoblastogenesis (Chen, 
Deng et al. 2012, Kim, Liu et al. 2013). Data from our group in Sheffield (unpublished) 
show that SOSTDC1 is upregulated in the bone marrow (BM) of mice with osteolytic 
bone disease associated with myeloma. It is unclear whether SOSTDC1 regulates 
signalling in bone directly and which cells in the BM express SOSTDC1. We hypothesise 
that SOSTDC1 disrupts Wnt and BMP signalling in bone and is expressed by both 
myeloma cells (MC) and osteoblast (OB) progenitors as a result of direct MC/OB contact. 
In the first part of the work presented in this thesis, I characterised the murine OB 
progenitor model in-vitro establishing that these cells differentiated exponentially 
between day 8 and 15 of culture. I then assessed the effect of SOSTDC1 in OB progenitor 
differentiation in the presence of activated BMP and Wnt signalling. I showed that 
Wnt3a, BMP2 and BMP7 stimulated OB progenitor differentiation and downstream 
signalling of the Wnt and BMP pathways. Recombinant human SOSTDC1 (rhSOSTDC1) 
protein reduced the Wnt and BMP-induced differentiation/signalling in OB progenitors 
on a protein and gene level. This effect was observed in early differentiation, indicating 
that the inhibitory effect of SOSTDC1 on Wnt/BMP-induced signalling is specific to 
osteoprogenitors rather than mature OB. I also showed rhSOSTDC1 had the highest 
affinity for BMP7 out of the BMP2, BMP7 and Wnt-receptor LRP-6, interactions tested.  
In the second part, I assessed whether OB progenitors and 5TMM myeloma cells 
produced SOSTDC1 and sought to determine the distribution of SOSTDC1 in MC/OB 
progenitor cultures and co-cultures. SOSTDC1 was detected in MC but not OB 
progenitors and that SOSTDC1 was upregulated in both myeloma and OB progenitors 
following direct OB/MC contact in co-cultures. SOSTDC1 protein was also detected in-
vivo in myeloma-infiltrated bone sections. Blocking SOSTDC1 in-vitro using an antibody 
specific to SOSTDC1 reversed the suppression of OB progenitor differentiation. Taken 
together from these results, I conclude that targeting SOSTDC1 may reduce the osteolytic 
bone disease observed in MM. 
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1.1 Multiple Myeloma 
 
Multiple Myeloma (MM) is a B-cell malignancy characterised by clonal proliferation of 
plasma cells (Egan, Shi et al. 2012). MM accounts for more than 10% of haematological 
cancers and accounts for approximately 1% of all cancer-related deaths in Western 
countries (Kyle and Rajkumar 2008). Myeloma is the 17th most common cancer in the 
UK (2011), accounting for around 1% of all new cases. In males, it is the 15th most 
common cancer (2% of the male total) and the 17th in females (1%). The latest statistics 
showed that in 201,4,792 new cases of myeloma were diagnosed in the UK. From this 
total 56% were men and 44% were women, resulting in a male:female ratio of 12:10 for 
the incidence of myeloma (Cancer Research UK 2014). In the United States, it is 
expected that by the end of 2104 over 24 000 new cases of MM will be diagnosed 
resulting in approximately half of these individuals to die (Siegel, Ma et al. 2014).  
 
In most cases, MM develops from a Monoclonal Gammopathy of Undetermined 
Significance (MGUS), a premalignant stage of clonal plasma cell proliferation displaying 
no obvious symptoms. Over 3% of the over 50 population will carry MGUS and 1% will 
develop myeloma or other related malignancies. Smouldering Multiple Myeloma (SMM) 
is another type of this disorder found in some patients who present with clinically 
recognisable symptoms of MM accompanying a more advanced premalignant stage 
(Mahindra, Hideshima et al. 2010).  
 
The acronym CRAB summarizes the typical clinical manifestations of MM: 
hypercalcemia, renal insufficiency, anaemia, and bone lesions (International Myeloma 
Working 2003). The CRAB features of MM can be used to distinguish between active, 
symptomatic MM and its precursor states MGUS and smouldering myeloma. The 
distinction is relevant not only for classification and diagnosis, but also for therapy: 
CRAB symptoms are critical for deciding when to initiate antineoplastic therapy, as 
asymptomatic cases of MM do not obtain survival benefit from treatment (Kyle and 
Rajkumar 2007). Beyond the usual CRAB symptoms, patients with MM can present with 
other relevant clinical manifestations including hyperviscosity syndrome, neurologic 
impairment from spinal cord compression, nephrotic syndrome or other signs of 
amyloidosis, cryoglobulinemia, recurrent infections, extramedullary involvement of 
various organs, and other complications. MM patients can be diagnosed only by chance, 
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in asymptomatic patients, often when tested for annual examination by primary care 
physician (Talamo, Farooq et al. 2010).. 
 
MM is the most common cancer to involve the skeleton with 80–90% of patients 
developing bone lesions during the course of the disease (Hameed, Brady et al. 2014). 
The bone lesions in myeloma are purely osteolytic and are associated with severe and 
debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, 
as well as increased mortality (Terpos, Berenson et al. 2010). It is estimated that 20% of 
MM patients present with pathologic fractures, 40% develop a fracture in the first year 
after diagnosis, and up to 60% develop pathologic fractures over the course of their 
disease. Additionally, patients with pathologic fractures have a 20% increase in mortality 
when compared to patients without pathologic fractures (Saad, Lipton et al. 2007). The 
bone destructive lesions can be extensive and severe and bone pain, frequently centred on 
the chest or back and exacerbated by movement, is present in more than two-thirds of 
patients at diagnosis (Sezer 2009).  
 
The increasing evidence highlighting the crucial role of tumour cells and the bone 
microenvironment in the pathogenesis of myeloma has created novel targets for the 
therapy of myeloma bone disease (Fowler, Edwards et al. 2011). The tightly controlled 
physiological process of bone metabolism can be disrupted by various genetic and 
environmental factors. These include factors related to the onset of age, menopause 
hormone related changes, drugs, mechanical loading and secondary diseases leading to 
bone disorders (Feng and McDonald 2010). Disruptions in the interaction and regulation 
of the various osteotropic cytokines and hormones involved in maintaining the bone 
formation/resorption balance can result in irregular bone turnover cycles (Rodan and 
Martin 2000).  
 
Treatment of myeloma bone disease requires management of both the underlying 
malignancy and the increased bone destruction and suppressed new bone formation. Until 
the 1990s, there were few advances in the treatment of MM the disease and a result 
myeloma was deemed incurable with a median survival of 2-3 years. The introduction of 
high-dose melphalan and autologous bone marrow (BM) transplantation towards the end 
of the 1990’s was a major breakthrough in MM therapy and saw improvements in patient 
survival (Attal, Harousseau et al. 1996). A decade later saw the introduction of highly 
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active agents including Thalidomide and bortezomib did not target DNA damage and 
subsequently, immunodulatory drugs (IMiDs) and proteasome inhibitors. The 
combinations of these novel agents resulted in positive responses to treatment in the 
majority of myeloma patients and are now routinely used for the treatment of newly 
diagnosed myeloma followed by stem cell transplant (Lonial and Boise 2013). Bone 
disease is managed with a combination of bisphosphonate therapy, localized radiation, 
(for control of bone pain, treatment of impending fractures or solitary plasmacytomas) 
and kyphoplasty, vertebroplasty, or surgery (Hameed, Brady et al. 2014). Taken together, 
the overall survival of myeloma patients has improved with 20-30% of patients surviving 
for >10 years (Boise, Kaufman et al. 2014).  
 
Bisphosphonates, potent inhibitors of bone resorption, currently remain the standard 
therapy of MM-related bone disease. Bisphosphonates slow the progression of lytic bone 
disease, preventing the development of new pathologic fractures and improving bone 
pain. (Zhang, Chang et al. 2012, Terpos, Roodman et al. 2013). There is also some in-
vitro evidence to suggest that bisphosphonates have a direct anti-myeloma effect (Avcu, 
Ural et al. 2005). However, there are now thought to be complications associated with 
bisphosphonate therapy associated with osteonecrosis of the jaw (ONJ), with reports of 
1.6–11% of myeloma patients developing ONJ  (Van den Wyngaert, Huizing et al. 2007). 
Importantly, bisphosphonates cannot restore bone formation and lytic lesions do not heal 
even in patients in prolonged remission. These evidence highlight the need for the 
development of anabolic agents, which could potentially reverse osteolytic bone disease 
and reverse the loss of skeletal integrity at sites of previous bone destruction in MM 
patients (Hameed, Brady et al. 2014).  
 
1.2 Bone remodelling  
 
The skeleton is a sophisticated metabolically active structure that functions to protect 
major organs, supports locomotion and stature and is involved in maintaining plasma 
calcium homeostasis (Crockett, Rogers et al. 2011). Bone is composed of various 
components including minerals (most of which are calcium), phosphates, proteins and 
bone cells (Strewler 2001). The cells of the bone are osteoclasts (OC), osteoblasts (OB) 
and osteocytes. OC are giant multinucleated cells often containing between two and ten 
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nuclei and are responsible for the removal of bone through the process of bone resorption. 
These cells are mobile and morphologically structured to maintain optimal contact with 
the bone’s mineralised surface. OC precursors have a haemopoietic origin and are derived 
from monocyte-macrophage lineage. OC progenitor cells are recruited from 
haematopoietic compartments and proliferate and differentiate into mature OC cells 
(Vinholes, Coleman et al. 1996). 
 
OB cells are responsible for bone formation and normally attach to the surface of bone in 
a monolayer (Vinholes, Coleman et al. 1996). OB cells are derived from mesenchymal 
stem cells (MSC), which undergo differentiation to become pre-osteoblasts. The pre-
osteoblasts further differentiate to become matrix synthesising OB (Vinholes, Coleman et 
al. 1996). OB are located on a narrow area of newly produced organic matrix known as an 
osteoid seam and regulate formation of un-calcified matrix (osteoid). Osteoid mainly 
comprises type I collagen, and subsequently mineralises to become bone (Karsenty, 
Kronenberg et al. 2009). The basophilic cytoplasm of OB cells produce alkaline 
phosphatase (ALP), an enzyme involved in bone mineralization, and hormones that target 
the bone itself (Ducy, Schinke et al. 2000). In addition, OB produce both type I collagens 
and non-collagenous proteins (Vinholes, Coleman et al. 1996) including osteopontin, 
osteonectin, osteocalcin, fibronectin, decorin, bone sialoprotein (BSP) and traces of others 
(Strewler 2001). Following active bone formation, some OB cells become embedded 
within the bone matrix where they differentiate into osteocytes.  
 
In order to maintain its multitude of functions during vertebrate life, bone is under 
continual adaptation. These adaptations areregulated through the two distinct mechanisms 
of bone modelling and remodelling. Bone modelling involves the coordinated yet 
independent processes of bone formation and bone removal at different anatomical 
locations (Raggatt and Partridge 2010). Once bone becomes mature, it is continuously 
renewed to ensure microfractures are repaired and calcium homeostasis is maintained 
though the remodelling process. The tightly regulated process of remodelling involves the 
removal and replacement of measurable bone packets (bone structural units) at the same 
anatomical location consistent with an activation, resorption and formation order of 
activity (Robling, Castillo et al. 2006). The process of bone remodelling involves 
resorption by OC and is followed by matrix formation via OB activity (Figure 1.1) (Feng 
and McDonald 2010). The molecular mechanisms and cellular activity involved in 
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remodelling are closely coordinated which ensures that the bone resorption-formation 
sequence is carried out at a mutual location thus sustaining bone mass (Raggatt and 
Partridge 2010).  
  
8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.1- Bone remodelling: Mature osteoclasts (OC) are recruited to the bone target 
site. Mature OC originates from haemopoietic precursor cells, which differentiate into 
pre-OC and then further differentiate into mature OC. Mature OC remove bone during 
bone resorption phase of bone remodelling. Once the resorption process is complete, OC 
undergo apoptosis and mature osteoblast (OB) cells are recruited to the site. Mature OB 
originate from Mesenchymal Stem Cells (MSC), that undergo differentiation to become 
pre-osteoblasts, and subsequently matrix synthesising OB responsible for bone formation 
(Vinholes, Coleman et al. 1996). 
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1.2.1 Regulation of bone resorption  
 
The remodelling process occurs in different parts and at different times of the skeleton 
asynchronously, highlighting the importance of locally generated and regulated factors in 
ensuring effective communication mechanisms between the cells involved (Henriksen, 
Karsdal et al. 2014). Osteoclastogenesis is predominantly regulated by the expression of 
cytokines which are produced by MSC and their derivative OB in response to pro-
resorption stimuli, and regulate OC formation, activation, and function (Vaananen, Zhao 
et al. 2000). The role of  the cytokine macrophage colony-stimulating factor (M-CSF) in 
osteoclastic activity has been demonstrated using mice deficient in M-CSF, which 
develop osteopetrosis characterised by significant reduction in OC number (Tanaka, 
Takahashi et al. 1993). M-CSF functions through interaction with its receptor colony 
stimulating factor 1 (c-fms) located on the OC. The c-fms is a transmembrane tyrosine 
kinase receptor that activates tyrosine kinase (Src). Both c-fms and Src are required for 
osteoclastogenesis and the differentiation of OC precursors (Aeschlimann and Evans 
2004).  
 
The recognition of the RANKL-RANK/OPG system in bone biology first brought to light 
in 1997 in a paper by Simonet et al (Simonet, Lacey et al. 1997). Receptor activator of 
nuclear factor-kappa B (RANK) also referred to as TRANCE Receptor, is a Type I 
membrane protein expressed on OC, which is activated upon adhesion to its ligand 
receptor activator of nuclear factor-kappa B ligand (RANKL). RANKL is a member of 
Tumour Necrosis Factor (TNF) family and is a key cytokine that operates as a system to 
maintain the bone resorption and bone formation cycle, ultimately sustaining skeletal 
integrity. RANKL couples to the soluble decoy receptor osteoprotegerin (OPG) expressed 
on OB progenitor cells and MSC. OPG competes with RANK for RANKL binding.  
RANKL-RANK interaction promotes differentiation of monocytic precursor cells to 
octeoclastic lineage (Kohli and Kohli 2011).  
 
Studies demonstrate osteotropic factors and hormones such as PTH, 1,25-
Dihydroxyvitamin D3 (1,25(OH)2D3), interleukin-11 (IL-11), interleukin-1β (IL-1β), 
TNF-α or prostaglandin E2 (PgE2) promote RANKL expression in OB/stromal cells. Also 
PgE2 has shown to suppress OPG expression, whereas oestrogens up-regulate its 
expression (Hofbauer, Khosla et al. 2000). Cytokines IL-11 and leukaemia inhibiting 
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factor (LIF) have also shown evidence of stimulating bone resorption through induction 
of OC differentiation (Girasole, Passeri et al. 1994). In-vitro studies have shown that 
other cytokines such as interleukin-4 (IL-4) and interferon-gamma (IFN-γ) inhibit OC 
differentiation. Transforming growth factor β (TGF-β) has a more complicated role in that 
it suppresses the proliferation of OC precursors and bone resorption (Roux and Orcel 
2000).   
 
1.2.2  Regulation of Bone Formation  
 
Bone formation is activated through a series of complex cascades involving the 
proliferation of MSC and formation of matrix that subsequently becomes mineralised. 
When bone resorption is terminated, bone formation is activated in the resorption lacunae, 
mediated by local factors produced during the resorption mechanism. The release of local 
factors by bone during resorption results in the inhibition of OC function, coupled with 
induction of OB activity. The OC release factors that have inhibitory effects, thus 
enhancing OB function. On completion of the OC-induced resorption cycle, the OC 
produce proteins that are substrates for OB adhesion. In-vitro studies show resorbing 
bone produce chemotactic factors for OB-like cells (Suda, Takahashi et al, 1999). OB 
proliferation is activated following the formation process. Although the exact mechanism 
is unknown, growth factors and proteinases including TGF-β, insulin-like growth factor -I 
(IGF-I), IGF-II and plasminogen activators, have been implicated in OB proliferation. 
Other autocrine and paracrine presenting factors that stimulate OB proliferation and are 
sequestrated in bone matrix include fibroblast growth factors (FGF) and platelet-derived 
growth factor (PDGF). In-vitro, these growth factors appear to prevent OB apoptosis 
(Suda, Takahashi et al. 1999, Raggatt and Partridge 2010). 
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1.2.3 The Role of Wnts in Osteoblast Differentiation  
 
An important pathway implicated in postnatal bone formation is the canonical Wingless-
type (Wnt) signalling pathway. Components of the Wnt pathway have been shown to 
effect OB proliferation, function and survival. Members of the Wnt protein family are a 
large group of soluble glycoproteins formed from a combination of two homologous 
genes: the wingless (Wg) gene and the Int gene. The Wg gene was initially identified 
owing to a recessive mutation in Drosophila melanogaster causing defects in the wing and 
haltere (Sharma and Chopra 1976). The Int genes were established as vertebrate genes 
located close to sites of mouse mammary tumour virus (MMTV) (Rijsewijk, Schuermann 
et al. 1987) resulting in overproduction of a Wnt genes (Nusse 2008).The Wnts are 
secreted glycoproteins involved in a range of biological processes including 
embryogenesis, organogenesis (Yavropoulou and Yovos 2007) and tumour formation. 
The central role of the Wnts in OB development is well documented. The Wnts initiate 
cell signalling by interacting with receptor complexes consisting of low-density 
lipoprotein receptor–related protein 5/6 (LRP5/6) and frizzled (Fz) G-protein-coupled 
receptor (Zhong, Zylstra-Diegel et al. 2012). As a result, molecular groups are formed, 
stimulating nuclear production of transcription factors via activation of various 
intracellular signalling cascades (Kikuchi 2003). The mutation of LRP5 can lead to 
osteoporosis-pseudoglioma syndrome, characterised by childhood onset of osteoporosis 
and loss of vision (Gong, Slee et al. 2001). Alternatively, there are gain of Wnt function 
mutations such as G171V in LRP5, which lead to  increased bone mass (Little, Recker et 
al. 2002).  
 
The canocnical Wnt signalling involves stabalisation of β-catenin (Figure 1.2), which 
aids transcription of genes controlled by lymphoid enhancer-binding factor 1/T cell–
specific transcription factor (LEF/TCF) enhancers (Hens, Wilson et al. 2005). There is 
evidence that Wnt/ β-catenin signalling is a physiological response to mechanical loading 
(Robinson, Chatterjee-Kishore et al. 2006) and is involved in the repair of bone fractures 
(Chen, Whetstone et al. 2007). Adhesion of Wnt glycoproteins to Frizzled/LRP 5/6 
complex stimulates phosphorylation of Dishevelled (Dsh) and LRP 5/6. Dsh and LRP 5/6 
bind to Axin and prevent activation of a ‘destructive’ protein complex consisting of 
adenomatous polyposis coli protein (APC), glycogen synthase kinase-3β (GSK-3β) and 
serine/threonine kinase (CK1γ).  Inhibition of the APC/GSK-3β/CK1γ complex, prevent 
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β-catenin loss. β-catenin is free to translocate to the nucleus and interact with LEF/TCF 
transcription factors to stimulate specific gene transcription (Westendorf, Kahler et al. 
2004). 
 
Extracellular Wnt antagonists are produced naturally and impair OB function, 
suppressing bone formation. The soluble Wnt antagonist family members are sub-
categorised into the secreted Frizzled-related proteins (sFRPs) and the dickkopfs (Dkks), 
each group specific in its Wnt-related function. sFRPs directly adhere to Wnt to block 
receptor binding, whereas Dkks  inhibit Wnt receptor complex activity via adhesion to the 
Wnt co-receptors LRP5/6 (Pearse 2006).  
13  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.2 - The proposed mechanism of the canonical Wnt signalling pathway. 
Axin and DSH are key proteins that bind to Wnt receptor complexes and result in the 
inhibition of the ‘destructive’ protein complex constituting of APC/GSK-β/CK1. β-
catenin is stabilised in the cytoplasm and translocates into the nucleus, where it 
interacts with LEF/TCF transcription factors. When Wnt signalling is inhibited, β-
catenin is phosphorylated by the APC/Axin/GSK-3β and subsequently relocated to 
the proteasome where it is degraded. Soluble Wnt antagonists such as Dkk1 and 
SFRPs block the interaction between Wnt ligands and their receptors suppressing 
osteoblast differentiation .  
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1.2.4 The Role of BMPs in Osteoblast differentiation  
 
As an extensive subgroup of the TGF-β family, the bone morphogenic proteins (BMPs) 
play an important role in embryogenesis by targeting the genes involved. Originally 
associated with bone formation by Wozney et al (Wozney, Rosen et al. 1988), the BMPs 
are now known to be exhibit a broad spectra of biological activities in various tissues, 
including blood vessels, heart, kidney, neurons, liver, lung cartilage and bone (Miyazono, 
Kamiya et al. 2010, Chen, Deng et al. 2012). Furthermore, after birth, BMPs regulate the 
pathophysiology of several diseases including osteoporosis, arthritis, renal diseases, 
pulmonary hypertension and cancer (Walsh, Godson et al. 2010).  
 
Once TGF-β is released from the bone following resorption, and exposed to OB 
precursors, OB cells undergo proliferation. As TGF-β exposure is brief, proliferating cells 
differentiate and then express BMPs. BMPs are produced in the bone marrow (BM) and 
adhere to their corresponding receptors, which in turn results in the production of the 
transcription factor Runt-related transcription factor 2 (Runx2) also referred to as core-
binding factor-1 (Cbfa1). Runx2/Cbfa1 is expressed on OPG cells and plays an essential 
role in the differentiation of OB cells from stromal cells of the BM, or MSC of the 
connective tissue. Of the 16 BMPs identified, BMP2 through to BMP7 and BMP9 
primarily mediate MSC differentiation into OB (Chen, Deng et al. 2012) 
 
BMP signalling occurs through activation of Smad proteins (Figure 1.3). Extracellular 
BMPs bind to type I and type II ligand-specific receptors. BMPs bind with a stronger 
affinity to type I and type II receptor heteromeric complexes. Upon binding of the BMP 
to a receptor heteromeric complex, the type I receptor becomes phosphorylated by the 
constitutively active serine/threonine kinase of the type II receptor. The Smad proteins are 
downstream intracellular messengers and are subdivided into receptor-mediated Smads 
(R-Smads), the common mediator Smad (C-Smad) and the inhibitory Smads (I-Smads). 
Smad1, 5 and 8 are R-Smads, which are phosphorylated by activated receptor complexes 
and are ligand specific. Smad4 is the C-Smad and forms a complex with the R-Smads 
once they have been activated by the type I receptor. The Smad complex translocates to 
the nucleus where it binds directly or indirectly (through BMP-binding partners) to 
specific promoters sequences within BMP target genes and regulates gene transcription 
(Varga and Wrana 2005). Although the mechanism by which the BMPs target genes is 
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not entirely understood, the Indian hedgehog (Ihh) gene has been identified as a BMP 
signalling target. Evidence of PTH and PTHLH regulation mediated through Ihh, which 
in turn maintains chondrocyte hypertrophy, has been determined in past studies (Seki and 
Hata 2004).  
 
In addition to the expression of tissue-specific BMP molecules and their associated cell 
surface receptors, BMP signalling is also tightly regulated by a family of soluble, 
extracellular secreted BMP antagonists. The relationship between BMP and their 
antagonists controls a variety of cellular processes including establishment of the 
embryonic dorsal–ventral axis, formation of neural tissue, development of joints in the 
skeletal system and brain neurogenesis. BMP antagonists function through direct 
interaction with BMP molecules and are characterized by their ability to block the action 
of BMPs through direct binding, stopping the BMPs from binding their receptors (Walsh, 
Godson et al. 2010). BMP antagonists are characterised by their ability to prohibit BMP 
signalling and include the Cerberus and DAN (CAN) family of proteins that include 
Cerberus and Gremlin (Pearce, Penny et al. 1999, Yeung, Gossan et al. 2014), Twisted 
gastrulation, Chordin and Crossveinless (Oelgeschlager, Larrain et al. 2000, Forsman, Ng 
et al. 2013) and Noggin (Tylzanowski, Mebis et al. 2006). Uterine sensitization-
associated gene-1 (USAG1) (Kiso, Takahashi et al. 2014) and Sclerostin are also more 
recently characterised BMP antagonists expressed in the kidneys and bones, respectively 
(Kiso et al. 2014; Krause et al. 2010b). The timing and concentration of BMP and their 
antagonists is essential to normal developmental processes. Modifications to the levels of 
BMP and BMP-antagonist can result in deformities in bone, limb and kidney formation, 
highlighting their role in the progression of human diseases including cancer (Walsh, 
Godson et al. 2010).  
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Figure 1.3 - BMP-dependent Smad phosphorylation: BMP ligands bind to the 
BMP heterotetrameric receptor complexes activating signalling through type II-
receptor-mediated phosphorylation of the type I receptor on the GS domain. This 
induces phosphorylation of regulatory Smad 1,5&8. The co-Smad 4 forms a new 
complex with the phosphorylated Smad 1,5&8 proteins. This newly formed pSFmad 
1,5&8/Smad 4 complex translocates into the nucleus where it binds to transcription 
factors/enhancers and regulates gene expression necessary for the differentiation of 
osteoblasts. BMP signalling is both extracellularly modulated (e.g., Noggin, 
SOSTDC1, Gremlin) and intracellularly modulated (e.g I-Smads).  
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1.3 Dysfunction of bone remodelling in MM: Cellular and molecular mechanisms 
 
Reduced formation of bone resorbing or forming cells, an increase in resorption or 
formation activity and abnormal mineral crystal formation, are all characteristic of 
disruptions in bone remodelling, which inevitably result in diseases such as Paget’s and 
osteoporosis (Russell, Mueller et al. 2001). The osteolytic and osteoblastic features of 
these diseases are characteristic of secondary tumours within the skeleton. Metastasis of 
the bone is the third most prevalent form of metastatic disease and most commonly results 
from tumours within the breast, prostate, thyroid, lung, bladder, kidney and MM (Chiang 
and Massague 2008). MM differs to bone disease occurring in other cancers, as the 
resorption of bone is not followed by further formation, and OB activation is reduced. 
Histomorphometric analysis of bone from patients with advanced MM shows a lack of 
bone formation within lesions, coupled by an increase in OC number at resorption sites. 
In addition, levels of bone resorption markers, including carboxyl-terminal telopeptide of 
type I collagen and tartrate-resistant acid phosphatase are elevated (Roodman 2009). 
The OC and OB activity that occurs during infiltration of MM through the marrow does 
not follow through when the disease advances. The coupling interaction between up-
regulated osteoblastic activity and increased bone resorption was initially reported in 
1991 by Bataille et al. They showed that this interaction occurs during early stages of 
MM, secondary to MGUS, and osteolytic disease does not develop in patients that 
maintained increased OB activity (Bataille, Chappard et al. 1991). Based on the 
observations that there is increased osteoclastic bone resorption coupled with decreased 
osteoblastic bone formation in myeloma bone disease, research has focused on OC and, 
more latterly OB activity.  
 
As reviewed by Fowler and Edwards et al, more recent research in MM bone disease has 
targeted the influence of other BM cell types, including immune cells, MSC and bone 
marrow stromal cells (BMSC) to determine potential therapeutic targets (Fowler, 
Edwards et al. 2011). The ‘seed and soil’ theory first described by Paget outlined the 
mechanisms existing between cancer cells and the bone microenvironment, where bone is 
the preferable soil in which cancer cells are seeded and go on to flourish. Growth factors 
within mineralized bone matrix are activated in the local microenvironment. Their release 
stimulates the physiological mechanisms between OC and OB (Guise and Mundy 1998). 
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In MM these mechanisms are disrupted, leading to aggressive bone disease in 
approximately 80% of patients (Yaccoby 2010).  
 
1.3.1 Dysfunction of bone resorption in MM 
 
Generation of OC activating factors by myeloma cells or the BM microenvironment can 
potentially result in the excessive bone resorption activity observed in MM. These factors 
function through mutual regulatory pathway involving RANKL/RANK (Roux and 
Mariette 2004).  Myeloma cells may express RANKL, while OPG binds both surface and 
soluble RANKL inhibiting OC development and bone resorption. Mouse 5T33MM 
myeloma model has been utilised to determine OPG-mediated changes in the local bone 
microenvironment and their effect on tumour activity/progression (Vanderkerken, De 
Leenheer et al. 2003). Inhibition of the RANK/RANKL-OPG interaction interferes with 
the progression of myeloma within bone and may reduce tumour growth and increase 
patient life span (Roux and Mariette 2004).  
 
Myeloma cells bind to BMSC via coupling of vascular cell adhesion molecule-1 (VCAM-
1) expressed on stromal cells and the α4β1 integrin VLA-4 located on the surface of MM 
cells. The interaction between MM cells and BMSC stimulates production of RANKL, 
OC activating function (OAF) cytokine activity and M-CSF and at the same time inhibits 
OPG production (Pearse 2006).  Therefore the role of RANKL in MM has mainly been 
researched on OPG, peptidominetics, anti-RANKL antibodies and soluble receptor 
constructs as targets (Buckle, Neville-Webbe et al. 2010). RANKL/RANK deficient mice 
and those with over-expression of OPG present a reduction in OC activity resulting in 
ostopetrosis, abnormal increased hardening of the bones (Dougall, Glaccum et al. 1999). 
OPG deficiency and excessive RANKL activity in mice has been linked to osteoporosis, 
although the mechanisms responsible are not clear (Mizuno, Amizuka et al. 1998). 
Evidence indicates that the crucial events in osteoclastic resorption in MM not only occur 
due to deregulation of the RANKL/OPG coupling (Brounais, Ruiz et al. 2008), but also 
through the various cytokines with OAF activity produced by MM cells and cells of the 
microenvironment. The OAFs that primarily mediate osteoclastogenesis are TNF, IL-1, 
IL-6 and specific chemokines including macrophage inflammatory protein-1α (MIP-1α), 
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macrophage inflammatory protein-1β (MIP-β) and stromal derived factor-1α (SDF-α) 
(Roodman 2004).  
 
Production of MIP-1α, hepatocyte growth factors (HGFs) up-regulate OC precursor 
proliferation and differentiation (Terpos and Dimopoulos 2005). HGF and the HGF 
receptor (c-met) are found on myeloma cells and promote OC activation, epithelial cell 
proliferation and angiogenesis. HGF increases IL-11 expression on OC-like cells and both 
IL-1 and TGF-β1 disrupt HGF activity on IL-11 (Seidel, Lenhoff et al. 2002). The 
cytokine VEGF is expressed on myeloma cells and increases osteoclastic bone resorption 
and survival, as it adheres to its OC receptor VEGFR-1. Studies have shown that in M-
CSF deficient mice, VEGFR is expressed as a substitute for OC recruitment.  In addition, 
the cells increase IL-6 expression from stromal cells in response to the increased levels of 
VEGF (Dankbar, Padro et al. 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.4 – Myeloma vicious cycle: MM cells interact with OB precursors inducing 
RANKL, OAF and M-CSF. Tumour-derived osteoclast activating factors upregulate OC 
precursor differentiation and osteoclastic resorption. Tumour-derived osteoblast 
supressing factor inhibit OB differentiation . RANKL/OPG ratio favours RANKL, 
promoting OC activity.  
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1.3.2 Dysfunction of Bone Formation in MM 
 
Based on the literature, it can be deduced that our understanding of the suppression of 
bone formation in myeloma disease is poor. Recently, animal models have been used to 
further investigate the pathways and molecules involved in the mechanisms responsible 
for the suppression of bone formation. Although a number of molecules have been 
implicated in these mechanisms, there is a lack of functional data supporting an 
underlying role. In myeloma patients, abnormalities in osteoprogenitors and the 
production of OB inhibitors by both myeloma cells and myelomatous bone 
microenvironment cells results in a reduction in osteoblastogenesis. In MM the osteolytic 
lesions arise in close proximity to the tumour, indicating that in addition to the soluble 
factors that regulate osteoblastogenesis suppression, the close contact between myeloma 
cells and MSC also influence bone remodelling (Yaccoby 2010). 
 
 The importance of the transcription factor RUNX2/Cbfa1, in the formation and 
differentiation osteoblastic cells has to date been established. RUNX2 interacts with other 
transcription factors including osterix, to activate the bone formation process. The 
activation of Runx2/Cbfa1 in human BMSC and osteoblastic cells induces the expression 
of the OB markers collagen I, ALP, and osteocalcin during OB differentiation (Giuliani, 
Rizzoli et al. 2006). The potential involvement of Runx2/Cbfa1-mediated transcription in 
MM-induced OB inhibition has previously been reported (Giuliani, Colla et al. 2005). 
Giuliani et al showed that blocking Runx2/Cbfa1 activity in human osteoprogenitors in 
myeloma-osteoprogenitor co-cultures resulted in myeloma-induced inhibition of OB 
differentiation in long-term bone marrow culture determined by a decrease in ALP, 
osteocalcin, and collagen I (Giuliani, Colla et al. 2005).  
 
The concept that myeloma-OB cell contact induces a detrimental effect on the 
differentiation of OB has been demonstrated in Giuliani et al findings showing that when 
stimulated by myeloma cells, MSC reduced expression of Runx2 through cell surface 
molecules VLA-4 and VCAM-1. Their data strongly suggests that the effect of myeloma 
cells on Runx2/Cbfa1 activity is primarily mediated by cell-to-cell contact between 
myeloma and osteoprogenitor cells (Giuliani, Colla et al. 2005). It has previously been 
reported that direct contact between human myeloma and OB-like cells results in the 
inhibition of osteocalcin production in OB-like cells (Barille, Collette et al. 1995). In 
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addition, other adhesion molecules appear to be involved in the inhibition of 
osteoblastogenesis by human myeloma cells. For example, Neural Cell Adhesion 
Molecule (NCAM)-NCAM interactions between myeloma and OB-like cells decreased 
osteoid and bone matrix production by osteoblastic cells in-vitro (Griffiths and Ling 
1991). Based on these reports, regardless of the molecular interaction, it would appear 
that myeloma-OB interaction is linked to the development of osteolytic bone disease in 
myeloma.  
 
There is mounting evidence indicating OB differentiation is inhibited by factors secreted 
by myeloma cells including Wnt-signalling inhibitor Dkk1 (Tian, Zhan et al. 2003), 
sFRP-2 (Oshima, Abe et al. 2005), IL-7 (Standal, Abildgaard et al. 2007) and HGF (Lee, 
Chung et al. 2004) and by microenvironmental cells within myelomatous bone (e.g. IL-3) 
(Ehrlich, Chung et al. 2005). In the past decade, extensive research on myeloma-produced 
soluble inhibitors of Wnt ligands has been carried out. Data implicates the critical 
inhibitory role of Wnt in MM bone disease. These implications have been strengthened 
by in-vitro studies that determine the impact of Wnt in the formation of bone (Tian, Zhan 
et al. 2003, Oshima, Abe et al. 2005).  
 
The relationship between Dkk1 and inhibition of OB activity has been established. Tian et 
al analysed ALP activity of C2C12 MSC treated with BMP2 in human MM patient 
samples with high Dkk1 levels. The findings determined the inhibitory function of the 
patients BM plasma and recombinant human Dkk1 on the cells ALP activity (Tian, Zhan 
et al. 2003). More recent in-vivo studies using 5T2MM murine myeloma model in the 
investigation of Dkk1 inhibitory effects on osteolytic lesions, show that administration of 
5T2MM cells into C5BL/KaLwRjj mice leads to osteolytic bone lesion formation 
consistent with increased OC number, decreased OB numbers and reduced bone 
mineralisation. Although no effect was seen on OC number, treatment of 5T2MM cell 
with anti-Dkk1 antibody increased both mineralised surface by 28% and rate of bone 
formation by 25% (Heath, Chantry et al. 2009). These findings are consistent with the 
earlier studies by Tian et al using neutralising anti-Dkk1 antibodies on BM plasma in 
C2C12 cells (Tian, Zhan et al. 2003), in that suppressing Dkk1 promotes bone formation 
and is therefore an effective therapeutic target for preventing  development of myeloma 
induced osteolytic bone disease (Heath, Chantry et al. 2009).   
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Other Wnt antagonists including sFRP-2 and sFRP-3 have been identified during MM 
related transcript screening. Although analysis of MM cell lines and primary samples 
showed evidence of SFRP-2 expression, the link between sFRP-3 and MM has yet to be 
established (Pearse 2006). In-vitro studies by Oshima et al on MC3T3-E1 and human 
BM-derived MSC, suggest that recombinant mouse S2FRP-2 in the presence of BMP-2, 
inhibits ALP activity and mineralisation. Similar to Dkk1, anti-sFRP-2 antibodies 
expressed neutralising effects on the myeloma cells (Oshima, Abe et al. 2005).  Taking 
into consideration the role of Wnts in osteoblastic activity, Wnt antagonists may be 
responsible for the mechanism in which MM affects OB and OC function (Glass, Bialek 
et al. 2005, Holmen, Zylstra et al. 2005).  
 
As the most abundant cell in the bone, we have extensive knowledge of the biology of 
osteocytes (Bonewald 2011). However, the contribution of osteocyte cells to MM 
development and progression in bone remains unclear. Osteocytes produce molecules that 
modulate bone formation and resorption (Xiong, Onal et al. 2011). Recently, the Giuliani 
group showed that the osteocytes life span is compromised in MM patients with bone 
lesions (Giuliani, Ferretti et al. 2012). They also showed that MM cells affect the 
osteocyte transcriptional profiles, resulting in the upregulation of RANKL and increasing 
osteoclastogenesis. Patients with active MM also have increased levels of osteocyte-
produced circulating sclerostin, a potent inhibitor of bone formation (Brunetti, Oranger et 
al. 2011). Therefore, understanding the role of osteocytes in  mechanisms associated with 
MM bone disease could provide important new therapeutic strategies that target MM-
osteocyte interactions (Delgado-Calle, Bellido et al. 2014).  
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1.3.3 MM Models 
 
The development of effective MM drug therapy is required for the development of 
biological systems for pre-clinical evaluation of potential therapeutic molecules and for 
better understanding of the disease (Mitsiades, Anderson et al. 2007). Most established 
human myeloma cell lines (HMCL) are derived from the advanced or extramedullary 
phases of MM and are obtained from BM, peripheral blood, ascites or pleural effusion. 
HMCL have revealed many of the molecular and biological aspects of myeloma including 
the complicated cytokine network influencing angiogenesis and the growth of plasma 
cells (Moreaux, Klein et al. 2011). RPMI 8266 and Y-266 were the first MM cell lines 
which were established in the in the 1960s (Matsuoka, Moore et al. 1967; Nilsson, 
Bennich et al. 1970). In the following twenty years, an estimated 112 MM cell lines have 
been described since in the literature The availability of the HMCL has also meant that the 
function of the target genes of chromosomal translocations and the activity of novel 
candidate therapeutic agents can be investigated (Seidl et al., 2003; Bergsagel and Kuehl, 
2005). However, the establishment of HMCL are rare and samples are usually derived 
from patients who have end-stage disease. This means that the cells retain oncogenic 
abnormalities found at the time of isolation and are only partially reflective of the 
heterogeneity found in MM patients (Chiron, Surget et al. 2012). In addition, the clinical, 
immunophenotypic, cytogenetic and cell culture features of the majority of these HMCL 
are either partially characterized or, in some cases, have not been described at all (Drexler 
and Matsuo 2000). 
 
An animal model that accurately reflects human myeloma and takes into account the 
protective nature of BMSC would be powerful in defining the efficacy of therapeutic 
agents in-vivo, and accelerate the drug development process. A number of different 
animal models are currently used to study myeloma, and these include the severe 
combined immunodeficiency (SCID)-hu/rab xenograft model and the Radl 5TMM 
models (Fryer, Graham et al. 2013). Several mouse models of MM bone disease have 
been developed exhibiting OB suppression (Hjorth-Hansen, Seifert et al. 1999; 
Vanderkerken, Asosingh et al. 2003; Epstein and Yaccoby 2005). Recently Italian 
scientists Pierfrancesco Tassone and bioengineer Filippo Causa devised the Xenograft 
model using HMCL (Calimeri, Battista et al. 2011in which, small cylindrical plastic 
scaffoldings punctured with pores are used as a substitute for human bone. The purified 
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MM cells (CD138+) from human BM aspirates are injected into the artificial bone 
scaffolds and the whole structure implanted under the skin of immune-deficient mice. 
Once the human MM cells start interacting with the artificial bone, it is possible to study 
the interaction between the MM cells and BM (DeWeerdt 2011).  
The 5T series are another MM mouse model in which the MM cells can be transferred 
between syngeneic mouse models. In the Radl 5T murine model, young mice are injected 
with myeloma cells, which originated spontaneously in aged C57BL/KaLwRij mice. 
Originally, the well characterised 5T2MM and the 5T33MM cell lines derived from these 
elderly C57BL/KaLwRij mice where used to study the mechanisms associated with 
myeloma cell-BM homing, myeloma tumour interaction with the bone microenvironment 
and to assess novel anti-MM therapies (Radl, De Glopper et al. 1979; Radl, Croese et al. 
1988). Both the 5T2MM and 5T33MM models were characterised by the MM cell 
infiltration restricted to the BM and spleen. The main difference between the two models 
was that only the 5T2MM cells caused the osteolytic disease observed in the long bones 
of patients with MM. In a further development of the model, in-vitro sub-clones of the 
5T33MM model were established, and subsequently named the 5T33MMvt and the 
5TGM1MM cells. It was found that mice intravenously injected with 5TGM1MM cells 
developed MM disease (Asosingh, Radl et al. 2000). The 5TGM1 cells have since also 
been labelled with green fluorescent protein (GFP) and luciferase for in-vivo imaging in 
MM studies. Despite the advantages of the syngeneic 5TMM models, one major 
limitation is their dependency on the specific C57BL/KaLwRij mouse strain 
(Vanderkerken, Asosingh et al. 2003). Both the Xenograft and 5T series models show 
suppression of OB activity and bone formation, coupled with OC activation in the MM-
infiltrated BM. These models have been important in determining which molecules 
modulate bone lesion formation, induced by MM, and in helping to evaluate novel 
therapeutic approaches aimed at reversing osteolytic bone disease in MM patients. 
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1.4 The role of novel SOSTDC1 in Wnt and BMP signalling in osteoblasts  
 
Sclerostin domain containing 1 (SOSTDC1) is also known as SOSTL (Sclerostin-like) 
due to its homology with the SOST gene (Brunkow, Gardner et al. 2001). Expression of 
SOSTDC1,  also referred to as uterine sensitisation-associated gene-1 (USAG-1), Ectodin 
and Wise in the literature, has been demonstrated in various tissues including surface 
ectoderm of the posterior axis, branchial arches, hair follicles, rat endometrium, vibrissae, 
mammalian tooth cusps, developing testis, interdigital tissues and the kidneys (Lintern, 
Guidato et al. 2009). SOSTDC1 was originally isolated as a secreted molecule by a 
functional screen of chick cDNA library of embryonic cells. SOSTDC1 (referred to as 
Wise in this study) altered the antero-posterior character of neutralised Xenopus animal 
caps, stimulating Wnt signalling (Itasaki, Jones et al. 2003). In other studies, SOSTDC1 
was isolated from a functional screen of specifically expressed rat endometrium genes 
sensitised to implantation, and named USAG-1 (Simmons and Kennedy 2002). The 
protein was again identified, this time called ectodin, as a mouse and human cDNA 
encoding antagonist of BMP for mouse pre-osteoblastic MC3T3-E1 cells (Laurikkala, 
Kassai et al. 2003).  
 
Within the literature, reports suggest that SOSTDC1 and its orthologs modulate Wnt 
signalling and inhibit BMP activity. Data implicates that SOSTDC1-Wnt signalling is 
regulated via interactions with Wnt co-receptor LRP6 and SOSTDC1 induced BMP 
inhibition is regulated via adhesion to BMP ligands (Lintern, Guidato et al. 2009). The 
SOSTDC1 protein is very likely structured to form a three looped cystine knot (Avsian-
Kretchmer and Hsueh 2004) and binds to LRP5/6 through one of these loops. SOSTDC1 
deletion construct lacking this loop domain, still bind BMP4 and inhibit BMP signals. 
BMP4 does not disrupt SOSTDC1-LRP6 interaction, implicating separate domains for 
binding. The information that we now have in relation to the interactions of SOSTDC1 
with the BMP family members, LRP6 and its molecular characteristics, has given some 
perspective into the proteins’ multifunctional existence on a molecular level (Lintern, 
Guidato et al. 2009).  
 
There is evidence of SOSTDC1 inhibitory effect on BMP in the dental ectoderm, where 
SOSTDC1 expression is seen to suppress BMP2 and BMP7 activity. Mice deficient in 
SOSTDC1 (referred to USAG-1 in this study) display altered tooth morphology and 
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increased tooth growth (Laurikkala, Kassai et al. 2003). In other studies, SOSTDC1 is 
seen to inhibit BMP2, -4, or -7 induced bone differentiation in a mouse myeoblast cell 
line (C2C12) (Yanagita, Oka et al. 2004).  More recent research in tooth development, 
demonstrates the importance of SOSTDC1 expression in mesenchyme-epithelial tooth 
formation. Munne et al investigated SOSTDC1 induction of mouse incisors and 
determined SOSTDC1 an antagonist of BMP signalling mesenchymal induced tooth 
formation. Munne et al also show that reductions in dental mesenchyme in SOSTDC-1 
deficient incisors result in development of additional de novo incisors resembling those 
that develop from activated Wnt signalling. In this study the inhibitory role of Dkk1 is 
determined as preventing additional incisor development, thus implicating BMP and Wnt 
signalling inhibition promotes the inhibitory function of tooth mesenchyme (Munne, 
Tummers et al. 2009, Munne, Felszeghy et al. 2010). In a similar study by Ahn et al, 
SOSTDC1 is shown to suppress of tooth cells via inhibition of LRP5/6–induced Wnt 
signalling. SOSTDC1 suppression up-regulates Wnt signalling, consequently tooth buds 
in toothless regions proliferate and result in tooth development (Ahn, Sanderson et al. 
2010).  
 
In Wnt/β-catenin mediated hair follicle regeneration, SOSTDC1 is seen to express an 
inhibitory role. SOSTDC1 is repressed by nuclear receptor co-receptor Hairless (HR) in 
progenitor keratinocytes consistent with the timing of follicle regeneration (Beaudoin, 
Sisk et al. 2005). Other data suggest SOSTDC1 function in the inhibition of Wnt 
antagonists; Wnt1, Wnt3a and Wnt10 (Yanagita, Oka et al. 2004, Beaudoin, Sisk et al. 
2005). There is little data on the role of SOSTDC1 on osteoblastogensis and bone disease. 
In one recent study on Chinese women, a common variation in the SOSTDC1 gene was 
associated with increased bone mass (He, Yue et al. 2011). In earlier in-vitro studies, 
SOSTDC1 was seen to inhibit BMP2, -4, or -7 induced bone differentiation in a mouse 
myoblast cell line (C2C12) (Yanagita, Oka et al. 2004). Although this data is limited, it 
does provide a rational for studying the potential role of SOSTDC1 in the dysfunction of 
osteoblastogenesis.  
 
There is evidence of crosstalk between Wnt and BMP signalling in MSC (Bennett, Longo 
et al. 2005) and pre-osteoblasts (Bain, Muller et al. 2003, Mbalaviele, Sheikh et al. 2005). 
Data has shown that the loss of BMRP-1A results in increased levels of Wnt signalling in 
OB cells, correlating to an increase in bone mass (Kamiya, Ye et al. 2008). Findings from 
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other studies suggest that BMP4/BMP6 and Wnt1/3 regulate OB differentiation through a 
GSK3β-dependent but β-catenin-independent mechanism.(Fukuda, Kokabu et al. 2010). 
Although this data is indicative of a dependency of the BMP and Wnt signalling in OB, 
the underlying mechanisms are poorly understood. The role of SOSTDC1 in Wnt-BMP 
dependent signalling has not been reported in OB differentiation. Understanding the 
molecular mechanisms associated with SOSTDC1-modulated Wnt-BMP signalling 
crosstalk in OB is a novel understanding which could produce new therapeutic targets in 
osteolytic bone disease.   
 
1.5 SOSTDC1 expression in cancer: Could SOSTDC1 have a role in MM? 
 
Although data are limited, there is evidence that SOSTDC1 can regulate cell activity 
through BMP and Wnt signalling pathways within cancer of the breast and kidney (Blish, 
Wang et al. 2008, Clausen, Blish et al. 2010). Findings from numerous studies show that 
both BMP and Wnt signalling are modulators of breast cancer (Alarmo, Rauta et al. 2006, 
Alarmo, Kuukasjarvi et al. 2007). Studies by Clausen et al into SOSTDC1 secretion and 
BMP/Wnt signalling in breast cancer cells, link decreased SOSTDC1 expression to 
increased tumour size. Intriguingly, this group showed that SOSTDC1 modulated Wnt 
and BMP signalling very selectively in that within breast tissue, SOSTDC1 increased 
Wnt3a signalling, reduced BMP7 signalling and had no significant effect on BMP2 
signalling (Clausen, Blish et al. 2010). This data suggests that SOSTDC1, through its 
ability to regulate Wnt or/and BMP signalling, may contribute to the development of 
breast cancer. Similarly, the function of SOSTDC1 as a potential tumour suppressor has 
also been implicated in Wilms paediatric renal tumour development. The gene encoding 
SOSTDC1 is proven relevant to tumour activity consistent with evidence that the protein 
is down-regulated in adult renal cancer and regulates BMP and Wnt signalling activity 
(Blish, Clausen et al. 2010).   
 
The evidence indicating that SOSTDC1 modulates tumourgenesis in breast and rental 
cancer suggests that SOSTDC1 could play a similar role in other cancers. There is 
currently no evidence to show that SOSTDC1 has any role in MM or bone disease 
secondary to MM. As mentioned previously there are a few well characterised molecules 
known to be involved in osteoblastic suppression secondary to MM (Alarmo, Rauta et al. 
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2006) including Dkk1 which is perhaps the best characterised (Pinzone, Hall et al. 2009). 
As mentioned previously over-expression of Dkk1 has been associated with MM bone 
disease and the use of anti-Dkk1 neutralizing Ab has demonstrated a pro-anabolic effect 
with associated anti-myeloma activity in-vivo (Heath, Chantry et al. 2009). Nevertheless, 
data shows that Dkk1 is not detectable in all serum samples obtained from MM patients 
(Tian, Zhan et al. 2003).  The Dkk1 absence from MM clones that still expressed 
morphological characteristics of OB dysfunction suggest other MM-mediating factors 
may exist (Pearse 2006).  
 
In the search to identify other molecules that that could have a potential causal role in the 
suppression of osteoblastogenesis in MM, our group identified SOSTDC1 (data 
unpublished), as a gene that was highly upregulated in the 5T2MM C5BL/KaLwRjj mice 
compared to naïve animals using Affymetrix GeneChip™ technology (Figure 1.5 A, 
***P<0.002). The expression of SOSTDC1 in 5T2MM compared to naïve mice was 
further confirmed using TaqMan™ gene expression assays (Figure 1.5 B). This 
compelling data coupled with reports highlighting the role of SOSTDC1 in Wnt and BMP 
signalling modulation encouraged the rational that SOSTDC1 may have a key role in the 
suppression of osteoblastogensis in MM. Targeting SOSTDC1 could be the ideal therapy 
for the reversal of osteolytic bone disease in MM, specifically in cases where patients do 
not exhibit elevated levels of Dkk1. 
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A 
B 
Figure 1.5 – SOSTDC1 was detected in 5T2MM myeloma model and not 
detected in naïve C5BL/KaLwRjj mice: SOSTDC1 was significantly upregulated 
in the 5T2MM mice compared to naïve animals, determined by Affymetrix 
GeneChip™ technology (A) and TaqMan™ gene expression assays (B) (Buckle et 
al, data unpublished). 
 
30  
 
1.6 Overall aims and objectives of the study 
 
1.6.1 Aims 
 
To date, there has been no evidence of work investigating the role of SOSTDC1 in the 
suppression of bone formation in myeloma. Determining the effect of SOSTDC1 on OB 
differentiation and proliferation in-vitro is key to understanding the role of this novel 
protein in myeloma-induced suppression of bone formation and perhaps bone resorption. 
Our recent data (unpublished) suggest a putative role for SOSTDC1 protein in Wnt 
signalling modulation, resulting in suppression of bone formation. Following array 
analysis and using experimental models of myeloma bone disease, we suggest that 
SOSTDC1 may be a modulator of Wnt signalling in MM. The regulatory role of 
SOSTDC1 has been implied in BMP signalling in other tissues (Ahn, Sanderson et al. 
2010, Blish, Clausen et al. 2010, Clausen, Blish et al. 2010), and BMPs are known to 
have a regulatory role in bone development (Chen, Deng et al. 2012). This provides the 
rational for investigating the effect of SOSTDC1 on Wnt and BMP signalling in 
differentiating OB cells at various stages cell development.  
 
There have been  recent reports of evidence of Wnt-BMP crosstalk in pre-osteoblasts, 
providing some insight into the role of other antagonists such as Sclerostin and noggin 
(Itasaki and Hoppler 2010). The potential regulatory role of SOSTDC1 in Wnt-BMP 
signalling in OB differentiation may be another target for osteolytic bone disease therapy 
in myeloma. Interestingly, there is no data in the literature to suggest that either myeloma 
cells, osteoblasts or cells in the BM actually express SOSTDC1. Here, I aim to determine 
whether the 5TMM series of mouse myeloma models and differentiating OB progenitor 
cells do produce SOSTDC1 both in-vitro and in-vivo. In MM disease, there is a link 
between increased suppression of osteoblastogenesis and myeloma-OB interaction (Chen, 
Orlowski et al. 2014). In this study I wanted to further investigate a potential role for 
SOSTDC1 in myeloma-OB interaction using an in-vitro co-culture system. The overall 
aim of this study is to provide insight into the molecular mechanisms involved in 
SOSTDC1-regulated Wnt-BMP signalling and establish the conditions required for 
SOSTDC1 expression myeloma bone disease.   
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1.6.2 Objectives 
 
This study will address the hypotheses of ‘SOSTDC1 suppresses OB progenitor 
differentiation’ and ‘myeloma cells express SOSTDC1 and promote SOSTDC1 
expression in OB progenitors’.  
 
The hypotheses will be tested by addressing the following objectives:   
 
1 To determine the proliferation, differentiation and mineralisation profile of 
murine OB progenitors in culture. 
 
2 To determine the effect of SOSTDC1 on Wnt and BMP-induced differentiation, 
mineralisation and downstream intracellular signalling in differentiating OB 
progenitors in-vitro. 
 
3 To determine a modulatory role for SOSTDC1 in BMP-Wnt signalling crosstalk 
in differentiating OB progenitors in-vitro. 
 
4 To determine whether the 5TMM series myeloma cells and differentiating OB 
progenitors produce SOSTDC1 in-vitro and in-vivo. 
 
5 To determine the optimal conditions under which SOSTDC1 in produced in a 
myeloma and OB contact dependent microenvironment. 
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Chapter 2 – Materials and Methods 
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All equipment, chemicals and solutions used in this research were assessed for health and 
safety precautions (Control of Substances Hazardous to Health (COSHH). All appropriate 
safety measures were used, including latex examination gloves and laboratory coat 
(Kimerley-Clarke). 
 
2.1 Cell culture  
 
 
  
Cell Culture Equipment     
IITEM SUPPLIER 
Haemocytometer - depth 0.1mm, 1/400mm
2
 Hawksley 
Cell culture flat bottom plates – 6, 12, 24, 48& 96 Corning® Costar®   
Nunc™ cell culture treated flasks with filter caps 
– T25cm3, T75cm3, T175cm3 
Nalgene, Nunc Ltd.   
BD Falcon™  centrifuge tube – 15ml, 50ml Fisher Scientific 
Cryovials, 1.5ml Nalgene, Nunc Ltd.   
Bjoux tubes (5, 15, 15, 50ml) Starstedt 
Eppendorph tubes (0.05 abd 1.5ml) Starstedt 
Cell scrapers  Nalgene, Nunc Ltd.   
GPR centrifuge Beckman Coulter 
Microcentrifuge IEC Micromase 
Water bath  Fisher Scientific 
Vortex mixer VLP® Scientifica 
Heater Thermomixer Comfort Eppendorf 
Z2 counter Bechman Coulter Inc. 
Coulter Counter Beckman Coulter Inc. 
Syringe filters, 25mm Acrodisc®  Pall® Life Sciences 
BD Sterifill SCF™ syringe  BD Biosciences 
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All cell culture procedures were carried out within microbiological class II safety cabinets 
(Walker, UK), using sterile equipment. Media were always filtered and warmed to 37°C 
prior to cell treatment. All cell cultures were incubated in a humidified atmosphere at 
37°C and 5% CO2.   
Cell Culture Reagents 
ITEM SUPPLIER 
Minimum Essential Media (MEM) -Alpha + 
GlutaMAX 
Gilbco
TM
, Invitrogen 
Roswell Park Memorial Institute (RPMI) 1640 
(1x)+ GlutaMAX 
Gilbco
TM
, Invitrogen 
Dulbeccos Modified Eagle Medium (DMEM) + 
GlutaMAX 
Gilbco
TM
, Invitrogen 
Keratinocyte-SFM Medium (Kit) with L-
glutamine, EGF, and BPE 
 
Gilbco
TM
, Invitrogen 
MEM Non-Essential Amino Acids (NEAA) x100 Gilbco
TM
, Invitrogen 
Sodium pyruvate Gilbco
TM
, Invitrogen 
Fetal calf serum (FCS) PAA Laboratories 
Penicillin: streptomycin solution (PenStrep) Gilbco
TM
, Invitrogen 
Fungizone® Antimycotic 250µg/ml amphotericin 
B and 205µg/ml sodium deoxycholate 
Gilbco
TM
, Invitrogen 
Phosphate buffered saline (PBS) Sigma-Aldrich 
0.05% Trypsin EDTA  (0.53mM) Sigma-Aldrich 
Collagenase I Sigma-Aldrich 
Hank's Balanced Salt Solution (HBSS) Gilbco
TM
, Life Technologies 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
L-ascorbic acid Sigma-Aldrich 
β-glycerophosphate disodium salt hydrate Sigma-Aldrich 
Trypan blue Sigma-Aldrich 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich 
70% Industrial methylated spirits (IMS) Fischer Scientific 
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2.1.1 Osteoblast progenitor cell culture  
 
Osteoblast cultures were prepared with a modification of the method of Ecarot-Charrier et 
al (Ecarot-Charrier, Glorieux et al. 1983). Mouse primary osteoblast (OB) progenitor cells 
were isolated from the calvarial bones of 2 to 4 day old C57BLKaLwRij mice, (Harlan, 
UK) using Collagenase I digestion (Figure 2.1). Typically, 12-15 dissected calvarial 
bones were cut into small pieces using a scalpel and placed in 50ml BD falcon™  tubes 
containing 3ml of 1mg/ml Collagenase I digestion solution and placed in a water bath at 
37°C on a shaker for 10 minutes. The Collagenase I solution (fraction 1) was then 
removed and the calvaria submerged in 3ml of fresh Collagenase I solution. The calvaria 
were incubated for 30 minutes at 37°C with the fresh Collagenase I solution and the cells 
collected (fraction 2). The solution containing fraction 2 were transferred to a new 15ml 
BD falcon™ tubes.  The calvaria bone cells were washed with 7ml of PBS and 
centrifuged at 1000 RPM for 5 minutes. The supernatant containing the cells added to 
fraction 2. The calvaria bone cells were incubated with 4µM EDTA solution for 10 
minutes at 37ᴼC (fraction 3).  
 
The calvaria were washed in 7ml Hank's Balanced Salt Solution (HBSS) and the wash 
added to fraction 3. 3ml of fresh Collagenase I solution was added to the calvaria and 
incubated for 30 minutes at 37ᴼC (fraction 4). The solution collected from calvarial cell 
cultures from the fraction 4 digestions containing were centrifuged at 250g RPM for 5 
minutes and re-suspended in standard Minimum Essential Medium (MEM) alpha 
containing 10% fetal calf serum (FCS), 1% Streptomycin (PenStrep) (100 units/ml 
Penicillin/100 μg/ml) and 1% Fungizone Antimycotic (250µg/ml amphotericin B 
/205µg/ml sodium deoxycholate). MEM-Alpha and all its constituents will be referred to 
as standard MEM-Alpha media unless specified otherwise. OB progenitor cells were 
cultured in 7ml of MEM -Alpha in T25cm
2
 culture flasks for a minimum of 2 days until 
the cells were 70-80% confluent and ready for use. All experiments using OB progenitors 
were carried out with cells that had been passaged up to an including passage 4.  
 
 
 
 
38  
 
Fraction 2 
Fraction 
4 
Fraction 
2 
Fraction 
3 
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and 4 
removal of 
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Figure 2.1 - Calvarial osteoblast isolation: Osteoblast progenitor cultures were 
derived from the calvaria of neonatal C57BLKaLwRij mice using Collagenase I 
digestion in 4 stages (fractions) of digestion.  
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2.1.2 Cell Lines 
 
2.1.2.1 5TMM myeloma Series 
 
The 5TMM myeloma series of cell lines were used as their features in-vivo are highly 
similar to human disease wherein they home and grow in the Bone Marrow (BM), as well 
as causing osteolytic bone disease. The 5TGM1MM murine multiple myeloma (MM) 
cells were derived from the 5T33MM murine myeloma cells (Fowler, Mundy et al. 2009). 
Both 5TGM1MM-GFP and 5T33MM-GFP myeloma cells were kindly provided by 
Claire Edwards at The University of Oxford, UK.  
The 5T33MM-GFP or 5TGM1MM-GFP cells were resuspended in 200µl PBS and 
injected via tail vein into 17-19 weeks old female C57BL/KaLwRijHSD 
(C57BLKaLwRij) mice at a cell density of 2 x10
6
. At the same time naïve mice were 
injected with PBS and used as tumour-negative controls. The growth of myeloma tumour 
was via the measurement of human Igλ in murine serum monitored by enzyme-linked 
immunosorbent assay (ELISA) (Human Lambda ELISA Kit; Bethyl Laboratories Inc). 
The assay was carried out as per the manufacturer’s protocol. Briefly, 100µl of standard 
or serum was added to designated wells and the plate incubated at room temperature for 1 
hour. Next, 100 µl of anti-Lambda detection antibody was added to each well and 
incubated at room temperature for 1 hour. Proteins were incubated with 100µl of HRP 
Solution for 30 minutes followed by the addition of 100µl of TMB Substrate in the dark 
at room temperature for 30 minutes. The reaction was stopped by adding 100µl of Stop 
Solution to each well. The absorbance was measured on a plate reader (Spectramax M5, 
Sunnyvalet) at a 450 nm wavelength.  
5T33MM and 5TGM1MM mice developed myeloma within 6-12 weeks of inoculation. 
At the first signs of illness (36 days 5T33MM-bearing mice and 21 days for 5TGM1MM-
bearing mice) animals were sacrificed by injection of pentobarbitone. In sterile 
conditions, the femora and tibiae were dissected free of soft tissue and the bone marrow 
of the animals were flushed out with 1000μl PBS. The cell suspension was mixed with 
3ml Roswell Park Memorial Institute (RPMI) medium and slowly overlaid onto 4ml of a 
Lymphoprep™ (Ficoll gradient). The cells were centrifuged at 400g for 20 minutes 
without any brakes. The mononuclear layer of cells were collected and washed twice in 
RPMI media. Isolated 5T33MM or 5TGMMM cells were then cultured in a T25 flask 
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containing 3 ml of RPMI medium with the following additive; 10% FCS, 1% PenStrep, 
1% sodium pyruvate and 1% NEAA. Cells were then sorted using a murine CD138 kit 
(Milteny Biotec) according to manufacturer’s instructions. Cell were cultured for 2 days 
and then frozen as outlined in section 2.1.4. All in-vivo animal work requiring an animal-
handling licence including the paraprotein ELISA and 5TMM cell isolation from the bone 
was kindly performed by Dr Shelly Lawson.  
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2.1.2.2 SAOS2 cells 
 
Human osteoblast-like SAOS2 cell were purchased from American Type Culture 
Collection (ATCC®).  SAOS2 cells are particular useful for the study of molecular 
mechanisms associated with OB differentiation due to their OB-like phenotype. SAOS2 
cells were cultured in T75 flasks containing 12 ml of Dulbeccos Modified Eagle Medium 
(DMEM) + GlutaMAX medium with the following additive; 10% FCS, 1% PenStrep, 1% 
sodium pyruvate and 1% NEAA. SAOS2 cells were passaged or frozen when not required 
for experimental purposes, as outlined in sections 2.2.2 and 2.2.3, respectively.  
 
2.1.2.3 Human Kidney Epithelial (HK-2)  
 
Human Kidney Epithelial (HK-2) cells were purchased from ATCC®. HK-2 cells are 
immortalised proximal tubule epithelial cells isolated from normal adult human kidney. 
HK-2 cells express SOSTDC1 and were used in experiments as a positive control for 
SOSTDC1 production. HK-2 cells were maintained in Keratinocyte-SFM media 
containing L-glutamine. Keratinocyte-SFM was supplied with prequalified human 
recombinant epidermal growth factor 1-53 (EGF 1-53) and bovine pituitary extract 
(BPE). The Keraticonyte media was supplemented with 30 µg/ml of BPE, 0.2 ng/ml 
rEGF, 10% FCS, 1% PenStrep, 1% sodium pyruvate and 1% NEAA. The HK-2 cells 
were passaged or frozen when not required for experimental purposes as outlined in 
sections 2.2.2 and 2.2.3, respectively.  
 
2.1.2.4 Endothelial STR-10 cells 
 
Human endothelial STR-10 cells were purchased from ATCC®. The SRT-10 cells were 
maintained in DMEM supplemented with 10% FCS, 1% PenStrep, 1% sodium pyruvate 
and 1% NEAA. STR-10 cells were passaged or frozen when not required for 
experimental purposes as outlined in sections 2.1.2 and 2.1.3, respectively.  
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2.1.3 Cell passage and routine counting using a haemocytometer  
 
OB progenitor cultures and cell lines were maintained in their standard media and 
passaged when cell confluence had reached 70-80%. All media was removed from T25, 
T75 or T175 flasks and discarded. Adherent cells were washed with sterile PBS to 
remove debris and remaining media, and 0.05% trypsin was used to re-suspend the 
adherent cells. The volume of trypsin used to detach cells from the culture surface was 
dependent on the size of flask i.e.0.5ml for T25, 1.5ml for a T75 and 3ml for T175. 10ml 
of media was added to the trypsinised cells to neutralise the effect of trypsin.  Cell 
suspensions were transferred into a BD Falcon™ tubes and centrifuged at 1000 RPM for 
5 minutes. Non-adherent cells were transferred directly into the BD Falcon™ tubes and 
also centrifuged at 1000 RPM for 5 minutes to pellet cells. The supernatant from cell 
pellets were discarded and the cells re-suspended in 10 ml of fresh media. Approximately 
1/5 or 1/10 dilution of the cells (dilution depended on the cell density and speed that was 
required for cell growth in preparation for an experiment) were placed in fresh flasks 
containing media and maintained in culture at 37℃ and 5% CO2. Cells were routinely 
passaged every 2-4 days when they became approximately 70-80 % confluent. 
  
Routine cell counting was performed on passaged cells prior to the set-up of experiments 
or freezing down of cells, using the Neubauer haemocytometer. The Neubauer 
haemocytometer has 4 large squares consisting of 16 smaller squares, each with a volume 
of 0.1mm
3
. Each of the 4 large squares of the haemocytometer, with a cover slip in place, 
represents a total volume of 0.1 mm
3
 (1.0mm X1.0mmX 0.1mm) or 10
-4
 cm
3 
(Figure 
2.2). The marked grid within the counting chamber allowed for the number of cells to be 
estimated. 10µl of this cell suspension was mixed with 10µl of 0.4% trypan blue solution 
in a 1:1 ratio and inserted into the counting chamber of the haemocytometer. The number 
of cells in each of the 4 squares was counted manually using a counter. The number of 
cells counted was divided by 4 to equate the average number of cells per grid. The 
calculated result was then multiplied by 2 to account for the dilution factor of adding 
trypan blue and then multiplied by the total volume of the large square; x 10
-4
 cm
3
. Since 
1 cm
3
 is equivalent to approximately 1 ml, the final value obtained was representative of 
the total number of cells per ml. The final number of cells/ml was used to calculate the 
volume of cell suspension required to seed the desired number of cells with a fresh flask.  
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For example: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.2 - Cells were counted using a Neubauer haemocytometer: The 
haemocytometer comprises 4 large squares consisting of 16 smaller squares, each 
with a volume of 0.1mm
3
. Each individual square from the 16 squares has a volume 
of 0.00625 mm
3
. Therefore each of the 4 large squares of the haemocytometer 
represents a total volume of 0.1 mm
3
 (1.0mm X1.0mmX 0.1mm) or 10-4 cm
3
.  
 
 
 
 
 
To calculate the number of cells in a 5ml cell suspension: 
Total number of cells counted in 4 squares: 56 cells 
Average number per square: 56/4 = 14 
X2 to account for the addition of trypan blue: = 14 x 2 
28 x 10,000 (volume of each large square 10-4 cm3) = 280,000 cells/ml 
= 280,000 cells/ml x 5ml  
= Total of 1,400,000 cells in 5ml 
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2.1.4 Cell counting using Coulter Counter 
 
The Coulter Counter technology is used for determining the number and size of cells in a 
suspension. Similar to the flow cytometer, the cell suspension is passed through a small 
aperture and cell number/size assessed by changes in the electrical conductance within the 
aperture. The coulter count was performed as described by Wood et al (Wood, Requa et 
al. 2007). Cells were harvested from culture surfaces using 0.05% trypsin as outlined in 
section 2.13 and centrifuged at 1000 RPM for 5 minutes in 50ml BD Falcon™ tubes. The 
supernatants were removed and cells were resuspended in 10ml of isotonic solution. The 
cell suspensions were transferred to plastic cuvettes and the cuvette was inserted in the 
sample holder of the counter. The counter sampled 500µl of cell suspension per run and 
recorded the cell number and modal size.  A threshold on the counter was set to only 
consider cells with a diameter of between 10 to 30µm.  The cell number within each 
sample was counted 3 times in consecutive analysis. The average of these 3 readings was 
then multiplied by 20 to account for the dilution factor (0.5ml samples from 10ml). The 
final value calculated was the estimated total number of cells within the cell suspension.  
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2.1.5 Freezing and thawing of cell cultures 
 
Cells were frozen down and maintained in liquid nitrogen until required for experimental 
purposes. OB progenitor cells were frozen down between 0-3 passages and cell lines were 
frozen down between 2-10 passages to be used when required. Briefly, adherent cells 
were washed with sterile PBS and 0.05% trypsin was used to re-suspend the adherent 
cells. Media was added to the tryspinised cells to neutralise the effect of trypsin.  Cell 
suspensions from adherent or non-adherent cultures were transferred into the BD 
Falcon™ tubes and counted using a haemocytometer as described in section 2.1.3. 
Following cell counting, 1x10
6
 cells per sample were centrifuged at 1000 RPM for 5 
minutes at room temperature. Each sample was resuspended in 1 ml of 10% dimethyl 
sulphoxide (DMSO) diluted in 90% FCS (10µl of DMSO and 90µl of neat FCS). The 
cells were transferred into cryovials and placed immediately into a Cryo 1℃ freezing 
container. The freezing container was transferred to a
 
-80°C freezer over-night and the 
vials were placed in liquid nitrogen for long-term storage.  
 
When cells were required, they were removed from the liquid nitrogen storage and 
immediately agitated at 37
o
C in a water bath to aid efficient thawing.  The cells were 
transferred into BD Falcon™ tubes containing 10 mL of pre-warmed standard media and 
centrifuged at 1000 RPM for 5 minutes. On discarding of supernatant, the pellets were re-
suspended in fresh medium and harvested into fresh, sterile flasks. Cell pellets were 
usually re-suspended into T75 flasks at a cell density of 1x10
6 
cells in ~12ml of media 
and maintained in culture at 37℃ and 5% CO2.  
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2.2 Osteoblast progenitor differentiation using osteogenic media 
 
OB progenitors were counted using a haemocytometer as outlined in section 2.1.3 and 
cultured in plates or flasks in standard MEM-Alpha media. OB progenitor cultures were 
differentiated as reported by Ecarot-Charrier et al (Ecarot-Charrier, Glorieux et al. 1983). 
Briefly, isolated OB progenitors were incubated at 37°C and 5% CO2 for 72 hours, to 
allow the cells to adhere to the culture surface in optimal conditions. Standard MEM-
Alpha osteogenic media was prepared containing; 4% FCS, 1% PenStrep, 10mM β-
glycerol and 50µg/ml L-ascorbic acid (vitamin C) according to Table 2.1. The β-
glycerophosphate was prepared to a stock solution of 1000mM diluted in distilled water 
and L-ascorbic acid was prepared in a stock solution of 50mg/ml in distilled water. The β-
glycerophosphate and L-ascorbic acid stock solutions were aliquoted and stored at -20ºC 
until use. On each occasion, the osteogenic media was prepared fresh and filtered prior to 
use using 25mm syringe filters. All future references made to standard osteogenic media 
refer to media prepared as outlined in this section unless stated otherwise.  
 
 
Table 2.1 - Preparation of standard MEM-Alpha osteogenic media. 
 
 
  
Preparation of Osteogenic Media 
INGREDIENT Final 
Concentration 
Volume from Stock (ml) to make 
500ml of osteogenic media 
L-ascorbic acid 10mM 5 
β-glycerophosphate  50µg/ml 0.5 
Alpha-MEM + 
GlutaMAX 
Neat 470 
Penstrep  1% 5 
Fungizone 1% 5 
FCS 4% 20 
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Standard MEM-Alpha media was removed from the OB progenitor cultures and cells 
were washed once with PBS. The PBS was aspirated from the cells and osteogenic media 
was added in a volume specific to the size of the well within the culture plates or size of 
the culture flasks, as specified in Table 2.2. OB progenitor cultures were differentiated in 
osteogenic media for up to 4 weeks. Osteogenic media from OB progenitor cultures were 
discarded and replaced with fresh media every three days. 
 
 
 
Table 2.2 - Volume of PBS used to wash each well or flask prior to media change. 
 
 
 
 
 
 
  
PBS Wash  Volumes 
Cell Culture Plate Volume of PBS, per well or flask 
96 well plate  100 µl 
48 well plate  250 µl 
24 well plate 500 µl 
6 well plate 1.5 ml 
T25cm Flask 7 ml 
T75cm Flask 10 ml 
T175cm Flask 20 ml 
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2.3 Alkaline phosphatase activity  
 
 
 
 
The p-Nitrophenyl phosphate (pNPP) is a soluble substrate used for the detection of 
alkaline phosphatase (ALP) activity. ALP hydrolyses colourless pNPP to a yellow 
coloured product, which is determined by reading the absorbance (OD) at 405. ALP 
activity was assayed according to the method of Kumegawa  (Kumegawa, Hiramatsu et 
al. 1983) with adaptions outlined by Gartland et al  (Gartland, Rumney et al. 2012). ALP 
assays were carried out on differentiated cells cultures in 96 well culture plates at a cell 
density of 6000cell/cm
2
. Briefly, the cell supernatant was removed from each well and the 
cells were gently washed twice with PBS, avoiding detaching the cells. Cells were then 
permeabilised with 20μl of 0.1% Triton with agitation on a shaker for 20 minutes at 200 
RMP at room temperature. At the same time, one tablet of pNPP and one of Tris buffer 
were added to 20ml of distilled water and dissolved with agitation on a shaker for 20 
minutes at 200 RMP and at room temperature. Next, 200μl of pNPP was carefully added 
to each well and immediately analysed for ALP using SoftMax Pro software on a plate 
reader. ALP was determined by taking OD readings at A405 every 5 minutes for up to 90 
minutes using the Beer-Lambert law (Figure 2.3). To maintain uniformly across 
biological experimental repeats, the most linear part of ALP curve was used to calculate 
the ALP activity of the cell cultures within each well. The ALP values were normalised to 
DNA contents (ng/ml) by PicoGreen analysis as outlined in section 2.4, taking into 
account dilution factors. 
 
  
Alkaline phosphatase Assay  
ITEMS SUPPLIER 
p-Nitrophenyl phosphate (pNPP) 
1.0mg/ml PNPP, 0.2 M Tris buffer 
Sigma Aldrich 
0.1% Triton  - 5µl of Triton X into 5ml of PBS  Sigma-Aldrich 
Plate reader Spectramax M5 Sunnyvale 
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                                                   U = (ODtl- ODt0) X V 
 
      t x ε x 
 
U = ALP activity (nmol Pi per min). 
OD t 1 = absorbance at 405 nM of sample at the end time point. 
OD t 0 = absorbance at 405 nM of sample at start (background). 
V = volume in microlitre of sample and reagent in well that is measured. 
t = reaction time in min. 
e = 17.8 m L/nM/cm for p NPP. 
l = path length of light in cm (specific to the plate reader which is 0.639). 
 
 
 
 
  
t 
OD t 1 
OD t 0 
Figure 2.3 - Alkaline phosphatase analysis:  (A) The ALP was determined by 
taking absorbance (OD) readings at A405 every 5 minutes for up to 90 minutes. The 
OD values at the most linear part of the ALP curves were used to calculate the ALP 
activity (U). (B) ALP activity was calculated using Beer-Lambert Law.  
 
 
 
 
A 
B 
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2.4 Pico Green assay 
 
 
 
PicoGreen® double-stranded DNA (dsDNA) quantitation reagent is a fluorescent nucleic 
acid stain used to quantify dsDNA and is used as a surrogate for cell number. PicoGreen 
analysis was performed according to the protocol outlined by Gartland et al. Picogreen 
assays were carried out on cells cultures in culture plates at a cell density of 6000cell/cm
2
. 
Media from cell cultures was discarded and the cells were gently washed twice with 
200µl of PBS, avoiding detaching the cells. Cells were then permeabilised with 20μl of 
0.1% Triton with agitation on a shaker for 20 minutes at 200 RMP at room temperature. 
A 2µg/ml dsDNA standard solution was prepared from a stock of 100 µg/ml dsDNA 
supplied with the PicoGreen kit. 8µl of the 100µg/ml was diluted in 392µl of 1X TE 
buffer in a 1 ml eppendorf tube.  Increasing concentrations of 0, 50, 100, 200, 400, 600, 
800 and 1000ng/ml of dsDNA standard were prepared in a fresh 96 well plate, using 
appropriate volumes of 1X TE buffer and the prepared 2µg/ml dsDNA standard (Table 
2.3). Next, 50μl of the unknown permeabilised samples were transferred into the 96 well 
culture plate, and 50μl of 1X TE buffer was added to these samples. 100μl of 1:200 
dilution of PicoGreen reagent was added to each standard and unknown sample and 
placed on a shaker at room temperature for 5 minutes in the dark. Quantitation of DNA 
was determined by exciting samples at 485nm and detecting fluorescence emission 
intensity at 530nm using the plate reader.   
PiocoGreen Reagents 
ITEM SUPPLIER 
Quant-iT™PicoGreen®dsDNA reagent  Invitrogen 
Lambda DNA standard Invitrogen 
X20 TE buffer; 200mM Tris-HCl, 20mM EDTA, pH 7.5 
1 ml X20 diluted in 19 ml of PBS 
Invitrogen 
0.1% Triton X Sigma-Aldrich 
Plate reader Spectramax M5 Sunnyvale 
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Plate well Final DNA 
Concentration 
(ng/ml) 
Volume of  
2 µg/ml DNA 
standard (µl) 
Volume of X1 TE 
Buffer (µl) 
A1 +A2 0 0 100 
B1+ B2 50 2.5 97.5 
C1 + C2 100 5 95 
D1 + D2 200 10 90 
E1+ E2 400 20 80 
F1 + F2 600 30 70 
G1 + G2 800 40 60 
H1 + H2 1000 50 50 
 
Table 2.3 - Preparation of dsDNA standard curve for PicoGreen analysis. 
 
 
The fluorescence readings were exported into an Excel template and used to generate the 
linear regression analysis with coefficient of determination (R
2
). The concentration 
(ng/ml) of DNA for unknown samples were extrapolated from the standard curve linear 
regression using the formula Y = a + bX; where each point on the line has a Y value that 
is calculated by multiplying the point’s X value by ‘b’ (slope of the line) and then adding 
‘a’ (distance of the line’s intercept).  The line of best fit was plotted through 0 at the 
intercept (a=0). The R
2 
was used as a measure of the consistency of prepared standard 
dilutions. The extrapolated concentration of the unknown ‘X’ was multiplied by 4 to 
account for the dilution factor of the DNA within each well (100µl of PicoGreen reagent 
+ 50µl TE for every 50µl of DNA sample) (Figure 2.4).  
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For example: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Known DNA Standard (ng/mL) 
 0 50 100 200 400 600 800 1000 
Fluorescence  6 68 122 217 430 627 817 961 
  5 62 112 212 408 597 771 930 
Average 5 65 117 215 419 612 794 946 
Figure 2.4 - Cell DNA contents were determined using PicoGreen analysis: 
PicoGreen® double-stranded DNA (dsDNA) quantitation was used to quantify the 
concentration of total dsDNA (ng/ml) of unknown samples. DNA for unknown 
samples were extrapolated from the DNA standard curve using the linear regression 
formula Y = a + bX. 
 
 
 
The DNA contents (ng/ml) of unknown samples with a fluorescent reading of 500 
can be determined using the above calculated linear regression data from the 
standard curve: 
 
Y=  a + bX 
Y= 500 
a = 0 
b = 0.982 
X = 500 / 0.982 
X = 509.2 ng/ml 
  
Final concentration of unknown sample taking into account the dilution factor: 
= 509.2 x 4 
= 2039 ng/ml 
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2.5 Mineralisation  
 
Osteoblasts produce an extracellular collagenous matrix that subsequently becomes 
mineralised by hydroxyapatite deposition (Coelho and Fernandes 2000, Jiang, et al 2013, 
McQuillan, et al 1995). Ascorbic acid promotes collagen secretion and serves as a 
cofactor for prolyl hydroxylase which catalyses the hydroxylation of proline residues, 
integral to the stability of the collagen triple helix (Franceschi, et al 1994, Murad, et al 
1981). Ascorbic acid also upregulates osteoblastic ALP and osteocalcin genes expression 
(Franceschi, et al 1994, Rickard, et al 1994). Inorganic phosphates initiate mineralisation 
by providing a source of phosphates to OB cells for the formation of hydroxyapatite.   
OB progenitor mineralisation was assessed using Alizarin red staining, an anthraquinone 
dye that binds to mineral deposits as confirmed by energy dispersive X-ray spectroscopy 
(Chang, et al 2000). OB progenitors were seeded in 48 well plates at a cell density of 
6000cm
2
 and cultured in 250µl per well of standard MEM-alpha media for 72 hours. OB 
Cultures were differentiated in standard osteogenic Alpha-MEM media containing 4% 
FCS for up to 21 days. Osteogenic media was replaced from the OB cultures every 3 
days. Mineralisation was assessed on various time points throughout differentiation. On 
these time points, the OB cultures were washed with 500µl of PBS and fixed in 100% 
ethanol for 1 hour on ice. To stain for mineral deposits, the wells were washed with PBS 
and incubated with 1% Alizarin red stain for 20 min on an orbital shaking platform. 
Excess stain was washed water until water ran clear. Stained cultures were also washed 
once with 200µl of 95% ethanol and plates air-dried overnight. The culture plates were 
scanned on a flatbed scanner and the percentage area of mineralisation per well was 
quantified using ImageJ (http://imagej.nih.gov/ij/). Values were expressed as a percentage 
response of the control.  
 
 
 
 
 
  
54  
 
2.6 Cell protein extraction  
 
 
 
 
Protein was extracted from cultured cells for protein quantification and subsequently 
western blotting analysis. Mammalian cell lysis buffer was prepared according to Table 
2.4; 1ml of mammalian cell lysis buffer was prepared and 1/100 dilution of protease 
inhibitor cocktail was added immediately prior to cell lysing procedure. For 
phosphorylation studies, 1/100 dilution of phosphatase inhibitor cocktail was also added 
to the lysis buffer. Cells were initially counted to establish cell number using the 
haemocytometer counting protocol outlined in the method section 2.1.3.  
 
 
 
Table 2.4 - Preparation of mammalian cell lysis buffer. 
  
Cell protein extraction 
ITEM SUPPLIER 
Mammalian cell lysis buffer kit Sigma-Aldrich 
Protease inhibitor cocktail Sigma-Aldrich 
Phosphatase inhibitor cocktail  2 Sigma-Aldrich 
Mammalian cell lysis buffer  
INGREDIENT Quantity 
Mammalian cell lysis buffer (kit): 
5X buffer Tris-EDTA  
5X Deoxycholic acid sodium salt  
5X Igepal CA 630  
5X Sodium dodecyl sulphate (SDS)  
5XSodium chloride 
 
1ml 
Protease inhibitor cocktail  10µl 
Phosphatase inhibitor cocktail  2: 
Sodium orthovanate 
Sodium molybdate 
Imidazole 
 
10µl 
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Media containing non-adherent cells were transferred into BD Falcon™ tubes and cells 
pelleted by centrifugation at 2000 RPM for 3 minutes. Media was removed from the cell 
pellets and pellets resuspended in 1ml of ice cold PBS. The PBS solution containing 
resuspended cells were transferred into 1.5ml eppendorf tubes and cells centrifuged for 
1000 RPM for 5 minutes. PBS wash was removed from cell pellets. Lysis buffer was 
added to cell pellets and the cell/lysis buffer solution vortexed for 2 minute to ensure 
membranes had sheared. The volume of lysis buffer added was dependent on the number 
of cells counted before seeding. Generally for every 500,000 cells, 100µl of lysis buffer 
was added to the cell pellets. After the vortex mix, eppendorfs containing cells/lysis 
buffer were placed on ice on an orbital shaker and agitated at 500 RPM for 30 minutes.  
 
Adherent cells cultured in 6 well culture plates containing adherent cells were placed on 
ice and the media removed carefully and quickly as to not disturb the cells. Cells were 
washed once with 1ml of ice cold PBS and lysis buffer added one well at a time. Based 
on proliferation assays, it was estimated that following cell seeding at a density of 6000 
cell/cm2 and at around 8 days in culture, each well within a 6 well plate contained 
approximately between 400,000 to 500,000 cells. 100µl of lysis buffer was added to each 
well and adherent cells were scraped off well surface using a plastic cell scraper one well 
at a time. The lysed cell solutions were transferred into 1.5ml eppendorfs and vortexed for 
2 minute to ensure membranes had sheared. Samples were placed on ice on an orbital 
shaker and agitated at 500 RPM for 30 minutes. 
 
Cells cultured in large T75 flasks were detached from the plastic surface by trypsination 
and resuspended in 1ml of ice cold PBS and counted using a haemocytometer as outlined 
in method section 2.1.3. Cell suspensions were transferred into 1.5ml eppendorf tubes 
and cells centrifuged for 1000 RPM for 5 minutes. PBS wash was removed from cell 
pellets and lysis buffer added. The volume of lysis buffer added to the cell pellet was 
dependent on the number of cells counted before seeding; in general the T75 flasks 
containing proliferating cells that were cultured for 8 days contained approximately 
1.5x105 cells and were therefore lysed with 300µl of lysis buffer. Eppendorfs containing 
cell/lysis buffer solution were vortexed for 2 minute to ensure membranes had sheared 
and placed on ice on an orbital shaker and agitated at 500 RPM for 30 minutes.  
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Cell lysates were centrifuged at 13,000 RPM for 15 minutes at 4ᴼC to remove any cell 
debris from the protein solution. The purified protein containing supernatants were 
transferred into fresh eppendorf tubes and the pellets discarded. A small volume (10-
20µl) of lysate was retained to perform protein assay and the remnants aliquoted to avoid 
protein degradation as result of freeze thawing. Protein lysate aliquots were either stored 
at -20ᴼC or diluted in Laemmli buffer in preparation for western blotting (section 2.8).  
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2.7 Bicinchoninic acid protein quantification assay  
 
 
 
Bicinchoninic acid (BCA) protein assay was performed to measure the concentration of 
protein in each sample. Copper (Cu2+) ions were added to the sample and consequently 
reduced to Cu1+ ions by the peptide bonds in the protein. As a result, the greater the 
amount of protein in the sample the greater the amount of Cu1+ ions present. Two 
molecules of BCA chelate with each Cu1+ ions and result in a green to purple colour 
product that strongly absorbs light at 563nm wavelength. At higher temperatures of 
around 37°C to 60 °C, peptide bonds stimulate the formation of the reaction product 
(Olson and Markwell 2007).  
 
BCA was prepared by diluting Copper II sulphate (CuSO4) 1:50 in BCA (for one 96 well 
plate, 250μl of CuSO4 was added to 12.25ml of BCA). A stock solution of 1000μg 
Bovine Serum Albumin (BSA) was prepared from 7.5% BSA; 10µl of 7.5% BSA was 
diluted in 740µl of distilled water. Next, 7.4% BSA and cell lysis buffer were combined 
to obtain 1000, 800, 600, 400, 200, 100 and 0μg/ml of BSA as outlined in Table 2.5. 10μl 
of each BSA concentration was added to duplicate columns A and B on a 96 well culture 
plate. Unknown samples were diluted with lysis buffer and 10μl of each sample was also 
added to duplicate columns on a 96 well plate.  
 
  
Bicinchoninic acid protein assay 
ITEMS SUPPLIER 
Mammalian cell lysis buffer Sigma-Aldrich 
7.5 % Bovine serum albumin (BSA) Sigma-Aldrich 
Bicinchoninic acid (BCA) solution In-house 
Copper (II) sulphate solution (4%) Sigma-Aldrich 
Plate reader Spectramax M5 Sunnyvale 
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Table 2.5 - Preparation BSA standards ranging from 0 to 1000µg for the BCA assay. 
 
 
200μl of BCA/Copper II sulphate solution was added to each well. BCA assay was 
performed at 37ᴼC in an incubator for 30 minutes. Colour change was quantified on a 
plate reader and values extrapolated standard protein solution. The absorbance was read 
at 562nm using a plate reader (Spectramax M5) and compared to the standard curve. 
Values from the standard curve were exported into Graphpad software (Prism V5) and 
un-known values extrapolated. Calculated values gave a standard amount of protein per 
sample (mg/ml). Based on the concentrations calculated, all protein samples within an 
experiment were diluted with lysis buffer to same concentration so limit any variability as 
a result of protein loading during western blot analysis.  
 
 
 
 
 
 
 
  
BSA standard curve for BCA assay 
BSA Concentration 
(μg) 
BSA Volume 
(μl) 
Lysis Buffer Volume 
(μl) 
1000 10 0 
800 8 2 
600 6 4 
400 4 6 
200 2 8 
100 1 9 
0 0 10 
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2.8 Western blot 
 
 
  
Western blotting   
EQUPTMENT SUPPLIER 
Mini PROTEAN electrophoresis system Bio Rad  
Mini Trans-blot cell Bio Rad  
Filter paper  Sigma-Aldrich 
Kodax Biomax MS film Sigma-Aldrich 
Gel Doc XR+ System and the Quantity One 
software 
Bio Rad  
GS-710 Calibrated imaging densitometer  Bio Rad 
Curix 60 film processor Curix, AGFA 
REAGENT SUPPLIER 
Molecular weight marker Bio Rad 
ß Mercaptorethanol Sigma-Aldrich 
Glycerol Fisher 
Bromophenol blue National Diagnostics 
ProtoGel resolving buffer -  0.4 M Tris-HCl, 0.1% 
SDS, pH 8.8 
National Diagnostics 
ProtoGel stacking buffer 1.0M Tris-HCL pH6.8 Life Sciences 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
30% Acrylamide Geneflow, LTD 
Ammonium persulfate (APS) Sigma-Aldrich 
TEMED Sigma-Aldrich 
Bovine serum albumin (BSA)  Sigma-Aldrich 
SuperSignal*West Dura chemiluminescent substrate Thermo-scientific 
Methanol  Sigma Aldrich 
Ethanol VWR International 
Skimmed milk powder Marvel 
0.05% PBS Tween  In-house 
PBS tablets Oxoid 
Tween X20 VWR International 
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Western blotting is a technique used to identify and locate proteins based on their ability 
to bind to specific antibodies against these proteins. The proteins within a sample are 
separated using polyacrylamide gel electrophoresis (PAGE), where polyacrylamide gels 
and buffers are loaded with sodium dodecyl sulfate (SDS). SDS-PAGE maintains 
polypeptides in a denatured state once they have been treated with strong reducing agents 
to remove secondary and tertiary structures and allows separation of proteins according to 
their molecular weight. 
 
2.8.1 Sample preparation  
 
Protein samples (either recombinant protein or cell lysate) were mixed with 5X Laemmli 
buffer, one part buffer and four parts sample, in 0.5ml eppendorf tubes according to 
Table 2.6. Protein sample and buffer solutions were mixed by vortex and briefly pulsed 
in a microcentrifuge. Protein samples were denatured for 5 minutes at 96⁰C on a hot 
block. Boiled samples were maintained on ice until the gel loading stage. Denatured 
protein samples were aliquoted into 0.5ml eppendorfs and frozen at -20ᴼC. 
 
 
 
 
 
Table 2.6 - Preparation of 5X Laemmli loading buffer 
 
 
 
  
5X Laemmli loading buffer  
INGREDIENT Quantity 
SDS 2g 
0.5M TrisHCl pH 6.8+ 0.4% SDS  2.13ml 
ß Mercaptorethanol 2.56ml 
Glycerol 5.0ml 
Bromophenol blue 0.1g 
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2.8.2 SDS-PAGE and protein migration  
 
For each experiment, two SDS gels were prepared constituting of a separating gel layer 
and stacking gel layer. The separating gel ingredients were combined in a 50ml BD 
Falcon™ tube according to Table 2.7 and TEMED was added last to initiate the 
polymerisation reaction. The combined ingredients were mixed by vortexing the 
separating gel solution for 1 minute. Immediately the separating gel was cast between two 
glass plates. To maintain an even gel level and inhibit gel dehydration, 70% ethanol was 
added covering approximately 0.5cm of the top of the separating gel. Once the separating 
gel had set, all traces of the ethanol were removed by washing the gel three times using 
distilled water. All traces of water were removed by inserting a flat resorbing paper 
between the casting classes.  
 
 
 
Table 2.7 - Preparation separating gel solution for 1 gel. 
 
The ingredients for the stacking gel were combined according to Table 2.8. TEMED was 
added to the stacking gel solution last, and the solution mixed by vortex for 1 minute. The 
stacking gel solution was poured immediately to the top of the separating gel and 8, 10 or 
15 plastic tooth combs were inserted between the casting glass plates into the separating 
gel to create wells for loading of protein samples. The gels were allowed to set 
completely, usually requiring 15-20 minutes and the combs were removed.  
  
Separating  gel  
INGREDIENT 12% 10% 
                Volume (ml) 
Distilled water 3.35 4.05 
Resolving buffer 2.5 2.5 
10% SDS 0.1 0.1 
30% Acrylamide 4.0 3.3 
10% APS 0.05 0.05 
TEMED 0.05 0.05 
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Table 2.8 - Preparation stacking gel solution for 1 gel. 
 
 
The glass casting plates were placed into an electrophoresis tank. The central portion of 
the tank were the gel was placed, was filled with cold X1 running buffer and the buffer 
allowed to overflow into the tank to ensure bubbles did not interfere with the 
electrophoresis. Each tank required approximately 1 Litre of buffer. Each gel was loaded 
with 5-100µg of protein sample and 5µl of a 10-250kD horse radish peroxidase (HRP)-
conjugated molecular marker was pipetted into the first (and sometimes last) lane of each 
gel. For the migration of proteins, samples were run through the stacking gel for 45-60 
minutes at 60 Volts per gel at room temperature and further run through the separating gel 
for a further 60-120 minutes at 100 Volts. 
 
 
 
Table 2.9 - Preparation of 1 litre of 10X running buffer. 
  
Stacking  gel  
INGREDIENT Volume (ml) 
Distilled water 6.1 
Stacking buffer 2.5 
10% SDS 0.1 
30% Acrylamide 1.3 
10% APS 0.1 
TEMED 0.01 
10 X Running buffer  
100ml added to 900ml distilled H20 for X1 working solution 
INGREDIENT Amount 
Distilled water 500ml 
0.25M Tris 15.13g 
0.2M Glycine 75.05g 
1% SDS 5g 
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2.8.3 Transfer 
 
Following protein migration, the stacking gels were cut off from the remainder of the gel 
and discarded. The separating gel was carefully dislodged from the glass pane. An 
arrangement constituting of a scouring pad, two pieces of cellulose blotting paper and a 
piece of polyvinylidene fluoride (PVDF) membrane previously soaked in methanol for 20 
seconds, were placed within an open transfer cassette. The gel was placed onto the PVDF 
membrane (marker facing top left of membrane). The PVDF membrane was cut slightly 
on the left upper corner to indicate the position of the first lane containing protein sample. 
The PVDF membrane was sandwiched with another two pieces of cellulose blotting paper 
and a scouring pad. The cassette was closed firmly and placed into an electrophoresis 
tank. The tank was then filled with 1 Litre of 1X transfer buffer, prepared according to 
Table 2.10. The transfer buffer was kept cool using an ice pack, which was placed at one 
side of the tank. A magnetic stirrer was also placed in the centre of tank to distribute the 
temperature within the tank and also stir the buffer solution.  Membranes were blotted at 
70V for 60-70 minutes (depending on the size of the protein) at 4ºC in a cold room.  
 
 
 
Table 2.10 - Preparation of 1 litre of 10X transfer buffer. 
 
 
 
 
 
  
10 X Transfer buffer  
100ml added to 900ml distilled H20 for X1 working solution 
INGREDIENT Amount 
Distilled water 500ml 
20% Methanol  100ml 
0.25M Tris 15.13g 
0.2M Glycine 75.05g 
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2.8.4 Blocking and immunological detection 
 
Each membrane was removed from the transfer cassettes and placed in 20ml of 5% milk 
blocking solution for 1 hour on an orbital shaker at room temperature. Probing with 
primary antibody varied depending on the antibody being used. Primary antibody was 
added in the membrane blocking solution and either incubated overnight at 4ºC or for 2 
hours at room temperature. Each membrane required at least 10ml of primary antibody 
solution to be submerged completely and evenly in flat square polystyrene containers. 
The primary antibody was removed and the membrane was washed 3 times in 0.05% 
PBS-Tween, for 20 minutes per wash on an orbital shaker at room temperature. Next, 
membranes were incubated with secondary antibody prepared in 5% milk for 1 hour on 
an orbital shaker at room temperature. Membranes were washed again with 0.05% PBS-
tween X3 20 minute washes.  
 
 
 
 
 
 
 
 
 
Table 2.11 - Preparation of 0.05%PBS-Tween washing buffer and 5% milk blocking 
solution.  
 
The detection method for protein is dependent on the enzyme to which the secondary 
antibody is conjugated. HRP is the most common enzyme used in western blotting, and 
the substrate used for detection is known as chemiluminescent substrate (Figure 2.4). For 
visualisation of bands, the membranes were incubated in the dark for 5 minutes with 
Supersignal West Dura chemiluminescent substrate made from equal volumes of 
peroxidase and enhancer mixed together. Blots were developed in a dark room on 
photographic paper using an automated film processor. Protein bands on X-ray films were 
inspected using the GS-710 Calibrated imaging densitometer and the Quantity One 
software. 
0.05% PBS-Tween washing buffer  
INGREDIENT Quantity 
Distilled water 2L 
PBS tablets 20 Tablets 
Tween X20 1ml 
5% Milk blocking solution  
INGREDIENT Quantity 
Skimmed milk 
powder 
5g 
0.05% PBS Tween  100ml 
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2.8.5 Membrane stripping 
 
Antigens on the membranes were ‘stripped’ of their primary and secondary antibody 
complexes using a mild stripping buffer according to the Abcam® protocol. Membrane 
stripping was performed for the detection of multiple proteins on the same blot, for 
instance a protein of interest and a loading control. In brief, the stripping buffer was 
prepared according to Table 2.12 and adjusted to pH 2.2. Each membrane was incubated 
with 10ml of stripping buffer for 10 minutes on an orbital shaker. The buffer was 
discarded and the membrane washed twice with 10ml of PBS followed by one wash with 
0.05% PBS Tween. The membrane was then blocked in 5% milk solution as outlined in 
section 2.8.4.  
 
 
 
 
 
 
 
 
Table 2.12 - Preparation of 1 litre of mild stripping buffer.   
Stripping buffer  
 
INGREDIENT Quantity 
Distilled water  1 L 
Glycine 15 g 
SDS 1 g 
Figure 2.5 - Diagrammatic 
representation of 
immunological protein 
detection using 
chemiluminescent substrate 
in western blot: Anti-antigen 
IgG antibody binds to its specific 
antigen which is bound to the 
blot. The species-specific 
secondary HRP-conjugated 
antibody binds to the protein-
primary antibody complex. A 
HRP chemiluminescent substrate 
is introduced to the complex 
which is bound to the blot, and 
the emitted X-ray light is 
captured on film.  
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2.9 Flow cytometry  
 
 
 
 
Flow cytometry is a quantitative method used for the analysis of various parameters 
including cell surface expression, detection of intracellular molecules and characterisation 
of different cells types within a heterogeneous cell population. Flow cytometry enables 
simultaneous analysis of single cells by measuring the fluorescence intensity produced by 
fluorescent labeled antibodies that are specific for the molecule of interest. Cells are 
pushed through a fluidic system in a monolayer and several prisms and lenses direct a 
laser light to the cuvette where it intercepts with the cells. It is at this point that the 
information associated with the fluorescence and scatter of each individual cell can be 
obtained. Light scattered in the forward direction is collected by the Forward Scatter 
Channel (FSC) photodiode and provides information on the cells relative size. Light 
measured at a 90° angle to the excitation beam of the laser is collected by the Side Scatter 
channel (SSC) photomultiplier tube (PMT) and is used as a measure of the relative 
granularity of the cell. Fluorescent light associated with a cell is detected by individual 
fluorescence channels (FL). The data generated is either plotted in a single dimensional 
histogram or in a two-dimensional dot plot or in some cases, in three dimensions. Based 
on fluorescence intensity, the regions on plots can be separated using subset extractions or 
‘gates’.   
 
  
Flow Cytometry    
ITEM SUPPLIER 
Formalin solution Sigma Aldrich 
Bovine serum albumin (BSA)   Sigma-Aldrich 
FACS perm buffer BD Phospflow 
Triton X Invirtrogen 
BD Falcon™ round bottomed flow cytometry tubes BD Biosciences  
BD FACSCalibur™ platform  and Cell Quest software BD Biosciences 
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Flow cytometry was used to determine the presence of specific proteins in cells cultures. 
Cells were seeded at a density of 6000cm
3
/ml in T25 or T75 flasks. Media was removed 
from the cell cultures. The cells in T25 flasks were washed with 5ml of ice cold PBS and 
cells cultured in T75 flasks were washed with 10ml of ice cold PBS. Adherent cell 
cultures were detached from the plates or flask surface by trypsinisation as outlined in 
section 2.1.3. Adherent cells were resuspended in 1ml of ice cold PBS in 1.5ml 
eppendorfs, transferred to 1.5ml eppendorfs and chilled on ice. Non-adherent cell cultures 
were centrifuged at 2000 RPM for 3 minutes and the supernatant discarded. The cell 
pellets were resuspended in 1ml of ice cold PBS in 1.5ml eppendorfs and chilled on ice.  
 
The cell pellets resuspended in PBS were centrifuged at 2000 RPM for 3 minutes on a 
bench-top microcentrifuge. The supernatant was discarded and cells fixed with 300μl of 
4% Formalin per 1x10
5 
cells for 10 minutes at room temperature in the dark on a rotator. 
Cells were washed twice in 1ml of PBS (washing refers to the addition of PBS followed 
by centrifugation at 2000 RPM for 3 minutes). Cell pellets were re-suspended in 0.1% 
Triton-X to permeabilise membranes for 10 minutes at room temperature in the dark on a 
rotator. Cells were washed twice with PBS to remove all traces of fixative and detergent. 
Cells were then blocked in 10% normal serum originating from the species in which the 
secondary antibody was produced. The 10% normal serum was made up in 0.5% BSA 
solution and cell pellets were blocked in 300µl serum per 1x10
5
 cells in the dark for 30 
minutes at room temperature. Cells were washed twice with PBS. Supernatant was 
removed thoroughly by inversion on an absorbent paper surface to remove all liquid. 
Pellets were resuspended in 40μl of X1 Sample Perm buffer and 20μl of this cell 
suspension was transferred to another tube. Each of the 20μl cell suspensions was 
incubated with either 100µl of primary antibody or 100µl of isotype control antibody (at 
the same concentration of as the primary antibody) made up in 3% BSA for 30 minutes in 
the dark. Cell suspensions were washed twice with PBS ensuring all the liquid was 
removed completely following the final wash. The cell pellets were resuspended in 100μl 
of species-specific biotinylated secondary antibody and incubated in the dark for 30 
minutes. Cells were washed twice in PBS and 300μl of X1 Sample Perm buffer was 
added to cells. The cells were centrifuged at 2000 RPM for 3 minutes and re-suspended in 
300μl of Sample Perm buffer. Samples were transferred to flow cytometry tubes prior to 
analysis. Flow cytometric analysis was performed using the BD FACSCalibur™ platform 
and the data analysed using the Cell Quest software. Cells of interest were sorted through 
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three modes of scatter plot; FSC vs SSC, single color vs. SSC and a two-colour 
fluorescence plot. GFP-cells were detected through FL4 fluorescence channel and all 
other through the FL2 fluorescence channel. Analysis of results was carried out by gating 
around the viable cells and the presence of the protein of interest was detected through 
comparison with isotype antibody staining. The threshold for the isotype controls were set 
at >1% on the scatter plots. The same gating used for the isotype controls were copied 
and pasted onto the scatter plots of corresponding samples. 
 
2.10 Cell sorting  
 
Flow cytometers are capable of sorting cell populations of purified cells with specific 
characteristic from mixed cell populations. The stream of cells, which have been passed 
though the sheath fluid and are required for sorting, are passed through a narrow vibrating 
orifice. This results in the breakup of the cell steam into droplets containing cells. The 
period of time between the cells passing through the laser as a stream and then as 
droplets, is regulated. The cells of interest within the droplets become charged and 
subsequently flow through high-voltage deflection plates. The charged droplets are 
deflected appropriately into a collection vessel and any uncharged droplets are disposed 
into the waste container. Co-cultures were separated into their individual populations 
using the FACS Aria Cell sorter. Cells were cultured alone or co-cultured with a different 
cell type. Media was removed from the cells cultured in T25 or T175 and the cells 
washed once with 5ml or 10 ml of PBS, respectively. Adherent cell cultures were 
detached from the culture surface by trypsinisation as outlined in section 2.1.3. Cell 
pellets were resuspended in 1ml of PBS. Non-adherent cell cultures were transferred from 
the culture flasks into BD Falcon™ tubes and centrifuged at 2000 RPM for 3 minutes. 
The supernatant was discarded and the cell pellets were resuspended in 1ml of PBS. 
Protein and RNA were isolated from sorted samples as outlined in sections 2.5 and 2.12, 
respectively. 
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2.11 Immunofluorescent microscopy  
 
 
 
Immunofluorescent microscopy is performed to detect the presence of proteins of interest 
in microbiological samples with the use of a fluorescent microscope. This technique uses 
the specificity of antibodies to their antigen to target fluorescent dyes to specific 
biomolecule targets within a cell, allowing the distribution of the target molecules within 
a sample to be visualised. Immunofluorescence is a widely used example of 
immunostaining which effectively makes use of fluorophores to visualise the location of 
the antibodies. 
 
Immunofluorescent microscopy was performed to determine the presence of specific 
cellular intracellular and extracellular proteins. Non-adherent cells were attached to the 
surface of culture plates using sterile tissue culture grade Poly-L-lysine polymer reagent. 
The culture surface was aseptically coated with 1.0 mL/25 cm
2
 of the Poly-L-lysine, with 
gentle rocking to ensure even coating of the culture surface and aspirated after 5 minutes. 
The culture surface was thoroughly rinsed using sterile tissue culture grade water. The 
culture surface was allowed to dry thoroughly for 4 hours before introducing cell cultures. 
Cells were cultured at the same cell density of 6000cm
2
 in 8 well slide chambers (BD 
Falcon
TM
), 24 or 48 well plates. Media was removed from the adherent cell cultures and 
the cells washed once with 1ml of ice cold PBS (washing refers to the addition of PBS to 
Immunofluorescent microscopy 
REAGENTS  SUPPLIER 
Poly-L-lysine Sigma-Aldrich 
Sterile distilled water In-house 
Formalin solution, neutral buffered Sigma Aldrich 
Triton-X Invirtrogen 
DAPI in mounting reagent Duolink 
Glass cover slips  Menzel-Glasser 
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the cell cultures and removal of PBS). The cell cultures were fixed with 4% Formalin for 
10 minutes at room temperature in the dark. Cells were washed twice in 1ml of PBS and 
cell membranes were permeabilised using 0.1% Triton X for 10 minutes at room 
temperature in the dark. The volume of PBS, fixative and permeabilisation reagent was 
dependent on the well size/cell density (Table 2.13).  
 
 
 
 
Table 2.13 - The volume of PBS, fixative and permeabilisation reagent used in 
immunofluorescence microscopy were dependent the size of each well within the 
culture plate.  
 
 
Cells were washed twice with PBS to remove all traces of fixative and detergent. Non-
specific antigen-antibody binding in cell cultures was minimized by using 10% normal 
serum diluted in 0.5% BSA solution. The normal serum used originated from the species 
in which the secondary antibody was produced. Cell cultures were blocked in 10% 
normal serum in the dark for 30 minutes at room temperature on a shaker. The blocking 
solution was removed from cell cultures and the cells incubated with a primary antibody 
specific to the antigen of interest or an antibody isotype control.  
 
Unconjugated antibodies were made up (concentrations optimised) to the required 
concentrations in 3% BSA solution. Depending on the size of the plate/chamber, cells 
were incubated with 200-500µl of unconjugated primary/isotype antibody over night at -
4ᴼC. Cell cultures using a biotinylated-primary antibody system (no secondary antibody 
required) were incubated with the antibody for 1 hour at room temperature in the dark. 
The culture plates were wrapped in parafilm to prevent evaporation and cell dehydration. 
The cell cultures were washed twice with PBS for 3 minutes on a rotator.  
 
Cell culture plate Volume of PBS, 4% formalin and 0.1 
Triton X per well  
8 well slide chamber  200µl 
24 well plate 500µl 
48 well plate 300µl 
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Cell cultures that had been stained with an unconjugated primary/isotype antibody were 
incubated with biotinylated secondary antibody prepared in 3% BSA for 1 hour at room 
temperature in the dark on a rotator. The cell cultures were washed twice with PBS for 3 
minutes on a rotator. All PBS was removed completely from the cell cultures and one 
drop of DAPI mounting reagent added to visualise nuclear staining. Slides and wells were 
mounted with coverslips and cellular staining observed by the Leica DM16000 Inverted 
microscope and analysed by corresponding AF6000LX software. The DAPI blue staining 
was visualised through filter cube A4, far-red APC staining visualised though filter cube 
Y5 and the green staining via the L3 filter. To allow for direct comparisons between the 
isotype control and positive staining, images were captured at the same exposure, gain 
and intensity setting within each experiment. 
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2.12 Immunohistochemistry  
 
 
 
 
Immunohistochemistry is the technique used for the detection of antigens within cells of a 
tissue section using the principle of specific antibody-antigen interaction. 
Immunohistochemical staining is widely used in basic research to establish the 
distribution and localization of biomarkers in biological tissue. Antibody-antigen 
interactions can be visualised using an antibody-conjugated enzyme, such as peroxidase, 
which catalyses a colour-producing reaction. Immunohistochemistry analysis was 
performed according to Nakane et al (Nakane and Pierce 1966) with protocol 
modifications proposed by Clausen et al (Clausen, Blish et al. 2011).  
 
In brief, tissue fixation, embedding and processing were performed by our in-house Bone 
Analysis Laboratory facility. Briefly, tissue sections were fixed in paraformaldehyde 
(PFA) and decalcified for 7 days, with solution change every 3 days. The tissue sections 
were processed through graded alcohol solutions ad xylene overnight. Sections were 
embedded longitudinally in paraffin wax contained in a square mould, according to 
embedding machine manufacturer’s instructions. The tissues were cut in 3µm thick 
sections at 2 levels 50µm apart, using a rotatory microtome (Leica Microsystems) and 
Immunohistochemistry  
ITEMS SUPPLIER 
Ethanol  VWR 
Xylene  VWR 
Haematoxylin solution Merck  
1% Eosin solution VWR 
Trypsin enzyme digestion kit  Menarini Diagnostics 
Formalin solution, neutral buffered Sigma Aldrich 
Hydrogen peroxide 30%  Suprapur® 
DAB substrate-chromogen system Vector 
Glass cover slips  Menzel-Glasser 
Aperio® ScanScope slide scanner  Leica Biosystems 
Microscope  DMI4000 Leica Biosystems 
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mounted on positively-charged Superfrost®PLUS slides. When required for 
immunohistochemical analysis, the tissue sections were first de-waxed by immersing the 
tissues in various solvents solutions in 5 steps for 4 minutes per step; xylene, xylene, 99% 
ethanol, 99% ethanol, 95% ethanol and 70% ethanol. Tissue sections were hydrated in 
running water for 2 minutes.  
 
A humid environment was prepared for tissue sections by moistening 
immunohistochemistry staining slide trays with distilled water. Heat-activated antigen 
retrieval was performed using 1:3 dilution of trypsin enzyme. The Trypsin was pre-heated 
in a 37ºC incubator for 30 minutes. Tissue slides were placed in the pre-moistened 
staining slide trays and 100µl of trypsin placed on each tissue section for 10 minutes at 
room temperature. Tissue sections were placed in staining racks containing PBS and 
placed on a rotator for 3 minutes. The PBS was discarded and tissue slides submerged in 
fresh PBS and washed again for 3 minutes. The tissue slides were removed from the 
staining racks and returned to the staining tray. The slides were tapped to discard any 
remaining PBS. A wax isolator pen was used to circle the area around the tissue, creating 
a reservoir surrounding the tissue.  
 
Tissue sections were incubated with 100µl of 3% hydrogen peroxide for 30 minutes at 
room temperature. The tissue sections were placed into staining racks containing PBS and 
washed twice. Sections were placed back in the staining trays and blocked with 100µl of 
10% normal serum blocking solution for 30 minutes at room temperature. The species 
from which the normal serum originated was dependent on the species from which the 
secondary antibody was produced. Unconjugated antibodies were made up 
(concentrations optimised) to the required concentrations in 3% BSA solution.  
 
Tissue sections were tapped gently on absorbent paper to remove blocking serum and 
then incubated with 100µl of unconjugated primary/isotype antibody over night at -4ᴼC. 
The tissue sections were placed into staining racks containing 0.05% PBS-Tween. 
Sections were washed twice for 3 minutes per wash on a rotator. Secondary biotinylated 
antibody was made up in normal serum to an optimal concentration. Sections were 
replaced into staining trays and incubated with 100µl of 1:500 dilution of secondary 
biotinylated antibody. The tissue sections were placed into staining racks and washed 
twice with 0.05% PBS-Tween for 3 minutes per wash on a rotator. To enhance antibody-
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antigen detection, sections were placed back in the staining trays and incubated with 
100µl of 1:300 Streptavidin solution for 30 minutes at room temperature. Sections were 
washed twice with 0.05% PBS-Tween for 3 minutes per wash on a rotator.  
 
Antibody-antigen specific staining was developed with DAB chromogen as per supplied 
kit; 1 drop of DAB was placed into 1ml of DAB buffer. Tissue sections were incubated 
with 100µl of the DAB solution for 5 minutes in the dark at room temperature. The tissue 
sections were placed into staining racks and washed under tap-water for 5 minutes. Tissue 
sections were counterstained with Gills haematoxylin for approximately 20 seconds and 
excess stain removed by washing sections gently under running tap water for 2-3 minutes.  
 
The tissue sections were dehydrated in solvent in consecutive steps; 70% ethanol for 12 
seconds, 95% ethanol for 12 seconds, 99% ethanol for 12 seconds, 99% ethanol for 12 
seconds, xylene for 30 seconds and xylene for 2 minutes. The sections were mounted with 
DPX and cover-slips and allowed to dry in a ventilated environment. Slides were scanned 
and images captured using the Aperio® ScanScope slide scanner or an upright light 
microscope (DMI4000, Leica Biosystems).  
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2.13 RNA Extraction 
 
 
Prior to RNA extraction, the following reagents were prepared: 
 
DNase I  
Lyophilised DNase I was reconstituted with 275μlof nuclease-free water (provided) as 
indicated on the vial label. The vial was gently mixed by swirling the vial of solution. A 
total of 3μl of rehydrated DNase I was required per RNA purification. The rehydrated 
DNase I was stored at –20°C for up to 6 months. 
 
BL-TG buffer  
The BL-TG buffer was prepared by adding 325μl of 1-thioglycerol (TG) to 32.5ml of BL 
buffer.  The BL-TG buffer was stored at 2°C–10°C for up to 30 days.  
  
RNA Extraction   
ITEM SUPPLIER 
ReliaPrep™ RNA cell miniprep system: 
ReliaPrep™ minicolumns (50/pack) 
Collection tubes (50/pack) 
Elution tubes (50/pack) 
BL buffer 
Column wash solution (CWE) 
1-Thioglycerol (TG) 
Nuclease-free water 
Yellow core buffer 
RNA wash solution (RWA) 
MnCl2, 0.09M 
DNase I (lyophilized) 
 
Progema  
Molecular-grade isopropanol  Sigma-Aldrich 
95% Molecular-grade ethanol Sigma-Aldrich 
Individual PCR tubes, 0.5 ml and 1.5ml  Thermo-Scientific 
384-Well standard PCR plates Thermo-Scientific 
Microseal® 'B' adhesive seals Bio Rad 
76  
 
RNA wash solution 
 
RNA wash solution was prepared by adding 60ml of 95% molecular grade ethanol to the 
bottle containing 35ml of concentrated RNA wash solution and stored at +15°C to +30°C.  
 
Colum wash solution 
Column wash solution was prepared with the addition of 7.5ml of 95% molecular grade 
ethanol to the bottle containing 5ml of CWE.  The column wash solution was stored at 
+15°C to +30°C.  
 
2.13.1 Column based RNA isolation  
 
RNA was extracted from cell cultures using the column-based ReliaPrep RNA cell 
Miniprep kit. RNA was extracted from adherent cells cultured in multiwall plates or 
flasks. The media from the cell cultures was removed and the cells washed with ice-cold 
sterile PBS followed by the addition of BL-TG buffer in a volume that was dependent on 
the estimated number of cells within each well or flask. RNA shearing was assisted with 
repeated pipetting of the lysate over the well surface. Non-adherent cell cultures were 
transferred into BD Falcon™ tubes and centrifuged at 1000 RPM for 5 minutes at room 
temperature. The supernatant was discarded and the cell pellets were washed in ice-cold 
PBS followed by the addition of BL-TG buffer in volumes according to Table 2.14. 
Lysates for adherent and non-adherent cell cultures were collected and transferred to 
PCR-grade microcentrifuge eppendorfs. Isopropanol was added to cell lysates in 1:3 
ratios; as an example, cells cultured in 6 well plates were lysed with 250µl of lysis buffer 
and 85µl of isopropanol was added to the lysed cells. The cell lysate and isopropanol 
were mixed thoroughly by vortex for ~10 seconds.  
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Table 2.14 – The manufacturer recommended wash and lysis buffer volumes used for 
harvesting adherent cells 
 
 
For each sample, a ReliaPrep™ minicolumn was placed into a collection tube and cell 
lysate transferred to the minicolumn. The lysate was centrifuged at 12,000 RPM for 30 
seconds at room temperature. The supernatant was discarded from the collection tube and 
500μl of RNA Wash Solution was added to the minicolumn and centrifuged at 12,000 
RPM for 30 seconds. The collection tube was removed the supernatant discarded. The 
RNA sample was DNase treated to remove any genomic DNA contamination. In a sterile 
tube, 30µl of DNase I solution was prepared by combining 24μl of Yellow Core buffer, 
3μl 0.09M MnCl2 and 3μl of DNase I enzyme per sample. The DNase I was mixed by 
pipetting and 3μl of freshly prepared DNase I solution was transferred directly to the 
membrane inside the minicolumn. RNA was incubated with DNase I solution for 15 
minutes at room temperature.  
 
Next, 200μl of Column Wash solution was added to the minicolumn and centrifuged at 
12,000 RPM for 15 seconds. 500μl of RNA Wash Solution was transferred into the 
minicolumn and centrifuged at 12,000 RPM for 30 seconds and the supernatant was 
discarded from the collection tube. The minicolumn membrane was washed a final time 
with 300μl of RNA Wash Solution and centrifuged at 13,000 RPM for 2 minutes.  The 
minicolumn was transferred to a new Elution tube, and nuclease-free water added to the 
membranes, ensuring the entire surface of membrane was covered with the water 
provided with the ReliaPrep™ Kit. The volume of water required to elude the RNA was 
dependent on the original number of cells cultured within the well/flask as recommended 
Manufacturer recommended wash and lysis volumes for harvesting adherent cells 
Plate/flask PBS wash volume 
per well 
Volume of BL-TG 
buffer 
Volume of 
isopropanol 
96-well 100 µl 100 µl 35µl 
48-well 250 µl 100 µl 35 µl 
24-well 500 µl 100 µl 35 µl 
6-well 2.0 ml 250 µl 85 µl 
T-25 5.0 ml 500 µl 175 µl 
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by the manufacturer (Table 2.15). The minicolumn was centrifuged at 13,000 RPM for 1 
minute. The elution tube containing the purified RNA was stored at –80°C.  
 
 
Recommended volume of nuclease-free water 
Cell number Nuclease-free water 
1 × 10
2
 to 5 × 10
5
                     15μl 
>5 × 10
5
 to 2 × 10
6
                   30μl 
>2 × 10
6
 to 5 × 10
6
                   50μl 
 
Table 2.15 – The addition of nuclease-free water required to elude the purified RNA 
was dependent on the original number of cells cultured in the well or flask.  
 
 
2.13.2 RNA quantification 
 
Nucleic acid concentration and purity were quantified using the NanoDrop-1000 
spectrophotometer (Thermo scientific) at an absorbance of 260nM (A260) and 280nM 
(A280). 1µl of RNA or DNA sample were required for the NanoDrop analysis. The 
concentration of nucleic acid was determined using the Beer-Lambert law, which 
calculates the change between light absorbance (A), the sample concentration (c) the 
specific extinction coefficient (ε) and the length of the pathway the light travels through 
the absorber (Ɩ), which is specific for every spectrophotometer: 
 
 
The Beer-Lambert Law: A = εƖc 
 
 
As an A260 reading of 1.0 was equivalent to approximately 40 µg/ml of RNA, the 
absorbance at 260 nm was used to determine the RNA concentration in an unknown 
sample. A A260/A280 ratio between 1.8 and 2.2 was considered an indicator of ‘clean’ 
RNA, which was free from contamination.  
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2.14 Reverse transcription-polymerase chain reaction (RT-PCR) 
 
 
 
  
Reverse Transcription and PCR   
REAGENTS  SUPPLIER 
RNAase-free eppendorfs Alpha Laboratories 
DEPC-treated water Ambion® Life Technologies 
100mM DNTP mix  Thermo-scientific 
Random primers supplied at 3µg/µl in 
3mM 
Invirtrogen 
Oligo(dT) 20 primer supplied at 50 µM. Invirtrogen 
5X First-strand buffer 375 mM KCl Invitrogen 
0.1M DTT Invitrogen 
RNasIN recombinant RNase inhibitor Invitrogen 
Superscript® III  supplied at 200Unites/µl Invitrogen 
End-point PCR primers Eurofins/MWS 
KAPATaq ready mix kit  Kappa Biosystems 
Gel Doc XR+ system BioRad 
Quantity One software BioRad 
Taqman gene expression assays Applied Biosystem 
2X Taqman universal master mix Applied Biosystem 
ABI 7900HT Platform Applied Biosystem 
Agarose Sigma-Aldrich 
Tris/Borate/EDTA (TBE) buffer  Applichem 
Ethidium bromide BioRad 
Full range100 BP DNA ladder Norgen 
X5 DNA loading buffer Kappa Biosystems 
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PCR is the in-vitro enzymatic amplification of a specific DNA sequence involving 
multiple cycles of template denaturation, primer annealing, and primer elongation. In the 
denaturation stage, the two strands of cDNA are cleaved. A temperature of 94ºC is 
required to denature the DNA due to the extremely strong stacking interactions and 
hydrogen bonds between the two stands. In the annealing step, specific oligonucleotide or 
primers anneal with their specific target sequences in each of the single stranded DNA 
templates. The annealing temperature typically ranges between 53ºC and 65ºC, depending 
on the length and guanine/cytosine (G/C) ratio of the primer. 
 
In the final elongation step, thermo-stable Taq polymerase replicates a DNA strand 
starting from the 3' end of the primer and synthesising new DNA in a 5' to 3' direction. 
The Taq polymerase is stable and active at high temperatures, typically to temperatures of 
72ºC. The PCR process is exponential in that the amplified products from each previous 
cycle serve as a template for the next amplification cycle. Typically, abundant 
amplification product is produced following 20 to 40 cycles of PCR. As a result this 
technique is highly sensitive and effective for detecting specific nucleic acids sequences. 
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2.14.1 Primer design 
 
Primer pairs were designed through the NCBI/BLAST software and ordered from Sigma 
Aldrich. Primers were designed on separate exons were possible, were 18-20 amino acids 
and contained 50% G/C ratio. The sequences of primers were checked by Blast. On 
arrival, the lyophilised primers were dissolved in DEPC-treated water to obtain a working 
concentration of 10µM. 
 
 
Table 2.16 - The sequences and the optimal PCR conditions for the reverse and 
forward primers specific to SOSTDC1 and GAPDH.  
 
  
Oligo Name Sequence ( 5’ -> 3’) Melting 
temperature  
Amplicon 
size 
SOSTDC1f CCGTCATGCTTCTCAGTTTC (20) 65 198 bp 
SOSTDC1r GCTGTCACACTCCAAGGGCC (20) 65 198 bp 
GAPDH f TTGTCAGCAATGCATCCTGC (20) 57 354bp 
GAPDH r GCTTCACCACCTTCTTGATG (20) 57 354bp 
Step Temperature Time 
Hot start PCR- 
denaturation  
T= 95℃ 2 minutes 
Second denaturation step  T=95℃ 1 minute 
Primer annealing 
temperature  
hSOSTDC1= 65℃ 
GAPDH= 57℃ 
1 minute 
Extension  T=72℃ 1 minutes 
Repeating 35 cycles 
Last extension  T=72℃ 5 minutes 
Hold at 4℃ 
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 2.14.2 Reverse Transcription and cDNA production  
 
Reverse transcription (RT) is a procedure based on the activity of the reverse transcriptase 
enzyme to catalyze the conversion of RNA template to complementary DNA (cDNA), 
required for the process of polymerase chain reaction (PCR) (Figure 2.5). Synthesis of 
cDNA is performed using a short piece of single-stranded DNA known as oligo(dT), 
which anneals to the stretch of the poly-A tail at the 3' end of most mRNA molecules. 
Although oligo(dT) primers are highly specific to  mRNA, they have the limitation of 
initiating RT at the 3´ end of the transcript resulting in incomplete cDNA synthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.6 - Reverse Transcription (RT) and cDNA production: Oligo(dT) and 
random primers can be used in RT to enable higher cDNA yield. Deoxynucleotide 
triphosphates (dNTPs) and under optimal salt and pH conditions, the RT enzyme 
extends a primer complementary to the RNA, producing cDNA.  
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In all experiments, RNA samples were converted to cDNA using SuperScript III 
following manufacturer’s instruction. Briefly, RNA samples isolated fresh or thawed 
from the -80°C storage were placed on ice for 20 minutes prior to the RT reaction. The 
working environment was sterilised using RNaseZap® RNase decontamination solution 
to eliminate RNases and this was followed by sterilisation with 70% ethanol. RNase-free 
eppendorfs, DEPC-treated water, pipettes and eppendorf racks were placed into a UV 
hood and irradiated for 20 minutes.  
 
In the RNase-free eppendorfs, 150ng-2µg of total RNA was isolated and quantified as 
outlined in Section 2.12. RNA was prepared in a total volume of 11 µl with DEPC-
treated water. For each RNA sample, a corresponding no-RT sample (RT-ve) was also 
prepared containing no RT enzyme (SuperScript III) to detect any DNA contamination. In 
addition, for every biological experiment, a no-RNA control was also included, in which 
DEPC-treated water was substituted for RNA in order to detect any contamination in the 
water (RT-H20).  
 
The following were added to 11µl of RNA; 0.25µl of random primers, 0.25µl of oligo 
(dT), 1.0µl 100mM dNTP and 1.0µl of DEPC-treated water. The reaction was heated to 
65ᴼC for 5 minutes on a Thermo Cycler and chilled on ice for approximately 2 minutes. 
The second part of the RT reaction was prepared in two separate tubes; one tube 
containing RT Superscript III enzyme and the other containing DEPC-treated water as a 
substitute for Superscript III. Each cDNA synthesis reactions contained 4µl of First 
Strand buffer, 1µl of 0.4M DTT, 1µl of RNAseIN and 1µl Superscript III (RT+ve) or 
DEPC (RT-ve). Each tube containing a total volume of 20µl of RNA/Supercript III or 
RNA/DEPC-treated water was incubated at 25ᴼC for 5 minutes, 50ᴼC for 60 minutes and 
inactivated at 70ᴼC for 15 minutes. The synthesised cDNA was stored at -20ᴼC for short 
period and -80ᴼC for longer term storage.  
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2.14.3 Polymerase Chain Reaction  
 
Polymerase chain reaction (PCR) is the in-vitro enzymatic amplification of a specific 
DNA sequence involving multiple cycles of template denaturation, primer annealing, and 
primer elongation. In the denaturation stage, the two strands of cDNA are cleaved. A 
temperature of 94ºC is required to denature the DNA due to the extremely strong stacking 
interactions and hydrogen bonds between the two stands. In the annealing step, specific 
oligonucleotide or primers anneal with their specific target sequences in each of the single 
stranded DNA templates. The annealing temperature typically ranges between 53ºC and 
65ºC, depending on the length and guanine/cytosine (G/C) ratio of the primer. 
 
In the final elongation step, thermo-stable Taq polymerase replicates a DNA strand 
starting from the 3' end of the primer and synthesising new DNA in a 5' to 3' direction. 
The Taq polymerase is stable and active at high temperatures, typically to temperatures of 
72ºC. The PCR process is exponential in that the amplified products from each previous 
cycle serve as a template for the next amplification cycle. Typically, abundant 
amplification product is produced following 20 to 40 cycles of PCR. As a result this 
technique is highly sensitive and effective for detecting specific nucleic acids sequences. 
 
2.14.3.1 End-point PCR  
 
The traditional PCR method of using agarose gels for the detection of final phase PCR 
amplification is referred to as End-point-PCR. Products of End-point PCR can be 
visualized on an ethidium bromide-stained agarose gel. The reaction includes a template 
(genomic/plasmid DNA and cDNA), forward primer, reverse primer, reaction buffer, 
magnesium, dNTP mix, and a thermostable DNA polymerase. The forward and reverse 
primers are specific to a sequence within the template and determine the length of the 
amplified product. Taq DNA polymerase is the most routinely used thermostable 
polymerase in amplifications. The concentration of magnesium ions have a direct effect 
on a range of factors including; enzyme activity, primer annealing, the template melting 
temperature and primer-dimer formation.   
 
PCR was performed using KAPATaq Ready Mix kit (Kappa Biosystems) following 
manufacturer’s instructions. Primer pairs were designed using the Primer3 software 
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(http:Frodo.wi.mit.edu/primer3) and ordered from Sigma Aldrich. On arrival, the 
lyophilised primers were dissolved in DEPC-treated water to obtain a working 
concentration of 10µM. The PCR reaction mix per cDNA sample comprised; 1-3 μl of 
cDNA (synthesised from 150ng-2µg of RNA), 2μl of 50mM magnesium chloride, 2μl of 
10x NH4 reaction buffer, 1μl of dNTP mix 10mM, 1μl of 10 μM forward primer, 1μl of 
10 μM reverse primer, 1μl of DNA polymerase, 1μl of loading buffer and DEPC-treated 
water to make up 20μl total reaction volume.   
 
For each experiment, the cDNA was also replaced with DEPC-treated control for one 
sample and used as a negative control in addition to the RT-ve control (section 2.14.2). 
PCR was performed setting the initial and secondary denaturing temperatures at 95ºC and 
an elongation temperature of 72ᴼC according the manufacturer’s instructions. The 
annealing temperature was specific to the melting temperature (Tm) of the primer and was 
optimised for each primer set.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
The annealing and extension steps of PCR were performed for 35 cycles: 
 
Initial denaturation:  95ºC for 2 minutes 
 
Secondary denaturation: 95ᴼC for 30s 
Annealing: 55ºC-65ᴼC for 30s 
Extension: 72ᴼC for 1min/kb 
 
Final extension: 72ᴼC for 2min 
 
35 Cycles 
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2.14.3.2 Agarose gel electrophoresis 
 
The presence of PCR products were verified using agarose-TBE gel electrophoresis. Gel 
electrophoresis was used to separate PCR productions based on their size (Bp). A 1.5% 
agarose gel was made by dissolving 1.5g of agarose (Sigma Aldrich) in 1X 
Tris/borate/EDTA (TBE) buffer. The agarose was dissolved by heating in a microwave 
for 2 minutes after which ethidium bromide was added to the agarose solution at a 
dilution of 1:100. A 16 or 32 well comb was placed in the gel plate and the agarose was 
poured into the gel cast and left to set for approximately 1 hour at room temperature. The 
set gel was placed in the electrophoresis tank and filled with TBE buffer. The comb was 
removed carefully from the set gel. 10µl of DNA ladder (full range100 BP Norgen) was 
loaded into the first well. 5µl of DNA loading buffer was added to 20µl of PCR product 
in a ratio. Each PCR product was loaded into the agarose gel at a volume of 10µl. The gel 
ran in TBE at 100V for 30 minutes and DNA fragments were inspected under UV light 
using the Gel Doc XR+ system and the Quantity One software.  
 
2.14.3.3 PCR product sequencing  
 
PCR products were sent into the DNA sequencing Core Facility housed within the 
University of Sheffield, Medical School and sequenced to verify SOSTDC1 expression 
(http://genetics.group.shef.ac.uk/dna-sequencing.html). Sequencing was performed using 
the Applied Biosystems' 3730 DNA Analyser. A 10µl of the 100ng/µl PCR product 
obtained from end-point PCR were initially purified by the Core Genomics Facility to 
remove excess primers and dNTPs using the Ampure bead purification kit (Beckman 
Coulter). Sequencing results were analysed using FinchTv software version 1.4.0 and the 
base pair sequences were assessed for nucleotide similarities to SOSTDC1 using the 
database on Basic Local Alignment Search Tool (BLAST)®. 
 
 
 
 
  
87  
 
2.14.3.4 Real Time quantitative Reverse Transcription-PCR 
 
Real time quantitative RT-PCR (qRT-PCR) enables accurate measurement of products 
generated during PCR cycles. This technique involves TaqMan  oligonucleotide probes 
have a fluorescent probe (reporter) bound to the 5' end and a ‘quencher’ molecule 
attached to the 3' end. During PCR amplification, these probes hybridize to the target 
sequences in the amplicon. As the polymerase enzyme replicates the TaqMan bound-
template, the reported is cleaved due to the polymerase 5'- nuclease activity. The close 
distance between the reporter and quencher molecule prevents fluorescence from being 
detected through Fluorescence resonance energy transfer (FRET). The uncoupling of the 
two molecules results in an increase in fluorescence intensity, which is proportional to the 
number of the probe cleavage cycles. 
 
Species-specific TaqMan® Assays were used to determine the expression genes of 
interest. For each gene of interest a 7µl reaction mix was prepared containing; 5µl of 
TaqMan® gene expression mastermix, 0.5µl TaqMan® Assay and 1.5µl nuclease-free 
water. 3µl of cDNA template as prepared in section 2.13.2 and 7µl of reaction mix were 
loaded into a well in a 384 well PCR plate. Each cDNA sample was loaded in duplicates.  
The reaction mix was also loaded with 2µl of nuclease-free water instead of cDNA 
template to detect any contamination in the PCR reaction mix. The plates were sealed 
using an optical adhesive covers. PCR plates were analysed using Applied Biosystems 
7900HT Real-Time PCR system and data analysis performed on the SDS 2.2.1 software. 
The cycle threshold (CT) value that was measured by the Real-Time PCR system was 
representative of the number of cycles at which each specific reaction crossed a selected 
threshold. The CT values were used as a relative measure of the concentration of the 
template sequences in a sample. The thresholds were positioned to lie in the middle of the 
linear region of the logarithm amplification plot, in an area where the increasing 
amplification was exponential. High CT values meant that higher numbers of 
amplification cycles were required to reach the fluorescence intensity threshold due to 
lower amount of sample cDNA template.  
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The baseline of a PCR reaction was set in the SDS 2.2.1 software to remove any 
background fluorescence. To maintain uniformity across samples, a constant threshold  
was set at 0.2CT and a constant baseline was also set at 3-15 cycles. Sample replicates 
were analysed by the ΔΔCT method described by Livak and Schmittgen (Livak and 
Schmittgen 2001). Relative quantification of gene expression was performed by 
normalising to β2-microglobulin (B2M) and hypoxanthine phosphoribosyl transferase 1 
(HPRTL) house-keeping genes using the formula; ΔCT = CTtarget - CThousekeeping. Fold 
changes in target gene expression were calculated using the ΔΔCT method, in which data 
are normalised by the 2
-ΔΔCT function (calculated by taking 2 to the power if ΔΔCT).  
 
 
 
Table 2.17 - The TaqMan assays specific for genes studied using qRT-PCR in this 
study.  
 
 
 
 
 
 
 
  
TaqMan®  assays  
ITEM ID SUPPLIER 
Mouse hypoxanthine 
phosphoribosyltransferase 1 
(HPRTL) 
Mm00446968-m1 Life Technologies 
Mouse β2-microglobulin (B2M) Mm00437762-m1 Life Technologies 
Runt related transcription factor 2 
(Runx2) 
Mm00501584_m1 Life Technologies 
Mouse CTNNB1 mm00483033-m1 Life Technologies 
Mouse COL1A2  Mm00483888-m1 Life Technologies 
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2.15 Bio-Layer Interferometry 
 
 
 
 
Biosensor technology is commonly used the specific and sensitive investigation of 
biomolecular interactions. The Bio-Layer Interferometry (BLI) developed by ForteBio 
(www.ForteBio.com), is amongst the well-established biosensor platforms used to 
evaluate protein/protein interactions in research and routine applications (Wallner, Lhota 
et al. 2013). The BLI technology used by the BLItz® system provides real-time data on 
protein interactions. The BLItz® system emits white light down a biosensor, and the light 
reflected back is then collected by a detector (Figure 2.6). The molecule of interest is 
biochemically bound to the surface of the biosensor, where it forms complexes with 
partner molecules (analyte). The carboxylated biosensor surface allows covalent coupling 
of proteins via N-Hydroxysuccinimide (NHS)/ethyl(dimethylaminopropyl) carbodiimide 
(EDC) mediated amide bond formation. The thickness of the coating on the optical layer 
affects the reflected wavelengths. The wavelength interference, which is categorised as 
constructive or destructive, is captured by a spectrometer and is reported in relative 
intensity units (nm). Changes in the number of molecules bound to the biosensor result in 
changes or ‘shifts’ in the wavelength interference which is measured in real time. The 
interference shifts are a direct measure of the change in optical thickness of the biological 
layer. Based on these principles, a range of kinetic applications are possible including 
protein kinetic and affinity characterisation.   
 
 
  
BLItz analysis    
ITEM SUPPLIER 
Amine reactive 2nd generation (AR2G) 
Biosensor 
ForteBio 
96-well, black, polypropylene flat-bottom 
microplate 
ForteBio 
NHS/EDC  ForteBio 
BLItz® System bioanalyser  ForteBio 
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2.15.1 BLI kinetics 
 
The affinity of one molecule for another is calculated using the association constant (ka) 
and dissociation constant (kd). The ratio of between the kd/ka gives rise to the affinity 
constant KD. The ka is defined as the rate of complex formation per second in a 1 molar 
solution of two reaction partners. The kd (1/s) indicates the stability of this complex. The 
affinity constant KD is calculated by the ratio of the kd/ka (Katsamba, Navratilova et al. 
2006). This relation can be described by a basic equation shown below, where A is the 
analyte and B is the molecule of interest: 
 
 
 
 
 
 
Interferometry data were globally fit to a simple 1:1 Langmuir model (O’Shannessy et al. 
1993), calculating the affinities and rate constants (Octet software, Version 6.4, 
Figure 2.7 – BLItz system: 
The BLItz system emits white 
light down the biosensor, and 
collects reflected light. 
Wavelengths interference are 
constructive interference (blue) 
or destructive (red). 
Interference shifts captured by 
a spectrometer and reported in 
relative intensity units (nm) 
and are a direct measure of the 
change in optical thickness of 
the biological layer. Image 
adapted from 
www.ForteBio.com.  
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ForteBio). This model describes a 1:1 interaction where one ligand molecule interacts 
with one analyte molecule. To produce a complete kinetic prolife for the molecule of 
interest and its associated analyte, the interaction is measured at multiple analyte 
concentration (µg/ml) and the data is used for Langmuir model fitting. Ligand-analyte 
associations were run at an injection period length long enough to observe a curvature of 
the binding response. The association and dissociation responses were baseline corrected 
and processed using the Octet Software (Version 6.4, ForteBio). The individual signal 
responses at each concentration as well as the maximum responses (Rmax) were 
calculated. 
 
2.15.2 Determining protein-analyte interaction using ARG2 biosensors 
 
A BLI assay involves an equilibrium step, ligand immobilization step, analyte association 
and analyte dissociation step (Figure 2.7). An example of loading conditions and curves 
for the association of a target protein (termed ligand) and its specific analyte are shown in 
Figure 2.7. The assay was initiated by establishing the equilibration of Amine reactive 
2nd generation (AR2G) biosensor tips with PBS buffer to measure the baseline signal 
(Step 1). Biosensors were hydrated for 10 minutes prior to use by inserting the biosensor 
into 200μl of PBS buffer within a 96-well microplate. Biosenors were activated with 
EDC/NHS mixture is a tube (Step 2). For the immobilisation step, the protein 
concentrations and loading performance were optimized. Ligand solutions were prepared 
for the loading step to bring to a concentration of 1–100μg/ml. ARG2 biosensor tips were 
captured to saturation with the ligand to obtain a loading signal (Step 3). Subsequently, 
an additional equilibration step was applied with buffer to remove the excess ligand and 
to obtain a constant loading baseline (Step 4). In the final dissociation step, the biosensor 
was ‘quenched’ with quenching solution (Step 5). The sensogram data was collected in 
real time and presented as binding (nm) affinity at the start of ligand-analyte association 
and the start of complex dissociation. The measured affinity of the interaction KD (M) 
between the two proteins was reported by the BLItz Pro™ software.  
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Run Settings  
STEP  STEP TYPE DURATION 
1 Initial Baseline 60 
2 Custom 300 
3 Loading 600 
4 Custom 300 
5 Baseline 120 
6 Association 300 
7 Dissociation 600 
1 2 3 4 5 6 7 
Steps 
Figure 2.8 – BLItz system association/dissociation binding curve sensogram and 
run settings. 
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2.16 Statistical analysis 
 
Statistical analyses were performed with the statistical software package, GraphPad Prism 
6 version 6.0.4 for Windows. Firstly the data were analysed for normal distribution using 
the D'Agostino and Pearson normality test. The data were analysed using an ANOVA test 
(one way analysis of variance) for more than two group comparison. A Holme-Sidak's 
test was used as post-hoc analysis when ANOVA test was used in normal distribution 
data. When data not normally distributed, ANOVA test (non-parametric Kruskal-Wallis 
test) was used for more than two group comparisons. The Dunns test was used as post-
hoc analysis when ANOVA test was used in not normally distributed data. For two group 
comparisons an unpaired student’s t-test was performed when the data was normally 
distributed or non-parametric Mann-Whitney test for two group comparisons in cases 
were data was not normally distributed. Data were considered statistically significant 
when a p-value was equal to or less than 0.05. Results are expressed as mean ± values of 
standard error Mean (SEM). 
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Chapter 3 – In-Vitro Characterisation of the 
Osteoblast Progenitor Model 
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3.1 Introduction 
 
To study the molecular mechanisms involved in the regulation of osteoblast (OB) 
differentiation and mineralisation, I wanted to first establish an in-vitro culture system 
using murine OB progenitor cells derived from calvaria primary bone cells, reflecting the 
different stages of osteogenic maturation from proliferation to differentiation. OB 
progenitor cells isolated from the calvaria of 2-4 days old neonatal C57BL/KaLwRij 
mouse pups were selected for the optimisation of the in-vitro model of osteoblastogensis. 
These cells have been shown to differentiate into cells with a  clear OB phenotype 
including ALP expression and extracellular matrix mineralisation (Ecarot-Charrier, 
Glorieux et al. 1983). OB cells are derived from multipontent mesenchymal stem cells 
(MSC) and regulate the deposition and maintenance of skeletal tissues. The OB 
phenotype is defined by the genes expressed and the proteins produced by the cells. 
Characterising the expression of bone-specific genes and proteins provide valuable 
markers that are characteristic of bone OB phenotype detected in- vitro (Del Fattore, Teti 
et al. 2012).  
 
MSC produce progenitor cells of restricted OB lineage that have the potential to 
proliferate or continue onto amplification stages where they express specific osteoblastic 
markers. MSC committed to an osteo/chondro-progenitor lineage become osteoprogenitor 
cells that subsequently differentiate into pre-osteoblasts, followed by differentiation into 
active mature OB cells (Figure 3.1). Runx2, osterix and β-catenin are essential for OB 
differentiation. Runx2 plays a fundamental role in directing the MSC to an osteoblastic 
lineage instead of an adipocytic or chondrocytic lineage. Once MSC have differentiated 
into pre-osteoblasts, Runx2, osterix and 𝛽-catenin drive differentiation into immature OB 
cells that produce bone matrix proteins, suppressing the cells potential to differentiate into 
the chondrocyte lineage. Runx2 expression prevents the OB cells from developing into 
osteocytes, maintaining them in the OB phenotype (Komori 2006, Sila-Asna, Bunyaratvej 
et al. 2007). Mature OB cells synthesize dense cross-linked collagen in addition to other 
proteins produced in smaller quantities including osteocalcin and osteopontin which make 
up the matrix of the bone. Mature OB produce calcium and phosphate-based minerals in a 
tightly regulated manner.  These minerals are deposited into the organic matrix forming 
the dense and strong mineralarised tissue which forms the matrix. OB mineralisation 
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components such as calcium are commonly used as markers to determine the level of 
mineralisation using chemical staining (Arnett 2003).  
 
Osteoblastic cells are usually cultured in MEM-alpha or DMEM. Studies have shown that 
variations in components and their concentrations added to the media can lead in the 
differences obtained within proliferation and differentiation assays (Coelho and 
Fernandes 2000). Media additives that have been shown to drive osteoblastic cell function 
in culture include dexamethasone, 1,25(OH)2D3, β-glycerophosphate and ascorbic acid 
(Jorgensen, Henriksen et al. 2004). The addition of sscorbic acid to the cell culture media 
is necessary for the hydroxylation of proline and lysine residues in collagen to synthesis 
of collagenous extracellular matrix (Takamizawa, Maehata et al. 2004). In the literature 
50µg/mL of ascorbic acid is generally the standard concentration used in mouse primary 
OB cultures and is a sufficient concentration to upregulate proliferation, collagen and 
ALP expression in these cells. Phosphate substrates are also added to in media and are 
necessary for matrix mineralisation in primary OB cell cultures. Supplementation of 
primary OB cell cultures isolated from mice with 5-10 mM β-glycerophosphate leads to 
spontaneous mineral deposition (Czekanska, Stoddart et al. 2012).  
 
Primary cells isolated from neonatal mice are difficult to isolate and culture routinely.  To 
study molecular mechanisms/signalling in OB cells, fast growing and well characterised 
OB-like cell lines are commonly used. The Sarcoma osteogenic (SAOS2) cell line was 
originally derived from the primary osteosarcoma of an 11 year old Caucasian girl in the 
1973 by Fogh et al and later determined as possessing osteoblastic features which would 
be useful as a permanent line of OB-like cells (Fogh, Fogh et al. 1977, Rodan, Imai et al. 
1987). The SAOS2 cells present a more mature OB phenotype in comparison to primary 
OB progenitor cells, making the SAOS2 cells a good model for studying events 
associated with late OB differentiation stage in human cells (Gundle and Beresford 1995). 
 
It is important to be able to correlate transcription factors, proteins production and 
mineralisation levels to develop a timetable for OB differentiation (Arnett 2003). In this 
chapter I selected gene, protein and mineralisation markers that were clearly established 
markers of OB cell differentiation and analysed these markers across a range of time-
points. The primary aim of this analysis was to create a proliferation, differentiation and 
mineralisation profile for the murine calvarial OB progenitor cultures. This profile could 
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then be used as the foundations for future experimental design and contribute in the 
understanding of the molecular mechanisms involved in OB dysfunction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.1 - Schematic diagram of the osteoblastogenesis: osteoblasts arise from 
MSC which under the required stimuli are driven toward an osteo/chondro-progenitor 
lineage that then differentiate into osteoblast progenitor cells, followed differentiation into 
pre-osteoblasts and finally become active, mature osteoblasts. Mature osteoblasts produce 
calcium and phosphate-based minerals which are deposited into the organic matrix forming 
the mineralised matrix. 
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3.2 Hypothesis and Objectives  
 
3.2.1 Aims 
The aim of this study was to characterise an in-vitro culture system using murine 
osteoblast progenitor cells. 
To achieve this, the following hypothesis was tested. 
 
3.2.1 Hypothesis 
Murine osteoblast progenitor cells differentiate into mature-nodule forming osteoblasts in 
osteogenic media. 
 
3.2.2 Specific Objectives  
 
To test this hypothesis the following were determined: 
 
Determine the conditions under which osteoblast progenitor cells proliferate, differentiate 
and mineralise    
 
Determine which differentiation markers are specific to the different stages of osteoblast 
differentiation  
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3.3 Chapter specific methods 
 
3.3.1 Assessing the relationship between total cell DNA contents and cell number 
 
PicoGreen analysis of total DNA has been frequently used as a surrogate for cell number 
(Kumar, Gittings et al. 2010). In my studies investigating ALP activity of OB progenitor 
cells, the PicoGreen method of determining total DNA contents the cells was to be used 
as a measure of cell number. PicoGreen and Coulter Counter analysis were used to assess 
the direct correlation between total DNA contents per cell and cell number, respectively. 
OB progenitors were used to assess the relationship between total DNA contents and cell 
number. OB progenitor cells were harvested from a near confluent T75 flask following 
trypsinisation, pelleted by centrifugation, resuspended in 10ml of PBS and counted using 
a haemocytometer as described in section 2.1.3.12,500 cells were transferred into 15ml 
BD Falcon™ tubes and counted using a Coulter Counter as described in section 2.1.4 to 
verify the haemocytometer count. The 12,000 cells were serially diluted 1:2 to obtain 
approximate cell densities of 62500, 3125, 1562, 781, 390 and 195 cells.  
 
Using the same batch of OB progenitors, cells of the same densities were also placed into 
1.5ml eppendorfs. Cells were centrifuged at 1000 RPM for 5 minutes to pellet the cells. 
The supernatants were removed and cells lysed with 40µl of Triton-X for 30 minutes at 
room temperature with agitation. 20µl of the cell lysate was transferred into a well within 
a 96 well culture plate. The total DNA contents (ng/ml) of the cell populations in the 96 
well plates were determined with a PicoGreen dsDNA quantitation kit as described in 
section 2.4. Data from the PicoGreen and Coulter Counter assays were exported to an 
excel spreadsheet and the linear regression determined.  
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3.3.2 Determining the optimal FCS concentration in which calvarial osteoblast 
progenitor cells proliferate and differentiate 
 
OB progenitor cells were obtained from bone cell cultures isolated from the calvarias of 
2-4 days old neonatal C57BL/KaLwRij mice using collagenase with the modified time 
sequential enzymatic digestion described by Bakker et al and outlined in detail in the 
main method section 2.1.1 (Bakker and Klein-Nulend 2012). To reduce variability and 
OB phenotypic modifications, all experiments using OB progenitors were carried out with 
cells that had been passaged up to an including passage 4. Mouse calvarial OB progenitor 
cells were harvested from a near confluent flask following trypsinisation. Cells were 
pelleted by centrifugation and counted using a haemocytometer, as described in section 
2.1.3.  
 
To determine the optimal growth conditions under which OB progenitors proliferate and 
differentiate, cells were seeded in 96 well plates at a density of 2000 cells per well. 
Following a 72 hour period in culture, the OB progenitor cells were carefully washed 
once with PBS and the media replaced with 100µl of osteogenic MEM-Alpha media 
containing 0, 0.1, 0.25, 1, 4, 6, 8 or 10 % FCS. Osteogenic Alpha-MEM media containing 
various FCS concentrations were replaced every three days. ALP analysis which was 
used as a marker of differentiation in OB progenitors was carried out on day 8, day 11, 
and day 15 of differentiation. In separate experiments assessing the OB progenitor 
differentiation in the minimum FCS concentration required (4%) by the cells, OB 
progenitors were cultured up to day 19 of differentiation. Total DNA content of OB 
progenitor cultures were also determined with a PicoGreen dsDNA quantitation reagent 
as outlined in section 2.4. Total DNA values were used to normalise ALP activity to total 
cell DNA content, as described in section 2.3.  
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3.3.3 Assessing Runx2, CTNNB1 and COL1A2 gene expression in differentiating OB 
progenitor cells  
 
Runx2, β-catenin and Collagen have been established as gene markers of OB cell 
differentiation in the literature (Beck, Zerler et al. 2001, Prince, Banerjee et al. 2001, 
Matsuo, Tanaka et al. 2008, Baron and Kneissel 2013). The expression of Runx2, 
CTNNB1 (gene ecodin the protein for β-catenin) and COL1A2 (encodes the protein α-1 
type I collagen) genes during the differentiation stages of OB progenitors were assessed 
using qRT-PCR. Mouse calvarial OB progenitor cells were harvested from a near 
confluent flask following trypsinisation. Centrifuged cell pellets were resuspended and 
counted using a haemocytometer, as described in the method section 2.1.3. OB 
progenitors were cultured in 6 well culture plates at a density of 57,000 cells per well in 
standard MEM-Alpha media containing 10% FCS. Cells were differentiated for up to 21 
days in standard MEM-Alpha osteogenic media containing 4% FCS prepared according 
to section 2.2. Following a 72 hour period in culture, OB progenitor cells were washed 
once with PBS per well, and the media replaced with 1.5ml of osteogenic MEM-Alpha 
media. The osteogenic media on the OB progenitors were replaced every three days. 
RNA was extracted from the differentiating OB progenitors on day 8, 11, 15 and 21 of 
differentiation and quantified using a NanoDrop bioanalyser according to section 2.13. 
Following cDNA synthesis from 1000ng of RNA, Runx2, CTNNB1 and COL1A2 gene 
expression were quantified using qRT-PCR analysis as described in section 2.14.  
 
3.3.4 Assessing mineralisation in differentiating osteoblast progenitor cultures 
 
To determine the level of mineralisation in differentiating OB progenitor cells, OB 
progenitor cells were harvested from a near confluent flask by trypsinisation. Cells were 
pelleted by centrifugation and counted using a haemocytometer, as described in section 
2.1.3. Cells were seeded in 48 well culture plates at a density of 5,700 cells per well in 
standard MEM-Alpha containing 10% FCS. Following a 72 hour period in culture, OB 
progenitor cells were carefully washed once with PBS per well, and the media replaced 
with 250µl of osteogenic MEM-Alpha media containing 4% FCS prepared according to 
section 2.2. Osteogenic media in which OB progenitors were differentiating was replaced 
every three days, for up to 21 days. Mineral deposition was used as a marker of 
mineralisation in OB cultures and was assessed using Alizarin red staining on days 8, 11, 
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15 and 21 of OB differentiation as described in section 2.5. Percentage area 
mineralisation of OB cells was quantified per well using ImageJ Software. 
 
3.3.5 Characterisation of differentiated SAOS2 cells culture system 
 
SAOS2 are OB-like cells that have a similar phenotype to primary murine cells and are 
commonly used in studies in OB studies (Czekanska, Stoddart et al. 2012). The SAOS2 
cells have previously been shown to have a mature OB phenotype with high levels of 
ALP activity (Saldana, Bensiamar et al. 2011). In this study I wanted to establish another 
in-vitro OB-like culture system with a more mature OB phenotype to compare to murine 
OB progenitor cells. SAOS2 cells were harvested from a near confluent flask following 
trypsinisation as described in the method section. SAOS2 cells were pelleted by 
centrifugation and counted using a haemocytometer, as described in section 2.1.3.  
SAOS2 cells were seeded in 96 well plates at a density of 2000 cells per well in 100µl of 
standard DMEM media containing 10% FCS. Cells were given 48 hours to adhere to the 
culture surface and DMEM media was removed, washed once with PBS and replaced 
with 100µl of osteogenic-DMEM media containing 10 mM of β-glycerophosphate and 50 
μg/ml of L-ascorbic acid additives as described by Saldana et al (Saldana, Bensiamar et 
al. 2011). SAOS2 cells were differentiated for 8 days and osteogenic-DMEM media was 
replaced every three days. ALP analysis of SAOS2 cells was carried out on days 2, 4, 6 
and 8 of differentiation. Total DNA content of SAOS2 cells per well were also 
determined with a PicoGreen dsDNA quantitation reagent to normalise ALP activity to 
total cell DNA content, as described in sections 2.3 and 2.4.    
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3.4 Results  
 
3.4.1 Total DNA contents within cells determined by PicoGreen analysis correlated 
with cell number 
 
OB progenitors of various cell densities ranging from approximately 12,500 to 200 cells 
were counted using the Coulter Counter and this count was compared to the total DNA 
contents using PicoGreen dsDNA quantitation. The regression analysis between the two 
sets of data obtained from the PicoGreen and Coulter Counter assay showed that as the 
number of cells increased, the total DNA contents per cell also increased linearly  (Figure 
3.4.1,  R=0.094).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.4.1 - Analysis of cell DNA contents correlated with cell number 
determined by Coulter Counter analysis. Coulter Counter analysis of cell number 
showed that an increase in the number of cells correlated with an increase in total DNA 
contents. N=4 independent experiments, Linear Regression analysis. ***P<0.0001, 
R=0.092.  
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3.4.2 Osteoblast progenitor cells differentiate exponentially from 8 to 15 days in 
osteogenic media 
 
To establish an in-vitro primary cell culture system to utilise in future experiments, I 
initially established the optimal growth conditions under which OB progenitors 
proliferated and differentiated. To ensure that the OB progenitor cells used in my studies 
also behaved comparably to those used in the literature under similar conditions, I first 
tested the optimal FCS concentration (%) in which OB progenitor cells proliferated and 
subsequently differentiated. OB progenitors isolated from the calvarias of neonatal pups 
C57BL/KaLwRij mice were differentiated for up to 15 days in osteogenic media 
containing various FCS concentrations ranging from 0 to 10 % FCS. ALP analysis of OB 
progenitors was carried out on day 8, day 11 and day 15 of differentiation and the results 
normalised to total DNA content of OB progenitor cells per well determined with a 
PicoGreen dsDNA quantitation assay.  
 
PicoGreen analysis showed that total DNA of OB progenitor cell in culture plate wells 
increased as FCS concentration increased. The exponential increase in total DNA was 
evident with as little as 4% FCS up to 10% FCS. By day 15 of differentiation, the total 
DNA contents of OB progenitors cultured in 10% FCS no longer increased indicated by 
the plateau phase of the growth curve  (Figure 3.4.2 A). The ALP analysis of OB 
progenitors showed that ALP activity was upregulated with increasing doses of FCS 
during all time points of differentiation, peaking in 10% FCS (Figure 3.4.2 B). 
 
Although I showed that the OB progenitor cultures differentiated optimally in 10% FCS, I 
wanted to carry out future experiments using the minimum dosage of FCS required by the 
cells. The rational for using a minimum FCS dosage and diluting the concentration of 
proteins in the FCS, any effects resulting from treatment with exogenous recombinant 
protein would not be masked. Based on the results in Figure 2.4.2, similar experiments 
were performed in which ALP analysis of OB progenitors cultured in 4% FCS were 
carried out on day 8, day 11 day 15 and 19 of differentiation. The OB progenitor cells 
proliferated and differentiated in 4% FCS concentration (Figure 2.4.2 C, D). The total 
DNA of OB progenitor cultures increased exponentially by approximately 40% 
(~300ng/ml to ~500 ng/ml) from day 4 to day 8 of differentiation. Subsequently, 4% FCS 
concentration was used in subsequent experiments.  
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Figures 3.4.2 - Osteoblasts exponentially differentiate in 4-10% FCS from day 8 
to day 15 of differentiation: The optimal FCS concentration (%) in which OB progenitor 
cells proliferated was determined using PicoGreen analysis of total DNA and the 
differentiation profile determined using ALP analysis. ( A, B) Total DNA increased as FCS 
concentration increased throughout day 8 to day 15 of differentiation. (C, D) OB 
progenitors proliferated and differentiated in a minimum concentration of 4% FCS. N=3 
independent experiments, One-way Anova. Data are displayed with mean ± SEM. **P=0.01, 
***P=0.001. 
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3.4.3 Runx2 and CTNNB1 gene expression decreased and COL1A2 expression 
increased during OB progenitor differentiation 
 
Quantitative RT-PCR was used to assess Runx2, CTNNB1 and COL1A2 gene expression 
during the differentiation of OB progenitors. Cells were differentiated for up to 21 days in 
standard osteogenic media containing 4% FCS. RNA was extracted from the 
differentiating OB progenitors on day 8, 11, 15 and 21 of differentiation. Runx2, CTNNB1 
and COL1A2 gene expression were quantified using qRT-PCR analysis. The qRT-PCR 
analysis showed that Runx2 gene was present at detectable levels on day 8, 11, 15 and 21 
of differentiation in OB progenitor cells. The OB progenitor Runx2 expression was at its 
highest level on day 8 of differentiation and decreased significantly compared to day 11, 
15 and 21 (***P<0.05, Figure 3.4.3 A).There were no differences between the level of 
Runx2 gene expression between day 11 and 21 of differentiation. The CTNNB1 
expression of differentiating OB progenitors was at its highest level on day 8 of 
differentiation and decreased exponentially until day 21 of differentiation (***P<0.001, 
Figure 3.4.3 B). Expression of COL1A2 gene was detected throughout the various time 
points of OB progenitor differentiation. COL1A2 expression did not change between day 
8 and day 11 of differentiation, but the expression decreased on day 15 compared to day 8 
(***P<0.001). Collagen expression of differentiating OB progenitor cells increased on 
day 21 compared to day 8 (*P<0.05) (Figure 3.4.3 C).  
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Average CT values 
 Day 8 Day 11 Day 15 Day 21 
Runx2 21.9 22.0 22.9 23.7 
COL1A2 18.3 18.4 20.3 20.1 
CTNNB1 19.6 20.6 24.4 23.7 
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Figures 3.4.3 - Runx2 and CTNNB1 expression decreased and COL1A2 gene 
expression increased during OB progenitor differentiation: Runx2, CTNNB1 and 
COL1A2 gene expression of differentiating OB progenitors were quantified using qRT-PCR 
analysis and the results normalised to B2M expression and day 8 values. (A) Expression of 
Runx2 within OB progenitor was present at detectable levels on day 8 and 11 of 
differentiation and increased on day 15 and 20. (B) Collagen gene expression was detected 
throughout day 8 to day 21 of OB progenitor differentiation. N=3 independent experiments, 
Unpaired t test. Data are displayed with mean ± SEM. *P=0.05, **P=0.01, ***P=0.001. 
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3.4.4 Osteoblast progenitor cells form visible nodules and mineralise from day 15 of 
differentiation 
 
To determine the level of mineralisation in differentiating OB progenitor cells, OB 
progenitors were differentiated in osteogenic media containing 4% FCS and were stained 
with Alizarin red on days 8, 11, 15 and 21 of OB progenitor differentiation. The 
percentage area of mineralisation in differentiation OB cells was quantified and 
normalised to the day 8 values. Alizarin red staining representative of mineral deposition 
showed that day mineralisation in OB was significant on day 15 and 21 of differentiation 
(***P<0.001). Nodules were visible to the eye on day 15 and 21 of differentiation. 
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Figure 3.4.4 - Osteoblast mineralisation increased from day 15 to day 21 of 
differentiation: OB progenitors were stained with Alizarin red to detect mineralisation on 
days 8, 11, 15 and 21 of OB progenitor differentiation. The percentage (%) area of 
mineralisation in differentiating OB cells was quantified using ImageJ Software and 
normalised to day 8. Mineralisation in OB progenitors was significant on day 15 and 21 of 
differentiation. Nodules were visible to the eye on day 15 and 21 of differentiation. Graph 
and image is representative of one experiment from N=3 independent experiments. 
Unpaired t test. Data are displayed with mean ± SEM. ***P<0.001. 
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3.4.5 SAOS2 cells had high basal levels of ALP activity, indicative of a mature 
osteoblast phenotype  
 
SAOS2 cells were differentiated in osteogenic-DMEM media containing 4% FCS for up 
to 8 days in culture. ALP analysis of SAOS2 cells was carried out on day 2, 4 , 6 and 8 of 
differentiation and the results normalised to total DNA content of SAOS2 cells per well 
determined with a PicoGreen dsDNA quantitation assay. Due to a high rate of 
proliferation, the SAOS2 cells became over-confluent within wells, lifted and died 
beyond the day 4 time point. PicoGreen analysis showed that total DNA of differentiating 
SAOS2 cells increased from day 2 up to day 4 of differentiation (Figure 3.4.5 A). SAOS2 
ALP activity was also upregulated from day 2 to day 4 of differentiation (Figure 3.4.5 B).  
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Figure 3.4.5 - SAOS2 cells proliferated and differentiated up to day 4 of 
differentiation determined by PicoGreen and ALP analysis: SAOS2 cells were 
differentiated in osteogenic-DMEM media containing 4% FCS for up to 8 days in culture. 
ALP analysis was normalised to total DNA contents per well determined with PicoGreen 
quantitation. (A) The total DNA of differentiating SAOS2 cells increased up to day 4 of 
differentiation. (B) ALP activity was upregulated from day 2 to day 4 of differentiation. 
Graph is representative one experiment from N=3 independent experiments. Unpaired t test. 
Data are displayed with mean ± SEM. ***P<0.001. 
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3.5 Discussion  
 
The primary objective of this chapter was to characterise the proliferation, differentiation 
and mineralisation profile of progenitor cells isolated from calvarial primary bone 
cultures obtained from neonatal mice. Characterisation and optimising of an in-vitro 
culture system reflecting the different stages of osteogenic maturation using progenitor 
OB cells was required to understand and validate future experimental data studying the 
molecular mechanisms involved in regulation of osteoblastogensis. Primary murine cells 
are commonly used in the bone cell studies as a source of osteoprogenitors as the cells are 
extracted directly from the bones of animal and there is the possibility of controlling the 
selection of the donor animals. The disadvantages associated with primary cell cultures 
are that there are interspecies and genomic differences and cell phenotype is sensitive to 
age and site of isolation. Although cells lines such as SAOS2 and MC3T3-E1-E1 cells are 
abundant in number and homogeneous in character, they do not reflect the entire range of 
OB phenotypic changes, making  primary OB cultures a more preferable OB model  
(Wang, Christensen et al. 1999, Fernandes, Harkey et al. 2007).  
 
Flourimetric assessment of DNA contents using PicoGreen dye is an established method of 
correlating DNA to cell number that is both sensitive and accurate (Rao and Otto 1992, Otto 
2005). To measure changes in cell number in future OB proliferation studies the PicoGreen 
method was validated to ensure it did correlate to cell number, in line with the literature. The 
Coulter Counter analyser has previously been used to accurately and efficiently determine 
human OB cell numbers in the literature (Slapnicka, Fassmann et al. 2008). OB progenitor 
cells were used to assess the direct correlation between total DNA contents and cell 
number via PicoGreen and Coulter Counter analysis, respectively. The data obtained from 
the PicoGreen and Coulter Counter analyser show that as the number of cells increased, 
the total DNA contents (ng/ml) also increased. These results validate the methodology of 
using PicoGreen analysis of DNA contents as a surrogate for cell number.  
 
The pre-osteoblasts are the first recognisable cell of the differentiating OB lineage.
 
While 
pre-osteoblast maintain their proliferative capacity, they can simultaneously express 
various proteins associated with a more mature OB phenotype, including ALP enzyme 
(Birmingham, Niebur et al. 2012). As a result, ALP is suitable marker to be to be used in 
determining the optimal conditions under which the calvarial OB progenitor cells 
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proliferated and differentiated.  Quantification of DNA contents and ALP enzymatic 
activity of FCS dose response experiments showed that OB progenitor cells proliferate 
and differentiate optimally in 10% FCS from day 8 to day 11 of differentiation. 
PicoGreen analysis of DNA contents and analysis of ALP activity showed that the 
exponential differentiation period of OB cells initiated at approximately day 8 following 
treatment with osteogenic media, and continued increasing up to day 15 and plateaued 
beyond this time-point indicating that OB progenitor cells had differentiated into mature 
OB cells by day 19 of differentiation. Similar results were observed by Hasegawa et al , 
who found that primary calvarial cells increased in cell number up to 10 days in culture and 
the ALP activity of these cells increased up to 15 days in culture (Hasegawa, Shimada et al. 
2008).  I wanted to further determine the minimum concentration of FCS which was 
require for the OB progenitor cells to differentiate in a similar time-frame to those cells 
cultured in the optimal 10% FCS dose. The rational for using a lower dose of FCS in 
osteogenic media relates to future planned experiments investigating the effect of OB 
signalling pathways/molecules, when the levels of growth factors in the FCS may mask 
effects of exposure to recombinant exogenous growth factors. In addition other studies 
have shown that the use of 10% FCS in culture media may lead to reduced ALP and type 
I collagen coupled with increase cell multiplication (Pradel, Mai et al. 2008). From the 
PicoGreen and ALP results, we can infer that OB progenitors exponentially proliferate 
and differentiate within roughly the same time-frame 8 to 15 days in osteogenic media 
containing 4% FCS. Under the light microscope, by day 15 of differentiation the adherent 
OB progenitors present normal morphology in 4% FCS and show no signs of physical 
stress.  
 
Although there are no one set of defined markers of OB differentiation that relate to the 
various stages of OB maturation ranging from osteoprogenitors to mature osteoblast 
phenotype, Runx2 and Collagen are amongst the well characterised. Based on the 
literature, Runx2 gene expression is detectable throughout OB differentiation but is 
suggested to be upregulated in differentiating progenitors and pre-osteoblasts compared to 
mature OB cells (Ducy, Zhang et al. 1997). In line with the literature, the qRT-PCR 
analysis of Runx2 expression showed the high levels of Runx2 on day 8 of OB progenitor 
differentiation reduced during differentiation as cells become mature.  
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In addition to Runx2, Wnt/β-catenin signalling is essential to OB differentiation during 
embryonic development. Conditional inactivation of β-catenin in skeletal progenitors in 
mouse embryos blocked OB differentiation (Day, Guo et al. 2005). The qRT-PCR results 
in this chapter showed that the gene encoding β-catenin, CTNNB1, was expressed at a 
high level in OB progenitor cultures on day 8 of differentiation compared to subsequent 
time points. This data suggests that although β-catenin is required throughout OB 
differentiation, it may have a more predominant role in osteoprogenitors.  Others have 
reported that when β-catenin is inactivated in early skeletal progenitors, low levels of 
Runx2, but not OB differentiation-specific transcription factor Osterix, is detected. 
Reports show that at later stages of OB maturation, the inactivation of β-catenin does not 
inhibit Osterix expression, indicating that β-catenin is not required for Osterix expression 
in OB with a more mature phenotype (Rodda and McMahon 2006, Zhang, Cho et al. 
2008). These results correlate with the decrease in CTNNB1 expression observed during 
OB differentiation in this chapter.  
 
COL1A2 gene expression was also detected throughout the various time points of OB 
progenitor differentiation. However, there were no significant differences or trends 
between the levels of COL1A2 expression on differentiation stage. The level of Type I 
Collagen did appear to increase on day 21 compared to day 8 and this in line with the 
similar qRT-PCR studies by Chitteti et al investigating OB specific bone matrix markers 
in during OB maturation (Chitteti, Cheng et al. 2010).  
  
To further characterise the OB model, the time-point at which differentiating OB 
progenitor cells started to mineralise was determined. Assessment of Alizarin red staining 
of mineral deposits showed that mineralisation in differentiating OB progenitor cells was 
significant on day 15 and 21 of differentiation, with matrix nodules visible to the eye on 
both these occasions. These results are similar in terms of mineralisation time-points to 
the studies carried out by other groups (Hasegawa, Shimada et al. 2008, Kawazoe, Katoh 
et al. 2008). These observations are in context with the results obtained from the ALP 
analysis and gene expression suggesting that the OB progenitor cells acquire a more 
mature phenotype following 2 weeks in osteogenic culture. Based on the optimisation 
studies carried out on murine calvarial OB progenitor cells, it can be concluded these 
cells can be classified as progenitor/pre-osteoblasts up to day 11 of differentiation. 
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Beyond this time point, differentiating OB progenitors presumably amplify into mature 
functional OB cells with the capability of forming mineralised matrix.  
 
The analysis of ALP activity of SAOS2 cells showed that these cells in line with 
information in the literature had a high basal level of ALP, increasing up to day 4 of 
differentiation and decreasing beyond this time point (Rodan, Imai et al. 1987, Pautke, 
Schieker et al. 2004). The more mature OB phenotype of the SAOS2 cells makes this OB 
model adequate for future comparison with the calvarial primary OB progenitor cells. In 
summary, these studies support the hypothesis that OB differentiation is induced in 
murine OB progenitor cultures by treatment with osteogenic media as measured by an 
increase in ALP and mineralisation up to 21 days. The lowest serum concentration that 
reliably supported the growth and differentiation of these cells was 4% FCS. Analysis of 
known genes involved in OB differentiation supported that these were expressed at their 
maximum on day 8 of differentiation with the exception of COL1A2 which did appear to 
increase at day 21.  
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Chapter 4 – SOSTDC1: An antagonist of Wnt 
and BMP signalling in Osteoblast Progenitors 
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4.1 Introduction 
 
In the canonical Wnt pathway, the activation of receptors results in β-catenin stabilisation 
and translocation into the nucleus. Nuclear β-catenin interacts with transcription factors 
such as Tcf or Lef and induces the transcription of target genes (Miller, Hocking et al. 
1999). Wnt-induced stabilisation of β-catenin is suggested to be the basis of the effect of 
Wnt ligands on proliferation and differentiation. Recently it was shown that in postnatal 
humans and mice, loss of function of the Wnt co-receptor LRP5 resulted in decreased 
bone formation (Gong, Slee et al. 2001, Kato, Patel et al. 2002). A point mutation in the 
LRP5 receptor also caused high bone mass (Boyden, Mao et al. 2002).
 
Although these 
studies highlight the crucial role of Wnt-LRP5 signal transduction in bone development, 
the exact mechanisms by which Wnt signalling regulate bone formation remain unclear.  
 
The transcription factor Runx2 plays an important role in OB differentiation (Ducy 2000) 
as mentioned previously. It has been reported that mice deficient in LRP5 express Runx2 
normally (Kato, Patel et al. 2002) which suggests that the mechanism by which LRP5 
regulates OB function is independent of Runx2. Interestingly, although several OB genes 
are controlled by Runx2, ALP is not one of these.  On the other hand, BMP proteins are 
capable of inducing ALP in Mesenchymal Stem Cells (MSC) (Gong, Slee et al. 2001). 
These reports show that Runx2 is relevant to both the Wnt and BMP signalling pathways 
in OB differentiation and can be used as a mutual marker studies investigating the 
molecular mechanisms of Wnt and BMP signalling.  
 
SOSTDC1 has been characterised as a BMP antagonist (Yanagita, Oka et al. 2004). There 
is less information on the effect of SOSTDC1 on Wnt signalling. In contrast to Itasaki et 
al identification of SOSTDC1 as a Wnt-stimulator in their genetic screen (Itasaki, Jones 
et al. 2003), other studies suggested SOSTDC1 can function as an inhibitor of canonical 
Wnt signalling, specifically in relation to Wnt1, Wnt3a and Wnt10 (Yanagita, Oka et al. 
2004, Beaudoin, Sisk et al. 2005). Data implicate that SOSTDC1-Wnt signalling is 
regulated via interactions with Wnt co-receptor LRP5/6 and that SOSTDC1-induced 
BMP inhibition is regulated via direct adhesion to BMP ligands (Lintern, Guidato et al. 
2009).  
 
120  
 
Previous studies have shown that BMP2, 4 and 7-induced alkaline phosphatase (ALP) 
activity was inhibited by Ectodin, the mouse ortholog of SOSTDC1 (Laurikkala, Kassai 
et al. 2003). Similarly recombinant SOSTDC1was found to bind directly to specific 
BMPs and suppress BMP2, -4 and -7 stimulated ALP activity in the mouse myoblast cell 
line, C2C12 (Yanagita, Oka et al. 2004). Taken together, these data provide compelling 
evidence that SOSTDC1 may suppress BMP-induced bone formation. BMP signals are 
regulated through type II and type I serine/threonine kinase receptors and are central for 
signal transduction. The Smad proteins which are type I BMP receptor substrates, are 
involved in transmitting the BMP signal from the receptor to target genes within the 
nucleus (Cho, Kwak et al. 2011). Although the mechanism by which SOSTDC1 inhibits 
BMP activity is unclear, there are suggestions that there is a direct interaction between 
SOSTDC1 and BMP, in which BMP (BMP2, -4 and -7 specifically) is prevented from 
binding to its co-receptors (Yanagita, Oka et al. 2004). There is some evidence of the 
inhibitory effect of SOSTDC1 on BMP action in the dental ectoderm, where SOSTDC1 
expression was shown to suppress BMP2 and BMP7 activity. In a similar study by Ahn et 
al, SOSTDC1 is shown to suppress development of tooth cells via inhibition of LRP5/6–
induced Wnt signalling. SOSTDC1 suppression up-regulated Wnt signalling, stimulating 
proliferation of tooth bud growth in toothless regions (Ahn, Sanderson et al. 2010). The 
evidence taken from Ahn’s studies initiated the rational for a functional role of SOSTDC1 
in BMP and Wnt signalling in OB cells.  
In the previous chapter, I characterised the calvarial OB progenitor model and established 
the time points at which these cells exponentially proliferated and differentiated. In the 
literature, the studies investigating the effect of SOSTDC1 on Wnt/BMP signalling in 
bone have been carried out using cell lines. In my studies I have provided data to support 
the functional role of human recombinant SOSTDC1 (rhSOSTDC1) in Wnt and BMP-
induced differentiation of OB progenitor cells. In this chapter, I initially assessed the dose 
responses of Wnt and BMP ligands on OB differentiation. Based on this, I investigated 
whether SOSTDC1 suppressed differentiation in OB progenitors through disruption of 
Wnt and BMP signalling via mechanisms similar to other known Wnt and BMP 
antagonists.  
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4.2 Hypothesis and Objectives  
 
4.2.1 Aims 
 
The aim of this study was to determine whether Wnt and BMP-induced OB progenitor 
differentiation could be suppressed in the presence of SOSTDC1. 
To achieve this, the following hypothesis was tested. 
 
4.2.1 Hypothesis 
 
SOSTDC1 suppresses Wnt and BMP-induced cell signalling in differentiating OB 
progenitors. 
 
4.2.2 Specific objectives  
 
To test this hypothesis the following were determined: 
 
The effects of Wnt and BMP dose response on OB progenitor proliferation and 
differentiation   
 
The effects of SOSTDC1 on Wnt and BMP-induced markers of OB progenitor 
differentiation  and mineralisation 
 
The effect of SOSTDC1 on Wnt and BMP-induced acute intracellular signalling in 
differentiating OB progenitors  
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4.3 Chapter specific methods 
 
 
 
 
 
 
Table 4.1 - Recombinant protein doses required for sole and combined treatments.  
Recombinant Proteins 
ITEM CATALOGUE  
NUMBER 
SUPPLIER 
Human bone morphogenic protein 2 (BMP2) 10µg/ml  
10µg lyophilised stock Reconstituted in 1ml of sterile 4 mM HCL 
containing 0.1% BSA. 
355-BM-010 R&D 
Systems 
Human bone morphogenic protein 7 (BMP7) 10µg/ml 
10µg lyophilised stock Reconstituted in 1ml of sterile 4 mM HCL 
containing 0.1% BSA. 
354-BP-010 R&D 
Systems 
Mouse Wnt3a  10µg/ml 
10µg lyophilised stock Reconstituted in 1ml of sterile PBS. 
 
1324-WN-002 R&D 
Systems 
Human Sclorstin Domain Containing 1 (SOSTDC1) 
38µg/ml 
Supplied as a 38ug/ml in50 mM Tris-HCI, 10 mM reduced 
Glutathione, pH=8.buffer. 
H00025928-P01 Abnova 
Mouse Dikkopf 1 (Dkk1) 10µg/ml 
10µg lyophilised stock Reconstituted in 1ml of sterile PBS containing 
0.1% BSA. 
5439-DK-010 R&D 
Systems 
Human noggin 25µg/ml 
25µg lyophilised stock Reconstituted in 1ml of sterile PBS containing 
0.1% BSA. 
6057-NG-025 R&D 
Systems 
Human glutatione S-transferase (GST) 200µg/ml 
Supplied at 200µg/ml in 25% Glycerol, 50mM Tris HCl, 150mM 
Sodium chloride, 0.25mM DTT, 0.1mM PMSF, pH 7.5buffer 
ab70456 Abcam  
Recombinant Proteins doses required  
 
 
Recombinant protein  
Treatment 
Dose 
(ng/ml) 
PBS n/a 
Wnt3a 50 
BMP2 30 
BMP7 30 
SOSTDC1 250 
GST 250 
Dkk1 100 
Noggin 100 
Combined Recombinant Protein 
treatments 
 
Recombinant    
protein 
 
Combination 
Recombinant 
Protein  
Wnt3a SOSTDC1 
Dkk1 
GST 
BMP2 SOSTDC1 
Noggin 
GST 
BMP7 SOSTDC1 
Noggin 
GST 
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4.3.1 Assessing Wnt3a and BMP2 and BM7 dose effect on OB progenitor 
differentiation using ALP analysis  
 
ALP enzyme levels were quantified in bone cell cultures to assess the effects of Wnt3a 
and BMP2 and BMP7 proteins at different doses on OB progenitor differentiation. OB 
progenitor cells were seeded in 96 well plates at a density of 2000 cells per well. Cells 
were differentiated for 11 days in standard osteogenic media; exponential differentiation 
time point for the cells was previously determined in section 3.4.2. Following 72 hours in 
culture, cells were carefully washed once with PBS and cultured with 100µl/well of 
osteogenic media containing various concentrations of recombinant mouse Wnt3a 
(rmWnt3a) protein; 0, 10, 30, 50, 100 and 150ng/ml. In separate wells, OB progenitors 
were also treated with 100µl of various concentrations of recombinant human BMP2 
(rhBMP2) or recombinant human BMP7 (rhBMP7); 0, 10, 30, 40, 50 60ng/ml. OB 
progenitor cells which were treated with osteogenic media only were used as control. 
Osteogenic media containing recombinant protein treatments were removed from OB 
progenitor cultures and replaced with 100µl of fresh media and trearment every three 
days. Total DNA content of OB progenitors was determined with a PicoGreen dsDNA 
quantitation reagent as described in section 2.4 and total cell DNA was used to normalise 
ALP activity analysed on day 11 of differentiation according to section 2.3. 
 
4.3.2 Assessing the effect of SOSTDC1 on the ALP activity of differentiating OB 
progenitors 
 
Preliminary experiments were carried out to investigate the dose effect of Glutathione S-
transferase (GST) tagged-rhSOSTDC1 on OB progenitor differentiation, OB progenitors 
were cultured in 96 well plates at a density of 2000 cells per well in MEM-Alpha. 
Following a 72 hour incubation period, OB progenitor cultures were carefully washed 
once with PBS and sub-cultured with 100µl/well of osteogenic media containing various 
doses of rhSOSTDC1:  0, 14, 8, 32, 63, 125, 250 and 500ng/ml. To determine if any 
effect of rhSOSTDC1 observed on OB progenitor differentiation was solely as a result of 
the SOSTDC1 molecules and not the GST tag protein, OB progenitors were also cultured 
with rhGST protein at the same concentrations as rhSOSTDC1 protein-treated cultures. 
OB progenitors were differentiated in osteogenic media for up to 15 days and osteogenic 
media containing the rhSOSDC1 or rhGST proteins were removed from the OB 
progenitor cultures and replaced with fresh media every 3 days. Total DNA content of 
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OB cultures determined using PicoGreen dsDNA quantitation reagent was used as 
surrogate for of cell proliferation. ALP analysis was used as a marker of OB progenitor 
differentiation and performed on cultures on day 8, 11 and 15 of differentiation. 
Calculated PicoGreen values for total cell DNA contents were used to normalise ALP 
activity. Based on the results of the SOSTDC1 dose responses on OB progenitor 
proliferation and differentiation in preliminary studies, the same experiments were 
repeated using a low 50ng/ml and high 250ng/ml dose of rhSOSTDC1 compared to cells 
cultured with PBS control. The experiments were set up in an identical manner to the 
experimental design outlined in the preliminary studies. The objective of these subsequent 
studies was to be able to select an optimal concentration of rhSOSTDC1 to be used in 
future studies.  
 
4.3.3 Determining the effect of SOSTDC1 on Wnt and BMP-induced alkaline 
phosphatase Activity in OB progenitors and SAOS2 cells 
 
Analysis of the ALP activity of OB progenitors was performed to investigate the effect of 
SOSTDC1 on Wnt and BMP-induced cell differentiation. OB progenitors were harvested 
from a near confluent flask following trypsinisation as outlined in the main method 
section. Cells were pelleted by centrifugation and counted using a haemocytometer as 
described in the method section. OB progenitor cells were resuspended in MEM-Alpha at 
2000 cells per well in 96 well culture plates (6000cells/cm
2
). Following a 72 hours period 
in culture, the media was removed from the adherent OB progenitor cultures and the cells 
were washed twice with PBS. Wnt3a protein was diluted to 50ng/ml concentration and 
BMP2/7 diluted to 30ng/ml concentration in a volume of osteogenic media that was 
sufficient for all replicates within plate/s. To test the effect of SOSTDC1 and Dkk1 on 
Wnt3a, osteogenic media containing 50ng/ml of rmWnt3a was combined with either 
250ng/ml rhSOSTSDC1 or 100ng/ml rhDkk1. To test the effect of SOSTDC1 and noggin 
on BMP2/7, osteogenic media containing 30ng/ml of rhBMP2/7 was combined with 
either 250ng/ml rhSOSTSDC1 or 100ng/ml rhnoggin. To establish whether the GST-tag 
attached to the SOSTDC1 molecule had any effect on OB progenitor differentiation, 
rhGST protein was used as a control. In all experiments, osteogenic media containing 
PBS was used as a negative control and 250ng/ml of rhGST at the same dose as the 
corresponding rhSOSTDC1 concentration was used as the vehicle. 100 µl of osteogenic 
media containing the required protein/protein combination was added to each well 
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containing OB progenitor cells. Osteogenic media from the OB progenitors was replaced 
every three days with 100 µl of fresh media containing the required recombinant proteins. 
ALP for OB progenitors was analysed as described in the method section at day 8, 11 and 
15 of differentiation. The total DNA content of OB progenitor cultures were also 
determined with a PicoGreen dsDNA quantitation reagent to normalise ALP activity to 
cell DNA content, as described in the method section.  
 
In previous studies, I investigated the effect of SOSTDC1 on Wnt and BMP-induced 
differentiation in OB progenitors with differentiating potential. I wanted to compare this 
SOSTDC1-induced effect on differentiation in the OB progenitors to the SAOS2 cells 
which have a mature OB phenotype as established in Chapter 3. The same experiment 
design which was used to analyse ALP activity of primary OB progenitor cultures was 
also used to investigate the effect of rhSOSTDC1 on Wnt and BMP-induced 
differentiation in SAOS2 cells. The only difference between the SAOS2 and primary OB 
progenitor culture experiments was that ALP activity of SAOS2 cells was analysed on 
day 4 and 7 of differentiation. The total DNA content of SAOS2 cultures were also 
determined with a PicoGreen dsDNA quantitation reagent to normalise ALP activity to 
cell DNA content, as described in the method section. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 - A time line for ALP and PicoGreen Analysis of OB progenitors 
 
  
OB 
progenitors 
Seeded 2000 
cells/well 
Change osteogenic media containing 
Wnt3a, BMP2, BMP7 in the absence and 
presence of SOSTDC1, Dkk1, noggin 
ALP and PicoGreen Analysis 
0 4 8 11 15 -2 12 
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4.3.4 Determining the effect of SOSTDC1 on Wnt and BMP-induced Runx2 gene 
expression in differentiating OB progenitors 
 
Runx2 expression was used as a second marker of OB progenitor differentiation to 
investigate the effect of SOSTDC1 on Wnt and BMP activity. OB progenitor cells were 
harvested from a near confluent flask by trypsinisation and cell pellets were counted 
using a haemocytometer as described in the method section. OB progenitor cells were 
resuspended in MEM-Alpha at 57,000 cells per well in 6 well culture plates containing 
1.5ml of media within each well. Following 72 hours in culture, the media was removed 
from the adhered OB progenitor culture and cells were washed twice with PBS. OB 
progenitors were differentiated in 1500µl/well of standard osteogenic media for up to 11 
days and osteogenic media was replaced with fresh osteogenic media every three days. 
On day 7 and 10 of differentiation, OB progenitor cultures were treated with recombinant 
protein for 24 hours. The rmWnt3a protein was diluted to 50ng/ml in 65µl of osteogenic 
media in a 0.5ml sterile eppendorfs. The rhBMP2 and rhBM7 proteins were diluted to 
30ng/ml concentration in 65µl of osteogenic media in 0.5ml sterile polypropylene 
centrifuge tubes. 
 
To assess the effect of SOSTDC1 and Dkk1 on Wnt3a, 50ng/ml of rmWnt3a was 
combined with 250ng/ml rhSOSTSDC1 and 50ng/ml of rmWnt3a was combined with 
100ng/ml rmDkk1 in a 65µl volume of osteogenic media. To assess the effect of 
SOSTDC1 and noggin on BMP2/7, 50ng/ml of BMP2/7 was combined with 250ng/ml 
rhSOSTSDC1 or 100ng/ml rhnoggin in a 65µl volume of osteogenic media. All 
eppendorfs containing 65μl of protein/protein combinations were placed in a water bath 
for 1 hour at 37ᴼC to allow interaction between combined proteins. From the 65µl of 
protein/protein combination, 50μl was added to each well containing OB progenitor 
cultures and the media containing protein treatments were mixed gently within wells by 
pipetting. Culture plates were placed in 37ºC culture incubators for 24 hours.  RNA was 
isolated from the OB progenitor cultures using the RNA mini Prep kit and quantified with 
a Nanodrop as described in section 2.12. The expression of Runx2, COL1A2 and 
housekeeper B2M gene were quantified using TaqMan® Assays for qRT-PCR analysis 
using the SDS2.2.1. Relative quantification of gene expression were performed by 
normalising to the house keeping B2M gene using the formula ΔCT = CT target – CT 
housekeeping as described in section 2.13.3.  
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Figure 4.2 - A time line for RNA extraction for the analysis of Runx2 gene expression 
of differentiating OB progenitors by RT-PCR.  
 
  
4.3.5 Determining the effect of SOSTDC1 on Wnt and BMP-induced OB progenitor 
mineralisation  
 
To investigate the effect of SOSTDC1 on Wnt and BMP-induced mineralisation in OB 
progenitor cells, Alizarin red staining was used to detect mineral deposition. OB 
progenitor cultures were harvested from a near confluent flask by trypsinisation. 
Centrifuged cell pellets were counted using a haemocytometer, as described in section 
2.13. OB progenitors cells were resuspended in MEM-Alpha at 5700 cells per well in 48 
well culture plates. Following a 72 hours period in culture, the media was removed from 
the adhered OB progenitor cultures and cells were washed with PBS.  Recombinant 
proteins were diluted to the correct concentrations from their stock solutions in a volume 
of osteogenic media that was sufficient for all replicates within a plate/s. The rmWnt3a 
protein was diluted to 50ng/ml concentration and the rhBMP2/7 diluted to 30ng/ml 
concentration in a volume of osteogenic media that was sufficient for all replicates within 
plate/s. To test the effect of SOSTDC1 and Dkk1 on Wnt3a, osteogenic media containing 
50ng/ml of rmWnt3a was combined with either 250ng/ml rhSOSTSDC1 or 100ng/ml 
rhDkk1. To test the effect of SOSTDC1 and noggin on BMP2/7, osteogenic media 
containing 30ng/ml of rhBMP2/7 was combined with either 250ng/ml rhSOSTSDC1 or 
0 4 8 11 -2 7 10 
OB 
progenitors 
Seeded 2000 
cells/well Treat OB progenitors with Wnt3a, 
BMP2, BMP7 in the absence and 
presence of SOSTDC1, Dkk1, Noggin 
Change osteogenic media  
RNA extraction for RT-PCR 
Runx2 expression 
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100ng/ml rhnoggin. 250 µl of osteogenic media containing protein or protein 
combinations was added to each well. Osteogenic media from the OB progenitors were 
removed every three days and 250 µl of fresh media containing the required protein 
treatments replaced. Alizarin red staining of OB progenitor cultures was carried out and 
quantified on day 8, 11 and 15 of OB progenitor differentiation as described in section 
2.5.  
 
 
 
 
 
  
 
 
 
 
 
Figure 4.3 - A time line for the analysis of differentiating OB progenitor 
mineralisation.  
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4.3.6 Determining the effect of SOSTDC1 on acute Wnt and BMP-induced 
intracellular protein signalling in OB progenitors 
 
 
 
Table 4.2 – Primary and secondary antibodies used in western blotting for investigating 
the effect of SOSTDC1 on acute Wnt and BMP-induced intracellular protein signalling 
in OB progenitors.  
 
 
To investigate the effect of SOSTDC1 on the acute regulation of Wnt and BMP-induced 
intracellular signalling in OB progenitors, phosphorylated Smads 1,5&8 and 
phosphorylated β-catenin protein levels were quantified using western blot analysis. OB 
progenitor cultures were harvested from a near confluent flask using trypsin and cells 
counted using a haemocytometer, as described in section 2.1.3. OB progenitor cells were 
resuspended in MEM-Alpha at 57,000 cells per well in 6 well culture plates containing 
1500μl of media within each well. Following 72 hours in culture, the media was removed 
from the adherent OB cells and cells were washed with PBS. OB progenitors were 
differentiated in 1500µl/well of standard osteogenic media for up to 15 days.  
 
On day 8, 11 and 15 of differentiation, OB progenitor cultures were treated with 
recombinant proteins. The rmWnt3a protein was diluted to 50ng/ml in 65µl of osteogenic 
media in a 0.5ml sterile eppendorf. The rhBMP2 and rhBM7 proteins were diluted to 
Primary and secondary antibodies for western blot 
Antibody CATALOGUE  
NUMBER 
SUPPLIER 
Phospho-Smad1 (Ser463/465)/ Smad5 
(Ser463/465)/ Smad8 (Ser426/428) antibody  
Rabbit polyclonal  
9511 Cell Signalling 
Anti-β-catenin (phospho Y142) antibody 
Rabbit polyclonal  
Ab-27798 Abcam 
Anti-GAPDH (6C5) antibody 
Mouse monoclonal 
Ab-37168 Abcam 
Goat anti-Rabbit  IgG –HRP antibody  
Rabbit IgG 
9511 Life Technologies 
Novex® 
Goat anti-Mouse IgG –HRP antibody  
Mouse IgG 
SC-2031 SantaCruz 
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10ng/ml concentration in 65µl of osteogenic media in a 0.5ml sterile eppendorf. To assess 
the effect of SOSTDC1 and Dkk1 on Wnt3a, 50ng/ml of rmWnt3a was combined with 
250ng/ml rhSOSTSDC1 and 50ng/ml of rmWnt3a was combined with 100ng/ml rmDkk1 
in a 65µl volume of osteogenic media. To assess the effect of SOSTDC1 and noggin on 
BMP2/7, 10ng/ml of BMP2/7 was combined with 250ng/ml rhSOSTSDC1 or 100ng/ml 
rhnoggin in a 65µl volume of osteogenic media. All eppendorfs containing 65μl of 
protein or protein combinations were placed in a water bath for 1 hour at 37ᴼC to allow 
interaction between combined proteins. From the 65µl of protein/protein combination, 
50μl was added to each well containing OB progenitor cultures and the media containing 
protein treatments were mixed gently within wells by pipetting. Culture plates were 
immediately placed in 37ºC culture incubators for 20 minutes.   
 
The protein from OB progenitor cultures were isolated using Mammalian cell lysis kit 
(Sigma Aldrich) containing phosphatase and protease inhibitor cocktails as described in 
section 2.6. Protein concentration within OB progenitor cell lysates were quantified using 
the BCA assay as outlined in section 2.7.  The effect of SOSTDC1 on Wnt-induced 
signalling in OB progenitors was determined by quantifying levels of phosphorylated β-
catenin (92kD). The effect of SOSTDC1 on BMP2 and BMP7-induced signalling in OB 
progenitors was determined by quantification of phosphorylated Smads 1,5&8 protein 
complex (52kD). Phosphorylated levels of β-catenin and Smads 1,5&8 were assessed 
using western blotting as outlined in section 2.8.  
 
In brief, 10% polyacrylamide gels were loaded with 10μg of sample protein. Each gel was 
also loaded with 10µl of a 10-250kD protein molecular marker at the first and last lane. 
Proteins were run through the stacking gel for 40 minutes at 60 Volts and then separated 
out for 2 hours at 100 Volts. Proteins were transferred onto PVDF membranes for 70 
minutes at 70 Volts. Membranes were washed once in 0.05% PBS-Tween and cut across 
at just above the 75kD and just above the 35kD mark using the pre-stained molecular 
markers as reference points. All three pieces of membrane were blocked in 3% BSA 
solution for 45 minutes. The blot cut just above the 35kD mark was placed in a 1/15000 
dilution of anti-GAPDH mouse antibody. The blot cut above 75kD was placed in a 1/300 
dilution of anti-pβ-Catenin rabbit antibody and the blot cut between 50-75kD was probed 
with 1/3000 of rabbit anti-Psmad1,5&8 antibody. Antibody incubations were all carried 
out overnight at 4ᴼC on a roller. Blots probed with anti-GAPDH antibody were incubated 
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with 1/30,000 dilution of secondary HRP-conjugated anti-mouse IgG antibody. Blots 
probed with anti-pβ-catenin or anti-pSmad1,5&8 antibody were incubated with 1/5,000 
dilution of secondary HRP-conjugated anti-rabbit IgG antibody. The average density of 
SOSTDC1 protein was normalised to the average density of GAPDH using the GST-710 
Calibrated Imaging Densitometer.  
 
4.4. Results 
 
4.4.1 Wnt3a, BMP2 and BMP7 dose dependently induced differentiation of OB 
progenitors 
 
PicoGreen quantification and ALP assays were used to analyse the proliferation and 
differentiation of OB progenitors, respectively. In experiments in which differentiating 
OB progenitors were cultured with increasing concentrations of rmWnt3a protein, 
PicoGreen analysis showed that continuous exposure to rmWnt3a induced OB progenitor 
proliferation (***P=<0.0001, Figure 4.4.1.1 A). ALP levels increased dose-dependently 
in differentiating OB progenitor cells cultured with 50 to 150ng/ml rmWnt3a protein, 
with 100ng/ml rmWnt3a maximally increasing ALP  levels (***P=<0.0001 Figure 
4.4.1.1 B).   
 
PicoGreen analysis showed that continuous exposure to rhBMP2 and rhBMP7 stimulated 
OB progenitor proliferation (*P=0.014, ***P=0.0001, Figure 4.4.1.2 A, B). ALP activity 
of OB progenitors treated with rhBMP2 increased in a concentration-dependant manner 
with significant increases in ALP observed from 10-60 ng/ml concentrations (Figure 
4.4.1.2 C). Maximal BMP2-induced ALP upregulation was achieved when differentiating 
OB progenitors were cultured with 40ng/ml of rhBMP2 (***P= <0.0001). Although ALP 
levels rose at >40ng/ml rhBMP2 concentrations compared to control, ALP levels 
plateaued beyond the 40ng/ml treatment of rhBMP2. ALP levels of differentiating OB 
progenitors cultured with rhBMP7 increased in a dose-dependent manner with significant 
increases in ALP observed from 30-50 ng/ml of rhBMP7 (Figure 4.4.1.2 D). Maximal 
BMP7-induced ALP upregulation was observed when OB progenitors were treated with 
50ng/ml of BMP7 (***P= <0.0001) and ALP levels fell beyond this concentration. The 
ALP levels observed as a result of rhBMP2 induction (5-15U/ml/min/ng/ml) were on a 
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comparatively higher scale than the rhBMP7-induced ALP levels (~0.5-1.2 
U/ml/min/ng/ml).  
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Figure 4.4.1.1 - Wnt3a increased ALP activity of differentiating OB progenitors 
in a dose dependent manner: OB progenitor cells were differentiated in osteogenic 
media containing increasing doses of mrWnt3a. PicoGreen quantification of total DNA 
contents and ALP analysis were performed to determine dose effect on cell proliferation and 
differentiation. (A, B) Total DNA contents and ALP activity of differentiating OB progenitor 
cells increased following treatment with Wnt3a in comparison to control and that this effect 
was dose dependent. N=3 independent experiment .One way ANOVA and Holme-Sidak’s 
post-test. Data are displayed with mean ± SEM. ***P<0.0001. 
 
 
 
A 
B 
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Figure 4.4.1.2 - BMP2 and BMP7 increased ALP activity of differentiating OB 
progenitors in a dose dependent manner – OB progenitor cells were differentiated 
in osteogenic media containing increasing doses of rhBMP2 or rhBMP7. PicoGreen 
quantification of total DNA contents and ALP analysis were performed to determine dose 
effect on cell proliferation and differentiation, respectively. Graphs are representative of one 
of two independent experiments. (A, B) rhBMP2 and rhBMP7 induced proliferation of OB 
progenitors. (C, D) OB progenitor ALP levels increased following treatment with rhBMP2 
or rhBMP7 in comparison to control and that this effect was dose dependent. N=3 
independent experiments. One way ANOVA and Holme-Sidak’s post-test. Data are displayed 
with mean ± SEM. *P<0.05, **P=<0.01, ***P<0.0001. 
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4.4.2 SOSTDC1 had no effect on ALP levels of differentiating OB progenitors  
 
ALP analysis was performed to analyse the effect of rhSOSTDC1 on the differentiation 
of OB progenitor cultures. PicoGreen analysis of total DNA contents within cells was 
used to normalise the ALP levels. Based on the preliminary data, I showed that ALP 
levels of differentiating OB progenitors were not affected when cultured with increasing 
concentrations of either rhSOSTDC1 or GST vehicle protein (4-500ng/ml). There was no 
difference in ALP levels of OB progenitors cultured in rhSOSTDC1 compared to GST 
vehicle on any of the day 8, 11 or 15 analysis time-points (Figure 4.4.2 A).  
 
In subsequent SOSTDC1 dose response studies, direct comparisons of the effect 50ng/ml 
SOSTDC1 and 250 ng/ml SOSTDC1 showed that the ALP levels of differentiating OB 
progenitors did not differ in cells cultured with  either concentration (Figure 4.4.2 B).  In 
addition there was no difference between ALP levels of OB progenitors cultured with 
rhSOSTDC1 or PBS control. This effect was applicable throughout all differentiation 
time points  
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Figure 4.4.2 - SOSTDC1 had no 
effect on the activity of primary 
osteoblasts at day 8, day11 or 
day 15: (A) ALP levels of OB 
progenitor cells were not affected 
following treatment with 
rhSOSTDC1 in comparison to GST 
vehicle at any dose. (B) Direct 
comparison of ALP levels in 
differentiating OB progenitors 
cultured in PBS, 50ng/ml 
rhSOSTDC1 or 250 ng/ml of 
rhSOSTDC1 showed that there was 
no difference between any of the 
rhSOSTDC1 doses or between the 
rhSOSTDC1 treated OB progenitors 
and PBS controls. N=3 independent 
experiments, Student’s t-test. Data 
are displayed with mean ± SEM.  
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4.4.3 SOSTDC1 suppressed BMP-induced but not Wnt-induced ALP activity in 
differentiating OB progenitors 
 
Differentiating OB progenitor cells were treated with rhSOSTDC1 in the presence or 
absence of recombinant Wnt3a, BMP2 or BMP7 proteins and differentiation was assessed 
via analyses of OB progenitors ALP activity. OB progenitor cultures were also treated 
with ligands in the presence of a well characterised antagonist specific to that ligand. The 
ALP activity of OB progenitors cultured with 50ng/ml rmWnt3a combined with 
100ng/ml rmDkk1 and 30ng/ml rhBMP2/7 combined with 100ng/ml rhnoggin were 
assessed. To ensure that the GST protein tag attached to the rhSOSTDC1 protein did not 
affect ligand-induced OB progenitor differentiation, each experiment contained a control 
in which 250ng/ml rhGST protein which was added to the Wnt or BMP ligand. ALP 
analysis showed that there were no differences between the ALP activity of rmWnt3a, 
rhBMP2 and rhBMP7 treated with or without rhGST suggesting that any effect of 
rhSOSTDC1 observed was solely due to the rhSOSTDC1 protein, and not the rhGST 
(Appendix 1).  
 
ALP analysis showed that 50ng/ml Wnt3a only had an inductive effect on OB progenitor 
differentiation on day 8 of differentiation (*P= <0.026, Figure 4.4.3.1, A). This Wnt3a-
induced ALP activity was not significant on any other time point during OB progenitor 
differentiation (Fig. 4.4.3.1 B, C). The rhSOSTDC1 had no effect on OB progenitor ALP 
activity when in the presence of rmWnt3a. Canonical Wnt-antagonist Dkk1 similarly had 
no significant effect on Wnt3a-induced ALP activity.  
 
Experiments assessing the effect of rhBMP on OB progenitor ALP activity showed that 
rhBMP2 upregulated ALP activity throughout day 8-11 of OB progenitor differentiation, 
although this effect lessened throughout as the OB progenitor cells matured (Day 8 ***P= 
<0.0001, Day11 **P=0.0051, Figure 4.4.3.2). The rhBMP7 also induced ALP activity of 
OB progenitor cells from day 8-11 of differentiation (Day 8 *P= <0.032, Day11 
*P=0.021, Figure 4.4.3.3). The rhBMP2 and rhBMP7 and had no significant effect on 
OB progenitor cells on day 15 of differentiation. The rhSOSTDC1 had a modest 
suppressive effect on rhBMP2-induced ALP activity on day 8 of differentiation only 
(*P=0.038, Figure 4.4.3.2, A). SOSTDC1 had no effect on rhBMP7-induced ALP 
activity in OB at any time point during differentiation. In the presence of rhBMP2 or 
138  
 
rhBMP7, rhnoggin had a suppressive effect on ALP activity up to day 11 of OB 
progenitor differentiation (BMP2; Day 8 ***P= <0.0002, Day11 *P=0.022, Figure 
4.4.3.2, BMP7; Day 8 **P= <0.006, Day11 *P=0.029, Figure 4.4.3.3).  
 
In similar experiments assessing the effect of SOSTDC1 on Wnt and BMP-induced ALP 
activity in SAOS2 cells, I showed that neither Wnt3a, BMP2 nor BMP7 had any effect on 
ALP activity on any of the differentiation time-points. The 250ng/ml rhSOSTSDC1 did 
not have any effect in the absence or presence of either ligand (Appendix 2).  
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B 
Figure 4.4.3.1 - SOSTDC1 had no effect on Wnt-induced ALP activity in 
differentiating OB progenitors: Differentiating OB progenitors were treated with vehicle 
or 250 ng/ml rhSOSTDC1 and also separately with 50ng/ml rmWnt3a in the presence or 
absence of rhSOSTDC1. (A) OB progenitor cells treated with rmWnt3a had increased ALP 
activity in comparison to PBS control on day 8 of differentiation and neither rhSOSTDC1 or 
rmDkk1had an  effect on Wnt3a-induced ALP activity. (B, C) Wnt3a and SOSTDC1 had no 
effect on day 11 or 15 of differentiation. N=4 independent experiments, One way ANOVA 
and Holme-Sidak’s post-test. Data are displayed with mean ± SEM. *P<0.05. 
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C 
Figure 4.4.3.2 - SOSTDC1 reduced BMP2-induced ALP activity in 
differentiating OB progenitors: OB progenitor cells were treated with vehicle or 
250ng/ml rhSOSTDC1 and also separately with 30ng/ml rhBMP2 in the presence or 
absence of rhSOSTDC1. (A, B) The rhBMP2 induced OB progenitor ALP activity up to day 
11 of differentiation and rhSOSTDC1 reduced rhBMP2 induction of OB progenitor ALP on 
day 8 of differentiation only. rhnoggin strongly suppressed BMP2-induced ALP activity up 
to day 11 of OB progenitor differentiation.  N=4 independent experiments, One way ANOVA 
and Holme-Sidak’s post-test. Data are displayed with mean ± SEM. *=P<0.05, **=P<0.01, 
***=P<0.001 
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Figure 4.4.3.3 - SOSTDC1 had no effect on BMP7-induced ALP activity in 
differentiating OB progenitors: OB progenitors were cultured with vehicle or 250ng/ml 
rhSOSTDC1 and also separately with 30ng/ml rhBMP7 in the presence or absence of 
rhSOSTDC1. (A, B) ALP activity of OB progenitor cultures treated with rhBMP7 increased 
up to day 11 of OB progenitor differentiation. The rhSOSTDC1 protein had no effect on 
rhBMP7-stimulated ALP on any differentiation time point analysed. rhnoggin strongly 
supressed BMP2-induced ALP activity up to day 11 of OB progenitor differentiation N=4 
independent experiments, One way ANOVA and Holme-Sidak’s post-test. Data are displayed 
with mean ± SEM. *=P<0.05, **=P<0.01. 
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4.4.4 SOSTDC1 inhibited Wnt and BMP-induced Runx2 gene expression in 
differentiating OB progenitors 
 
Quantitative RT-PCR was performed to assess to effect of rhSOSTDC1 on Wnt and 
BMP-induced Runx2 gene expression in differentiating OB progenitor cultures. RNA 
from OB progenitor cells was isolated on day 8 and 11 of differentiation following 
protein treatments in culture for 24 hours. Runx2 and housekeeping B2M gene expression 
were quantified using qRT-PCR. Differences in Runx2 gene expression were normalised 
to B2M expression and overall fold changes in gene expression were calculated using the 
ΔΔ-CT method. The effect of 100ng/ml rhDkk1 on rmWnt3a-induced Runx2 expression 
was also assessed as a known Wnt-antagonist control. 100ng/ml noggin was used as a 
known BMP antagonist in experiments investigating Runx2 expression. Data were 
normalised to PBS control. Data obtained from qRT-PCR analysis showed that 250ng/ml 
SOSTDC1 inhibited Wnt3a-induced Runx2 gene expression on day 8 of OB progenitor 
differentiation and this relationship was not statistically significant on any other occasion 
with the differentiation time course (**P=0.0052, Figure 4.4.4.1 A). The rhDkk1 had no 
significant effect on rmWnt-induced Runx2 expression during OB progenitor 
differentiation (Figure 4.4.4.1 A, B).   
Analysis of qRT-PCR analysis showed that rhBMP2-induced Runx2 gene expression on 
day 8 of OB progenitor differentiation and rhSOSTDC1 inhibited this inductive effect 
(**P=0.0047, Figure 4.4.4.2, A).  Furthermore, rhnoggin had a similar effect to 
rhSOSTDC1 in that is also down-regulated rhBMP2-induced Runx2 gene expression 
levels in OB progenitors on day 8 of differentiation (*P=0.049, Figure 4.4.4.2, A).  
Similarly, qRT-PCR showed that rhBMP7 stimulated Runx2 expression in the early 
stages of OB progenitor differentiation and rhSOSTDC1 was able to reverse this effect 
significantly (*P=0.024, Figure 4.4.4.3, A).  The rhnoggin had no effect on Runx2 
expression in OB when in presence of rhBMP7.  
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Wnt3a-Induced Runx2 CT values 
On Day 8 of OB differentiation 
Protein 
Treatment  
Average CT 
Value 
Control (CT) 21.7 
SOSTDC1 22.2 
Dkk1 22.3 
Wnt3a 20.7 
Wnt3a+SOSTDC1 23.0 
Wnt3a+Dkk1 22.5 
Wnt3a-induced Runx2 CT values 
On Day 11 of OB differentiation 
Protein 
Treatment  
Average CT 
Value 
Control (CT) 21.4 
SOSTDC1 22.3 
Dkk1 21.2 
Wnt3a 21.2 
Wnt3a+SOSTDC1 22.4 
Wnt3a+Dkk1 21.6 
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Figure 4.4.4.1 - SOSTDC1 suppressed Wnt3a-induced Runx2 gene expression in 
differentiating OB Progenitors: Differentiating OB cells were treated with 50ng/ml 
rmWnt3a in the presence or absence of 250ng/ml rhSOSTDC1 or 100ng/ml rmDkk1. (A) OB 
progenitors stimulated with Wnt3a resulted in significant induced levels of Runx2 which 
were down-regulated in the presence of rhSOSTDC1 on day 8 of differentiation and (B) not 
day 11. N=4 independent experiments, One way ANOVA and Holme-Sidak’s multiple 
comparisons test. Data are displayed with mean ± SEM. *P=0.05, **P=0.01. 
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BMP2-induced Runx2 CT values 
On Day 8 of OB differentiation 
Protein 
Treatment  
Average CT 
Value 
Control (CT) 21.7 
SOSTDC1 22.2 
Noggin 21.5 
BMP2 21.1 
BMP2+SOSTDC1 21.9 
BMP2+noggin 21.8 
BMP2-induced Runx2 CT values 
On Day 11 of OB differentiation 
Protein 
Treatment  
Average CT 
Value 
Control (CT) 21.4 
SOSTDC1 22.3 
Noggin 20.9 
BMP2 20.8 
BMP2+SOSTDC1 20.9 
BMP2+noggin 22.5 
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Figure 4.4.4.2 - SOSTDC1 suppressed BMP2-induced Runx2 gene expression in 
differentiating OB progenitors: Differentiating OB progenitor cells were treated with 
30ng/ml BMP2 in the presence or absence of 250ng/ml rhSOSTDC1 or 100ng/ml rhNoggin. 
(A) OB progenitors stimulated with rhBMP2 resulted in significant induced levels of Runx2 
which were reduced in the presence of rhSOSTDC1 on day 8 of differentiation and (B) not 
day 11. N=4 independent experiments, One way ANOVA and Holme-Sidak’s multiple 
comparisons test. Data are displayed with mean ± SEM. *P=0.05, **P=0.01. 
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BMP7-induced Runx2 CT values 
On Day 8 of OB differentiation 
Protein 
Treatment  
Average CT 
Value 
Control (CT) 21.7 
SOSTDC1 22.2 
Noggin 21.5 
BMP7 21.2 
BMP7+SOSTDC1 21.8 
BMP7+noggin 21.8 
BMP7-induced Runx2 CT values 
On Day 11 of OB differentiation 
Protein 
Treatment  
Average CT 
Value 
Control (CT) 21.4 
SOSTDC1 22.3 
Noggin 20.9 
BMP7 20.8 
BMP7+SOSTDC1 20.9 
BMP7+noggin 22.5 
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Figure 4.4.4.3 - SOSTDC1 suppressed BMP7-induced Runx2 gene expression in 
differentiating OB progenitors: Differentiating OB progenitor cells were treated with 
30ng/ml rhBMP7 in the presence or absence of 250ng/ml rhSOSTDC1 or 100ng/ml 
rhnoggin. (A) OB progenitor stimulated with BMP7 resulted in significant induced levels of 
Runx2 which were reduced in the presence of rhSOSTDC1 on day 8 and (B) not day 11 of 
differentiation. N=4 independent experiments, One way ANOVA and Holme-Sidak’s 
multiple comparisons test. Data are displayed with mean ± SEM. *P=0.05, **P=0.01. 
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4.4.5 SOSTDC1 suppressed Wnt and BMP-induced OB progenitor mineralisation  
 
Alizarin red staining was used to investigate the effect of rhSOSTDC1 on OB progenitor 
mineralisation in the presence of rmWnt3a, rhBMP2 or rhBMP7. Percentage (%) 
mineralisation relative to area was measured at day 8, day 11 and day 15 of differentiation 
following treatment and values were normalised to PBS control. As in the ALP 
experiments, the effect of 100ng/ml rmDkk1 on mineralisation when in the presence of 
rmWnt3a was used as an antagonist control. 100ng/ml rhnoggin was also used as a known 
BMP antagonist in all mineralisation experiments. When compared to PBS control, 
50ng/ml rmWnt3a stimulated mineralisation of OB progenitor cells on day 8 of 
differentiation which was apparent visually as a result of a darker red colour in staining 
(***P=0.0001, Figure 4.4.5.1 A, C). A trend in Wnt3a-induced OB progenitor 
mineralisation was evident up to day 11, although this was not statistically significant 
using a One-Way Anova test. Addition of rhSOSTDC1 to rmWnt3a treated OB 
progenitors, resulted in a moderate reduction of OB progenitor mineralisation on day 8 of 
differentiation (*P=0.016, Figure 4.4.5.1, A). The rhSOSTDC1 protein did not inhibit 
Wnt3a-induced OB progenitor mineralisation at any further differentiation time-point. 
The rhDkk1 had no suppressive effects on Wnt3a-induced mineralisation on any 
differentiation time-points. Analysis of Alizarin red staining showed that rhBMP2 
significantly induced OB mineralisation up to day 11 of differentiation (Day 8 **P= 
<0.0026, Day11 **P=0.0023, Figure 4.4.5.2). The rhBMP7 also stimulated 
mineralisation in differentiating OB progenitor cells (Day 8 *P= <0.049, Day11 
***P=0.0004, Figure 4.4.5.3). Although not significant, rhSOSTDC1 appeared to have 
some suppressive effect on rhBMP2 and BMP7-induced OB progenitor mineralisation on 
day 8 of differentiation. On day 11 of OB progenitor differentiation, rhSOSTDC1 
significantly inhibited BMP2-stimulated OB progenitor mineralisation (*P=0.044, Figure 
4.4.5.2, B) and also suppressed BMP7-induced OB progenitor mineralisation (*P=0.018 
Figure 4.4.5.3, B). When OB progenitor cultures were treated with rhnoggin in the 
presence of rhBMP2 or rhBMP7, the Alizarin red staining of OB progenitors did appear 
to be reduced visually. However this suppressive effect was not statistically significant at 
any time-point during OB progenitor differentiation. 
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Figure 4.4.5.1 - Wnt3a induced 
mineralisation in OB progenitor cultures 
and SOSTDC1 reduced this effect on 
day 8 of differentiation: OB progenitor 
cells were treated with 250 ng/ml rhSOSTDC1 
or 100ng/ml rmDkk1 and also separately with 
50ng/ml rmWnt3a in the presence or absence 
of SOSTDC1/Dkk1. The image is 
representative of mineralisation on day 11 of 
differentiation. (A) On day 8 of OB progenitor 
differentiation, rmWnt3a induced 
mineralisation and rhSOSTDC1 reduced this 
effect. The rmDkk1 had no significant effect on 
Wnt3a-stimulated mineralisation. (B, C) 
SOSTDC1 had no effect on mineralisation on 
day 11 or 15 of differentiation. N=4 
independent experiments, One way ANOVA 
and Holme-Sidak’s multiple comparisons test. 
Data are displayed with mean ± SEM. 
*P=0.05, ***P=0.001.  
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Figure 4.4.5.2 - BMP2 induced 
mineralisation in OB progenitors and 
SOSTDC1 reduced this effect on day 11 
of differentiation: OB progenitor cultures 
were treated with 250 ng/ml rhSOSTDC1 or 
100ng/ml rhNoggin and also separately with 
30ng/ml rhBMP2 in the presence or absence of 
SOSTDC1/Noggin. The image is representative 
of mineralisation on day 11 of differentiation. 
(A, B, C) The rhBMP2 induced OB progenitor 
mineralisation up to day 15 of differentiation 
and SOSTDC1 reduced this effect significantly 
on day 11 of differentiation only. The rhNoggin 
had no significant effect on BMP2-stimulated 
mineralisation. N=4 independent experiments, 
One way ANOVA and Holme-Sidak’s multiple 
comparisons test. Data are displayed with 
mean ± SEM. *P=0.05, **P=0.01. 
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Figure 4.4.5.3 - BMP7 induced 
mineralisation in OB progenitors and 
SOSTDC1 reduced this effect on day 11 
of OB differentiation: OB progenitor 
cultures were treated with 250ng/ml 
rhSOSTDC1 or 100ng/ml rhnoggin and also 
separately with 30ng/ml rhBMP7 in the 
presence or absence of SOSTDC1/Noggin.  The 
image is representative of mineralisation on 
day 11 of differentiation. (A, B, C) The rhBMP7 
induced OB progenitor mineralisation up to 
day 15 of differentiation and SOSTDC1reduced 
this effect significantly on day 11 of 
differentiation.  The rhnoggin had no 
significant effect on BMP7-stimulated 
mineralisation. N=4 independent experiments, 
One way ANOVA and Holme-Sidak’s multiple 
comparisons test. Data are displayed with 
mean ± SEM. *P=0.05, ***P=0.001. 
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4.4.6 SOSTDC1 inhibited acute Wnt and BMP-induced intracellular signalling  
 
To investigate the effect of SOSTDC1 on Wnt and BMP-induced intracellular signalling, 
downstream signalling molecules of the Wnt and BMP pathways were separately 
assessed following addition of rhSOSTDC1 protein treatment to OB cultures. OB 
progenitor cultures were differentiated for up to 15 days and on days 8, 11 and 15, cells 
were stimulated with single or combination protein treatments for 20 minutes, after which 
OB progenitor cultures were lysed. To assess the effect of rhSOSTDC1 on Wnt-induced 
intracellular signalling, phosphorylated levels of β-catenin (pβ-Catenin) protein were 
measured using western blot analysis. The effect of SOSTDC1 on BMP2 and BMP7-
induced downstream signalling was further determined via quantification of 
phosphorylated levels of Smads 1,5&8 protein using the same western blotting technique. 
100ng/ml rmDkk1 and 100ng/ml rhnoggin were used in all experiments as known Wnt 
and BMP antagonists, respectively. The average density of the bands on the X-ray images 
representing each OB progenitor sample were quantified and normalised to the 
corresponding GAPDH relative density and the calculated values normalised to PBS 
control.  
 
Western blot analysis showed that rhSOSTDC1 in the presence of rmWnt3a, suppressed 
pβ-Catenin protein levels in OB progenitor cultures on day 8 of differentiation 
(**P=0.0059, Figure 4.4.6.1, A, C). Although the post hoc test between the average 
density values of PBS control and rmWnt3a  was not statistically significant, the overall 
trend in pβ-Catenin levels between CT, rmWnt3a and rmWnt3a+rhSOSTDC1 were 
statistically significant on day 8 (**P=0.0092, Figure 4.4.6.1, A). No further inhibitory 
effects of rhSOSTDC1 on Wnt3a-induced pβ-Catenin levels were evident at other time 
points in differentiation. The rmDkk1 protein had no significant effect on Wnt-induced 
pβ-Catenin protein levels. Densitometry showed that rhBMP2 and rhBMP7 both induced 
pSmad 1,5&8 levels on day 8 of differentiation and rhSOSTDC1 reversed this effect 
(BMP2; *P=0.032, Figure 4.4.6.2, BMP7; ***P=0.0002 Figure 4.4.6.3). Similarly, 
rhnoggin also down-regulated BMP-induced pSmad 1,5&8 protein levels in the early 
stages of OB progenitor differentiation (BMP2; *P=0.033, Figure 4.4.6.2, BMP7; 
***P<0.0001 Figure 4.4.6.3).  
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Figure 4.4.6.1 - SOSTDC1 suppressed acute Wnt3a-induced β-catenin 
phosphorylation protein levels in differentiating OB progenitors: Phosphorylated 
levels of pβ-Catenin protein were measured using western blotting. The western blot image 
is representative of one out of three experiments. (A) The rmWnt3a acutely induced pβ-
Catenin protein levels in OB progenitors on day 8 of differentiation and (B, C) not on day 11 
or 15 .N=4 independent experiments, One way ANOVA and Holme-Sidak’s multiple 
comparisons test. Data are displayed with mean ± SEM.*P=0.05, **P=0.01. 
 
 
 
 
 
A B 
C 
E ffe c t  o f  S O S T D C 1
o n  W n t3 a -in d u c e d  O B  p B -C a te n in  le v e ls
o n  D a y  1 5  o f  d iffe re n tia t io n
A
v
e
ra
g
e
 D
e
n
s
it
y
 N
o
rm
a
li
s
e
d
 t
o
 G
A
P
D
H
0 .0
0 .5
1 .0
1 .5
2 .0
W n t3 a S O S T D C 1 D k k 1
+  W n t3 a
 (5 0 n g /m l)
P B S
n s n s
n s
C 
152  
 
 
 
 
 
` 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
E ffe c t  o f  S O S T D C 1
o n  B M P 2 -in d u c e d  O B  p S m a d  le v e ls
o n  D a y  8  o f d if fe re n tia t io n
A
v
e
ra
g
e
 D
e
n
s
it
y
 N
o
rm
a
li
s
e
d
 t
o
 G
A
P
D
H
0
1
2
3
4
**
P B S B M P 2 S O S T D C 1 N o g g in
+  B M P 2
(3 0 n g /m l)
*
E ffe c t  o f  S O S T D C 1
o n  B M P 2 -in d u c e d  O B  p S m a d  le v e ls
o n  D a y  1 1  o f  d iffe re n tia t io n
A
v
e
ra
g
e
 D
e
n
s
it
y
 N
o
rm
a
li
s
e
d
 t
o
 G
A
P
D
H
0 .0
0 .5
1 .0
1 .5
2 .0
P B S B M P 2 S O S T D C 1 N o g g in
+  B M P 2
(3 0 n g /m l)
n s n s
n s
A B 
C 
Figure 4.4.6.2 - SOSTDC1 suppressed acute BMP2-induced phosphorylation of 
Smad 1,5&8 complex levels in differentiating OB progenitors: Phosphorylated 
levels of Smads 1,5&8 (pSmads 1,5&8) protein were measured using western blotting. Data 
represents the average density normalised to GAPDH. The western blot image is 
representative of one of three experiments on day 8 of differentiation. (A) The rhBMP2 
acutely induced pSmad protein levels in OB progenitors on day 8 of early differentiation 
only. The rhSOSTDC1 and rhNoggin inhibited pSmad levels on day 8 of differentiation. (B, 
C) SOSTDC1 had no effect on BMP-2 induced  Smad phosphorylation on day 11 or 15 of 
differentiation. N=4 independent experiments, One way ANOVA and Holme-Sidak’s multiple 
comparisons test. Data are displayed with mean ± SEM.*P=0.05. 
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Figure 4.4.6.3 - SOSTDC1 suppressed acute BMP7-induced phosphorylation of 
Smad 1,5&8 complex levels in differentiating OB progenitors: Phosphorylated 
levels of Smads 1,5&8 (pSmads 1,5&8) protein were measured using western blot analysis. 
The western blot image is representative of one of three experiments on day 8 of 
differentiation. (A) The rhBMP7 acutely induced pSmad protein levels in OB progenitors on 
day 8 of early differentiation only and both rhSOSTDC1 and rhnoggin strongly inhibited 
pSmad levels on day 8 of differentiation. (B, C) SOSTDC1 had no effect on BMP-7 induced  
Smad phosphorylation on day 11 or 15 of differentiation. N=4 independent experiments, 
One way ANOVA and Holme-Sidak’s multiple comparisons test. Data are displayed with 
mean ± SEM. ***P=0.0001. 
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4.5 Discussion  
 
In this chapter, I investigated the effect of rhSOSTDC1 on the Wnt and BMP pathways in 
OB progenitors during various maturation stages of differentiation. The aim of this part of 
the study was to firstly determine whether SOSTDC1 antagonised Wnt and BMP 
signalling in OB progenitors on a similar level to well characterised Wnt and BMP 
antagonists. The second aim was to determine whether any antagonistic SOSTDC1 effect 
observed was dependent on OB maturity. My data support the hypothesis of this 
particular part of the study in that SOSTDC1 suppresses Wnt and BMP-induced cell 
signalling in differentiating OB progenitors. 
 
ALP and Runx2 were selected as well characterised markers of OB differentiation. ALP 
is an early marker of OB differentiation and is secreted by differentiating OB cells. 
Runx2 is an early to mid-marker of OB differentiation and is detected in pre-osteoblasts, 
with the expression increasing in immature OB and decreasing in mature OB (Komori 
2010). OB matrix mineralisation was assessed by detection of mineral deposition by 
quantification of Alizarin red staining as described by Hesegawa et al (Hasegawa, 
Shimada et al. 2008). 
 
Firstly to observe the effects of SOSTDC1 on Wnt/BMP-induced OB progenitor 
differentiation, each experiment contained a control in which GST protein at the same 
concentration as the –GST component of the GST-SOSTDC1 fusion protein was added to 
the ligand. ALP analysis showed that there were no difference between Wnt3a, BMP2 
and BMP7-induced differentiation of OB progenitor cultures treated with or without GST. 
This data confirmed that the GST protein component of the SOSTDC1 molecule had no 
regulatory effect on Wnt3a/BMP-induced OB differentiation. Secondly, as can be seen 
from the presented data demonstrating the effects of potential regulators of OB 
differentiation, systematic and exhaustive experimentation was required over time courses 
in low doses of FCS and specific concentrations of Wnt and BMP molecules and 
antagonists. At least three independent experiments with a minimum of four replicates 
were used in each of analysis.  
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In preliminary experiments investigating the effect of SOSTDC1 on ALP activity of OB 
progenitors, my findings show that SOSTSDC1 has variable effect on OB progenitor 
differentiation depending on cell maturity. In agreement with the literature my findings 
showed that continuous exposure to recombinant Wnt3a, BMP2 and BMP7 induced ALP 
in cultured OB cells (Rawadi, Vayssiere et al. 2003). In the later stages of the OB 
progenitor cell differentiation (day 11 onwards), the same dosage of 50ng/ml Wnt3a and 
30ng/ml BMP2/7 no longer significantly induced differentiation.  Presumably as towards 
the end of the exponential phase of OB progenitor differentiation when differentiation 
potential of cells reaches their peak, OB progenitor cultures require a higher 
concentration of ligand to induce ALP activity. Interestingly in similar experiments 
assessing the effect of SOSTDC1 on Wnt and BMP-induced ALP activity in SAOS2 
cells, I showed that SOSTSDC1 did not have any effect in the absence or presence of 
either Wnt or BMP ligand, even in the very stages of differentiation (Appendix 2) This 
data is not surprising as the SAOS2 cells have a more mature/differentiated OB 
phenotype compared to primary OB progenitor cells and the all the effects of SOSTDC1 
observed in my studies have been in early differentiation time-points.  
 
Similar to the effect Laurikkala, Kassai et al found using MC3T3-E1 cells (Laurikkala, 
Kassai et al. 2003), I showed that SOSTDC1 inhibited BMP2-induced ALP activity. This 
antagonistic effect of SOSTDC1 was only observed in BMP2 and not BMP7-induced 
ALP activity. I further showed that SOSTDC1 had no significant effect on Wnt3a-
induced ALP activity. This differed from the data in the literature, where an inhibitory 
effect of SOSTDC1 was seen in MC3T3-E1 cells over expressing Wnt3a (Rawadi, 
Vayssiere et al. 2003). The contradictory results may be due to the phenotypic differences 
observed between cell-lines and primary OB cells and also the differences in 
methodology. 
 
To compare results obtained from ALP analysis, the more sensitive approach of 
investigating Runx2 gene expression by qRT-PCR was utilised. From the the qRT-PCR 
data I showed that on the early day 8 time point when Runx2 expression is known to be 
high in immature differentiating OB progenitor cells (Prince, Banerjee et al. 2001), 
SOSTDC1 had a clear inhibitory effect on Runx2 when in the presence of recombinant 
Wnt3a, BMP2 or BMP7 proteins.Next the effect of SOSTDC1 on Wnt and BMP-induced 
mineralisation in OB using Alizarin red staining was investigated. Again, the antagonistic 
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effect of SOSTDC1 when in the presence of Wnt and BMP ligands was evident when OB 
progenitor cells were in immature stages of differentiation. Although results indicated 
towards the inhibitory role of SOSTDC1 in OB progenitor differentiation and 
mineralisation, which was in line with the data in the literature, we wanted a clearer 
insight into the molecular mechanisms by which SOSTDC1 interfered with Wnt and 
BMP signalling. To determine whether SOSTDC1 antagonised acute Wnt/BMP 
signalling in OB progenitors, western blotting was used to quantify protein levels 
downstream of either Wnt or BMP signalling pathways. Western blot analysis showed 
that when differentiating OB progenitors were treated with SOSTDC1 in the presence of 
Wnt3a, the protein level of molecular mediator pβ-catenin reduced significantly. 
Similarly, western blotting was used for the quantification of pSmad 1,5&8 protein 
complex levels following treatment with rhSOSTDC1 in the presence of BMP2 or BMP7. 
In line with the literature, addition of recombinant BMP2 and BMP7 for just 20 minutes 
was able to induce pSmad levels in differentiating OB progenitor cells. Addition of 
rhSOSTDC1 to OB progenitor cells was able to effectively reverse BMP-induced Smad 
phosphorylation 
 
Wnt-antagonists such as Dkk1 function by interacting physically with Wnt-receptor 
LRP5/6 and as a result intracellular pβ-catenin protein levels are reduced. In the 
experiments investigating ALP, Runx2 and mineralisation, only a trend in Dkk1-induced 
Wnt3a suppression was observed. Interestingly, where SOSTDC1 inhibitory effects on 
Wnt3a-induced differentiation and mineralisation were significant, Dkk1 appeared less 
effective (no significant effect) in the same experiments. This could mean that LRP5/6 
may have higher affinity for SOSTDC1 in comparison to Dkk1. BMP antagonist noggin 
had variable suppressive effect on OB progenitors throughout differentiation and 
mineralisation. Noggin inhibited BMP-induced ALP activity and Runx2 expression on 
day 8 and 11 of OB progenitor differentiation. Interestingly, the negative effect of noggin 
on OB progenitor mineralisation was not significant at any time point throughout 
differentiation compared to SOSTDC1 in the same experiments.  
 
In this chapter I showed that SOSTDC1 suppressed Wnt-induced differentiation and 
mineralisation in immature OB progenitor cells by blocking the Wnt-signalling pathway. 
I also showed that SOSTDC1 suppressed BMP-induced differentiation and mineralisation 
via interference with the regulation of Smad phosphorylation. Thus, my data support the 
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hypothesis of this particular part of the study in that SOSTDC1 suppresses Wnt and 
BMP-induced cell signalling in differentiating OB progenitors. 
 
It is interesting to note that the suppressive SOSTDC1 effects within this study were only 
observed when OB progenitors were in the presence of Wnt or BMP ligand. 
Immunohistochemical and in situ hybridization analyses carried out as early as the 1970’s 
demonstrated that OB express BMPs and their receptors during bone formation, skeletal 
development and fracture repair (Helder, Ozkaynak et al. 1995, Lyons, Hogan et al. 1995, 
Yamaguchi, Komori et al. 2000). The canonical Wnt proteins have been shown to induce 
OB differentiation (Westendorf, Kahler et al. 2004, Kubota, Michigami et al. 2009). 
These studies correlate with data that indicate towards SOSTDC1’s regulatory role on OB 
is evident when BMP and Wnt protein levels in OB are very high.  
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Chapter 5 – SOSTDC1 is a Dual Regulator of 
Wnt-BMP Crosstalk 
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5.1 Introduction 
 
In the regulation of differentiation and haemostasis, it is highly likely that the actions of 
one signalling pathway can influence that of others, resulting in cellular responses that 
differ from the one achieved by just one single signalling cascade. The availability of 
intrinsic factors including cofactors and target genes, and the link between signalling 
pathways amplifies both the level and complexity of cell responses. The dependency 
between two signalling pathways is often referred to as the “crosstalk” of multiple 
signalling pathways. The Wnt and BMP signalling pathways are function independently 
of each other according to their own unique ligands, receptors and cytoplasmic/nuclear 
signal transducers, without requiring components of the other pathway. However recent 
studies have shown that in some biological contexts there is evidence of Wnt-BMP 
crosstalk. Depending on the cellular context, this Wnt-BMP crosstalk is found to be either 
synergistic or antagonistic (Azpiazu et al.,1996; Carmena et al.,1998). For example, in 
early Xenopus embryos, Wnt8 and BMP4 are co-expressed in overlapping domains and 
are both reliant on each other to regulate normal vertebrate development (Hoppler and 
Moon,1998). On the other hand, Wnt signalling is required for melanocyte development, 
whereas BMP signalling represses melanogenesis (Jin et al.,2001).  
 
In bone formation, Wnt and BMP pathways function cooperatively. The activation of Wnt 
signalling stimulates the differentiation of pluripotent MSC into OB progenitors and 
maintains the precursor lineage of these osteoprogenitors. BMP signalling then stimulates 
these cells to further differentiate into OB cells. Once the OB progenitors have become 
mature functional OB cells, both the Wnt and BMP pathways induce differentiation, 
evidenced by increased ALP activity and mineralization (Bain, Muller et al. 2003, Hill, 
Spater et al. 2005). Studies have shown the interaction between BMP and Wnt signalling 
results in synergistic effects on OB differentiation and bone development (Fukuda, 
Kokabu et al. 2010). Zhou et al showed BMP2 increased the nuclear β-catenin levels and 
the expression of Wnt15, 3a, 5b in pre-osteoblastic cell (Zhou 2011). The same group 
also showed that β-catenin directs osteogenic lineage allocation by enhancing MSC 
responsiveness to BMP-2 via Tcf/Lef response elements (TREs). This synergism is 
known to increase new bone formation in-vivo (Mbalaviele and Sheikh et al, 2009).   
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Various molecular studies have shown that the functional communication which exists 
between Wnt and BMP signalling pathways involves several mechanisms. On an 
intracellular level, Smads have been shown to form complexes with molecules 
downstream of the Wnt signalling pathway including β-catenin, Dishevelled-1, Axin and 
GSK3. The formation of these complexes consequently regulates the phosphorylation and 
activity of Smads and β-catenin (Edlund, Lee et al. 2005, Liu, Tang et al. 2006, 
Fuentealba, Eivers et al. 2007). Interestingly, the transcriptional regulation of Wnt and 
BMP common target genes can involve both Smad and TREs. In response to BMP-Wnt 
dependent signalling the Smads can form transcriptional complexes with β-
catenin/Tcf/Lef and co-activate transcription of various target genes including Msx2 and 
Myc via these binding elements (Hussein, Duff et al. 2003, Hu and Rosenblum 2005).  
 
Some extracellular proteins, such as sclerostin, cerberus and sFRPs, are known to bind 
ligands and/or receptors of both the BMP and Wnt pathways (Piccolo, Agius et al. 1999, 
Kusu, Laurikkala et al. 2003, Misra and Matise 2010). Data suggests that SOSTDC1-Wnt 
signalling is regulated via interactions with Wnt co-receptor LRP5/6 and that SOSTDC1-
induced BMP inhibition is regulated via direct adhesion to BMP ligands (Lintern, 
Guidato et al. 2009). X-raycrystallography  has revealed that the SOSTDC1 protein 
consists of 3 cystine loops, 2 of which provide stability whilst the third has a functional 
role in receptor/ligand binding, specifically binding to LRP5/6 (Avsian-Kretchmer and 
Hsueh 2004). Lintern’s study showed SOSTDC1 deletion construct lacking the LRP-
specific loop domain still bound BMP4 and consequently inhibited BMP signalling 
(Lintern, Guidato et al. 2009). This data suggests that SOSTDC1 may function 
simultaneously as a dual Wnt and BMP antagonist. However, to my knowledge no studies 
have investigated the regulatory role of SOSTDC1 in Wnt-BMP cooperative signalling in 
OB progenitors. In light of my previous data suggesting SOSTDC1 down-regulated both 
Wnt and BMP signalling in OB progenitor cultures at early stages of differentiation, the 
objective of this study were to investigate the potential regulatory role of SOSTDC1 in 
the cooperative mechanisms between Wnt and BMP signalling in differentiating OB 
progenitors. In this study I also assessed the strength of the molecular interactions of 
SOSTDC1-LRP receptor and SOSTDC1-BMP ligands to provide clearer insight into the 
regulatory role of SOSTDC1 on Wnt-BMP dependent signalling.   
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5.2 Hypothesis and Objectives  
 
5.2.1 Aims 
The aim of this study was to determine whether SOSTDC1 had an antagonistic effect on 
Wnt-BMP dependent signalling within OB progenitor cells  
To achieve this, the following hypothesis was tested. 
 
5.2.2 Hypothesis 
 
SOSTDC1 suppresses Wnt-BMP crosstalk in signalling OB progenitor cells. 
 
5.2.3 Specific objectives  
 
To test this hypothesis the following were determined: 
 
Whether intracellular downstream signalling molecules of Wnt and BMP pathways in OB 
progenitor cells are dependent on each other 
 
The effect of SOSTDC1 on Wnt and BMP-induced acute intracellular signalling in OB 
progenitors 
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5.3 Chapter specific methods 
 
 
Table 5.1 - Recombinant proteins required for investigating the effect of SOSTDC1 on 
Wnt-BMP dependent signalling in OB progenitors. 
 
 
 
 
 
 
 
 
 
Table 5.2 - Recombinant protein doses required for sole and combined treatments to 
investigate the effect of SOSTDC1 on Wnt-BMP dependent signalling in OB 
progenitors.   
Recombinant Proteins 
ITEM CATALOGUE  
NUMBER 
SUPPLIER 
Human bone morphogenic protein 2 (BMP2) 
10µg/ml  
10µg lyophilised stock Reconstituted in 1ml of sterile 4 mM HCL 
containing 0.1% BSA. 
355-BM-010 R&D 
Systems 
Human bone morphogenic protein 7 (BMP7) 
10µg/ml 
10µg lyophilised stock Reconstituted in 1ml of sterile 4 mM HCL 
containing 0.1% BSA. 
354-BP-010 R&D 
Systems 
Mouse Wnt3a  10µg/ml 
10µg lyophilised stock Reconstituted in 1ml of sterile PBS. 
1324-WN-002 R&D 
Systems 
Human Sclorstin Domain Containing 1 (SOSTDC1) 
38µg/ml 
Supplied as a 38ug/ml in50 mM Tris-HCI, 10 mM reduced 
Glutathione, pH=8.buffer. 
H00025928-P01 Abnova 
Human glutatione S-transferase (GST) 200µg/ml 
Supplied at 200µg/ml in 25% Glycerol, 50mM Tris HCl, 150mM 
Sodium chloride, 0.25mM DTT, 0.1mM PMSF, pH 7.5buffer. 
ab70456 Abcam   
Mouse Dikkopf 1 (Dkk1) 10µg/ml 
10µg lyophilised stock Reconstituted in 1ml of sterile PBS 
containing 0.1% BSA. 
5439-DK-010 R&D 
Systems 
Human noggin 25µg/ml 
25µg lyophilised stock Reconstituted in 1ml of sterile PBS 
containing 0.1% BSA. 
6057-NG-025 R&D 
Systems 
Combined Recombinant Protein 
treatments 
Recombinant    
protein 
 
Combination 
Recombinant Protein  
Wnt3a SOSTDC1 
Dkk1 
BMP2 SOSTDC1 
Noggin 
BMP7 SOSTDC1 
Noggin 
Recombinant Protein doses 
Recombinant protein  
Treatment 
Dose 
(ng/ml) 
PBS n/a 
Wnt3a 50 
BMP2 30 
BMP7 30 
SOSTDC1 250 
Dkk1 100 
Noggin 100 
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5.3.1 Determining the effect of SOSTDC1 on Wnt-BMP dependent intracellular 
protein signalling in differentiating OB progenitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3 - Recombinant protein doses required for sole and combined treatments to 
investigate the effect of SOSTDC1 h on Wnt-BMP dependent signalling in OB 
progenitors. 
 
 
The objective of the first part of this chapter was to establish whether intracellular Wnt 
signalling was dependent on BMP signalling. At the same time I also wanted to determine 
whether SOSTDC1 had a regulatory role on potential Wnt-BMP dependency.  OB 
progenitor cultures were harvested from a near confluent flask using trypsin and cells 
counted using a haemocytometer, as described in section 2.1.3. OB progenitors were 
resuspended in MEM-Alpha at 57,000 cells per well in 6 well culture plates containing 
1500μl of media within each well. Following 72 hours in culture, the media was removed 
from the adherent OB progenitors and cells were washed with PBS. OB progenitors were 
differentiated in 1500µl/well of standard osteogenic media for up to 15 days and 
osteogenic media was replaced with fresh media every three days. On day 8, 11 and 15 of 
differentiation, OB progenitor cultures were treated with recombinant proteins on day 8, 
11 and 15 of differentiation. The rmWnt3a protein was diluted to 50ng/ml in 65µl of 
osteogenic media in a 0.5ml sterile eppendorf. The rhBMP2 and rhBM7 proteins were 
diluted to 10ng/ml concentration in 65µl of osteogenic media in 0.5ml sterile eppendorfs. 
Primary and Secondary antibodies for western blot 
ITEM CATALOGUE  
NUMBER 
SUPPLIER 
Phospho-Smad1 (Ser463/465)/ Smad5 
(Ser463/465)/ Smad8 (Ser426/428) 
antibody  
Rabbit polyclonal  
9511 Cell Signalling 
Anti-β-catenin (phospho Y142) 
antibody 
Rabbit polyclonal  
Ab-27798 Abcam 
Anti-GAPDH (6C5) antibody 
Mouse monoclonal 
Ab-37168 Abcam 
Goat anti-Rabbit  IgG –HRP antibody  
Rabbit IgG 
9511 Life Technologies 
Novex® 
Goat anti-Mouse IgG –HRP antibody  
Mouse IgG 
SC-2031 SantaCruz 
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50ng/ml of rmWnt3a was combined with 250ng/ml rhSOSTSDC1 and 50ng/ml of 
rmWnt3a was combined with 100ng/ml rmDkk1 in a 65µl volume of osteogenic media. 
In separate tubes, 10ng/ml of rhBMP2 or rhBMP7 was combined with 250ng/ml 
rhSOSTSDC1 or 100ng/ml rhnoggin in a 65µl volume of osteogenic media. All 
eppendorfs containing 65μl of protein/protein combinations were placed in a water bath 
for 1 hour at 37ᴼC to allow interaction between combined proteins. From the 65µl of 
protein/protein combination, 50μl was added to each well containing OB progenitor 
cultures and the media containing protein treatments were mixed gently within wells by 
pipetting. 6 well culture plates were immediately placed in 37ºC culture incubators for 20 
minutes.  The protein from OB progenitor cultures were isolated using Mammalian cell 
lysis kit containing phosphatase and protease inhibitor cocktails as described section 2.6. 
Protein concentrations within OB progenitor cell lysates were quantified using the BCA 
assay as outlined in the method section 2.7. 
 
The effect of Wnt3a ligand on downstream intracellular BMP signalling was tested via 
quantification of Wnt3a-induced phosphorylated levels of Smad 1,5&8 protein complex 
(52kD). The effect of BMP2 and BMP7 ligand on downstream intracellular Wnt 
signalling was determined by quantifying the level of BMP-induced phosphorylated β-
catenin protein (92kD). The influence of SOSTDC1 on Wnt-induced Smad 
phosphorylation and BMP-induced β-catenin phosphorylation in differentiating OB 
progenitors was determined by western blotting as outlined in section 2.8.  
 
In brief, 10% polyacrylamide gels were loaded with 10μg of sample protein. Each gel was 
also loaded with 10µl of a 10-250kD protein molecular marker at the first and last lane 
and the proteins were run through the stacking gel for 40 minutes at 60 Volts. Proteins 
were separated with the separating gel according to their molecular weight for 2 hours at 
100 Volts. Proteins were transferred onto PVDF membranes for 70 minutes at 70 Volts. 
Membranes were washed once in 0.05% PBS-Tween. Membranes were blocked in 3% 
BSA solution for 45 minutes. Transferred proteins from Wnt-induced OB progenitor cell 
lysates were cut just below the 50kD mark using the pre-stained molecular markers as 
reference points and then incubated with 1/3000 of rabbit anti-Psmad1,5&8 antibody. 
Transferred proteins from BMP-induced OB progenitor cell lysates were cut just above 
the 75kD mark and incubated with a 1/300 dilution of anti-pβ-Catenin rabbit antibody. 
The remainder of the blot containing proteins <50kD was placed in a 1/15000 dilution of 
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anti-GAPDH mouse antibody. Antibody incubations were all carried out overnight at 4ᴼC 
on a roller. Blots incubated with anti-pβ-catenin or anti-pSmad1,5&8 antibody were 
probed with 1/5,000 dilution of secondary HRP-conjugated anti-rabbit IgG antibody. 
Blots incubated with anti-GAPDH antibody were incubated with 1/30,000 dilution of 
secondary HRP-conjugated anti-mouse IgG antibody. Protein bands were visualised and 
the average density quantified using GelDoc software. The average density of SOSTDC1 
protein was normalised to the average density of GAPDH to account for any loading 
variability.  
 
5.3.2 Determining the effect of SOSTDC1 on Wnt-BMP dependent CTNNB1 gene 
levels in differentiating OB progenitors 
 
To investigate the effect of SOSTDC1 on BMP-induced Wnt signalling in differentiating 
OB progenitors on a gene expression level, CTNNB1 (the gene encoding β-catenin 
protein) was determined using qRT-PCR as described in section 2.14.3. Wnt3a-induced 
CTNNB1 expression was also assessed as a positive control for CTNNB1 expression.  OB 
progenitor cells were harvested from a near confluent flask by trypsinisation and cell 
pellets were counted using a haemocytometer as described in section 2.1.3. OB 
progenitor cells were resuspended in MEM-Alpha at 57,000 cells per well in 6 well 
culture plates containing 1.5ml of media within each well. Following 72 hours in culture, 
the media was removed from the adhered OB progenitor culture and cells were washed 
with PBS. OB progenitors were differentiated in 1500µl/well of standard osteogenic 
media for up to 11 days and osteogenic media was replaced with fresh media every three 
days. On day 7 and 10 of differentiation, OB progenitors were cultured with recombinant 
protein for 24 hours. To determine the effect of Wnt and BMP on CTNNB1 expression in 
differentiating OB progenitors, rmWnt3a protein was diluted to 50ng/ml in 65µl of 
osteogenic media in a 0.5ml sterile eppendorf. The rhBMP2 or rhBM7 proteins were 
diluted to 30ng/ml concentration in 65µl of osteogenic media in 0.5ml sterile eppendorfs.  
To assess the effect of SOSTDC1 and Dkk1 on Wnt3a-induced CTNNB1 expression, 
50ng/ml of rmWnt3a was combined with 250ng/ml rhSOSTSDC1 and 50ng/ml of 
rmWnt3a was combined with 100ng/ml rmDkk1 in 65µl volumes of osteogenic media. 
The effect of SOSTDC1 and noggin on BMP2/7-induced CTNNB1 levels were assessed 
by combining 50ng/ml of rhBMP2/7 with 250ng/ml rhSOSTSDC1 or 100ng/ml rhnoggin 
in a 65µl volume of osteogenic media. All eppendorfs containing 65μl of protein 
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sample/protein combinations were placed in a water bath for 1 hour at 37ᴼC to allow 
interaction between combined proteins. From the 65µl of protein sample/protein 
combination, 50μl was added to each well containing OB progenitor cultures and mixed 
gently within wells by pipetting. Culture plates were placed back in 37ºC culture 
incubators for 24 hours.  
 
 RNA was isolated and quantified from the OB progenitor culture as described in section 
2.13. The CTNNB1 and B2M gene expression were quantified using TaqMan® Assays for 
qRT-PCR analysis using the SDS2.2.1. Relative quantification of CTNNB1 expression 
was performed by normalising to the house keeping B2M gene using the formula ΔCT = 
CT target – CT housekeeping as described in section 2.13.3.   
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5.3.3 Determining the affinity (KD) of recombinant SOSTDC1 for LRP-6, BMP2 
and BMP7 by Bio-layer interferometry  
 
 
 
Table 5.4 - Recombinant proteins required for determining the affinity of SOSTDC1 
for LRP-6, BMP2 and BMP7 by Bio-layer interferometry 
 
 
The affinity of Wise, the mouse orthologue to SOSTDC1 for LRP-6 receptor, BMP2 and 
BMP7 ligands has been previously been tested using BIAcore technology and 
Immunoprecipitation analysis (Laurikkala, Kassai et al. 2003). However to my 
knowledge, there are currently no reported KD values associated with the binding affinity 
of rhSOSTDC1 for LRP-6, BMP2 or BMP7. In this study the affinity of rhSOSTDC1 
protein for LRP-6, BMP2 and BMP7 was determined using the Bio-layer Interferometry 
technology of the Blitz Analysis system according to section 2.15. 
 
Briefly, all recombinant proteins were purchased in the carrier-free state in a lyophilised 
form. The rmLRP-6 protein was reconstituted to 100µg/ml concentration in the 
recommended buffer. The rhBMP2 and rhBMP7 proteins were reconstituted to 100µg/ml 
concentration in the recommended buffer. Recombinant protein samples were prepared in 
their corresponding buffers to 1, 10, 25, 50 and 100 µg/ml (neat) concentrations within 
sterile 0.5ml eppendorfs. 100 µg/ml of rhSOSTDC1 was immobilized on a pre-hydrated 
disposable ARG2 biosensor. For each SOSTDC1-analyte binding assay, a blank (buffer 
only) negative control was also performed to establish any non-specific binding.  
 
Recombinant Proteins 
ITEM CATALOGUE  
NUMBER 
SUPPLIER 
CF Human bone morphogenic protein 2 
(BMP2) 10µg  - lyophilised 
355-BM-010-CF R&D 
Systems 
CF Human bone morphogenic protein 7 
(BMP7) 10µg -  lyophilised 
354-BP-010-CF R&D 
Systems 
CF Mouse Wnt3a  10µg/ml 
Lyophilised 
1324-WN-002-
CF 
R&D 
Systems 
Human Sclorstin Domain Containing 1 
(SOSTDC1) 38µg/ml 
H00025928-P01 Abnova 
Human glutatione S-transferase (GST) 
200µg/ml 
. 
ab70456 Abcam   
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Eppendorf tubes containing LRP-6, BMP2 or BMP7 recombinant proteins in their various 
concentrations were placed on the Blitz Analyser one at a time starting with the highest 
100 µg/ml concentration. The rhSOSTDC1-coated ARG2 biosensor was placed into an 
eppendorf containing the analyte (LRP-6, BMP2 or BMP7 recombinant proteins). The 
molecular interaction between rhSOSTDC1 and decreasing concentrations of the protein 
analyte were assessed one at a time using the BLItz Pro™ software. The ARG2 
Biosensors were replaced following the assessment of the association of rhSOSTDC1 
with each concentration of analyte. Due to the fact that the rhSOSTDC1 had a GST-tag, 
the binding interaction between rhGST protein and rmLRP-6, rhBMP2 and rhBMP7 was 
also assessed as a control. The 100µg/ml rhGST protein was immobilised on an ARG2 
disposable biosensor and the binding affinity of rhGST for 100µg/ml of rmLRP-6, 
rhBMP2 or rhBMP7 assessed. The sensogram data was collected in real time and 
presented as binding (nm) affinity at the start of rhSOSTDC1-analyte association and the 
start of complex dissociation. The measured affinity of the interaction KD (M) between 
the two proteins was reported by the BLItz Pro™ software as outlined in section 2.15.1  
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5.4 Results  
 
5.4.1 SOSTDC1 down regulated Wnt-BMP dependent intracellular in differentiating 
OB progenitors 
 
Western blotting was performed to determine whether Wnt3a upregulated Smad 
phosphorylation downstream of the BMP signalling pathway in differentiating OB 
progenitors. Wnt-induced levels of phosphorylated Smads1,5&8 protein were quantified 
as the average density of the bands on x-ray images and normalised to the corresponding 
GAPDH relative density. Western blot analysis showed that 50ng/ml Wnt3a acutely 
induced pSmad1,5&8 protein levels in differentiating OB progenitors and this effect was 
significant on day 8 of differentiation (Figure 5.4.1.1 A, *P<0.05).  In the same 
experiments, the effect of SOSTDC1 and Dkk1 on Wnt3a-induced Smad phosphorylation 
was assessed. I showed rhSOSTDC1 and rhDkk1 both suppressed Wnt3a-induced pSmad 
1,5&8 protein levels on day 8 of OB progenitor differentiation (Figure 5.4.1.2 A, 
*P<0.05).  The pSmad protein levels within OB progenitors were not affected in the 
presence of rhSOSTDC1 or rmDkk1 (Figure 5.4.1.2 D).  
 
The effect of BMP ligands on downstream canonical Wnt signalling was assessed by 
western blotting. The level of β-Catenin phosphorylation within differentiating OB 
progenitors was assessed following stimulation with rhBMP2 or rhBMP7 protein. I 
showed that both rhBMP2 and rhBMP7 were able to induce pβ-Catenin protein levels 
downstream of the Wnt signalling pathway (Figure 5.4.1.3 A and B 5.4.1.5 B, *P<0.05). 
The BMP2-induced phosphorylation of β-Catenin protein levels was significant on day 8 
and day 11 of differentiation whereas BMP7-induced pβ-Catenin levels significantly on 
day 11 only (*P<0.05). Within the same experiments, the effect of SOSTDC1 and noggin 
on BMP-induced phosphorylation of β-Catenin protein was assessed using western 
blotting. I showed rhSOSTDC1 and rhnoggin both suppressed BMP2-induced pβ-Catenin 
levels on day 8 and 11 of OB progenitor differentiation (Figure 5.4.1.4 A, *P<0.05). The 
rhSOSTDC1 and rhnoggin recombinant proteins also suppressed BMP7-induced pβ-
Catenin levels on day 11 of OB progenitor differentiation (Figure 5.4.1.6 B, *P<0.05).  
The phosphorylated levels of β-Catenin protein within OB progenitors were not affected 
in the presence of rhSOSTDC1 or rhnoggin alone (Figure 5.4.1.6 D).   
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Figure 5.4.1.1 - Wnt3a induced phosphorylated Smad protein levels 
downstream of the BMP pathway in differentiating OB progenitors:  Western 
blot analysis was used to determine whether Wnt3a upregulated pSmad 1,5&8 protein levels 
in differentiating OB progenitors. Data represent the Average Density of pSmad 1,5&8 
levels normalised to GAPDH.  The western blot image is representative of one out of three 
experiments. Recombinant rmWnt3a acutely induced pSmad1,5&8  protein levels in OB 
progenitors on day 8 of differentiation (A) and not on any other occasion (B, C). N=3 
independent experiments, Students unpaired t-test. Data are displayed with mean ± 
SEM.*P=0.05.  
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Figure 5.4.1.2 - SOSTDC1 reduced 
Wnt3a-induced Smad phosphorylation 
in differentiating OB progenitors:  
Western blot analysis was used to determine 
whether SOSTDC1 down-regulated Wnt3a-
induced pSmad 1,5&8 protein levels 
downstream of the BMP signalling pathway in 
differentiating OB progenitors. Data represent 
the Average Density of pSmad 1,5&8 levels 
normalised to GAPDH.  The western blot 
image is representative of one out of three 
experiments. 250ng/ml rhSOSTDC1 and 
100ng/ml rmDkk1 reduced Wnt3a- induced 
pSmad1,5&8  protein levels in OB progenitors 
on day 8 of differentiation (A). N=3 
independent experiments, Students unpaired t-
test. Data are displayed with mean ± 
SEM.*P=0.05. 
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Figure 5.4.1.3 - BMP2 induced phosphorylated β-Catenin protein levels 
downstream of the Wnt pathway in differentiating OB progenitors:  Western blot 
analysis was used to determine whether 30ng/ml rhBMP2 upregulated pβ-Catenin levels in 
differentiating OB progenitors. Data represent the Average Density of pβ-Catenin levels 
normalised to GAPDH.  The western blot image is representative of one out of three 
experiment. Recombinant hBMP2 acutely induced pβ-Catenin protein levels in OB 
progenitors on day 8 and 11 of differentiation (A, B). N=3 independent experiments, 
Students unpaired t-test. Data are displayed with mean ± SEM.*P=0.05.  
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Figure 5.4.1.4 - SOSTDC1 reduced 
BMP2-induced phosphorylated β-
Catenin protein levels in differentiating 
OB progenitors:  Western blot analysis was 
used to determine whether SOSTDC1 down-
regulated BMP2-induced pβ-Catenin protein 
levels downstream of the canonical Wnt 
signalling pathway in differentiating OB 
progenitors. Data represent the Average 
Density of pβ-Catenin levels normalised to 
GAPDH.  The western blot image is 
representative of one out of three experiments. 
250ng/ml rhSOSTDC1 reduced BMP2- induced 
pβ-Catenin protein levels in OB progenitors on 
day 8 and 11 of differentiation (A, B). N=3 
independent experiments, Students unpaired t-
test. Data are displayed with mean ± 
SEM.*P=0.05. 
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Figure 5.4.1.5 - BMP7 induced phosphorylated β-Catenin protein levels 
downstream of the Wnt pathway in differentiating OB progenitors:  Western blot 
analysis was used to determine whether 30ng/ml rhBMP7 upregulated pβ-Catenin levels in 
differentiating OB progenitors. Data represent the Average Density of pβ-Catenin levels 
normalised to GAPDH.  The western blot image is representative of one out of three 
experiments. Recombinant h BMP7 acutely induced pβ-Catenin protein levels in OB 
progenitors on day 11 of differentiation only (B). N=3 independent experiments, Students 
unpaired t-test. Data are displayed with mean ± SEM.*P=0.05.  
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Figure 5.4.1.6 - SOSTDC1 reduced 
BMP7-induced phosphorylated β-
Catenin protein levels in differentiating 
OB progenitors:  Western blot analysis was 
used to determine whether SOSTDC1 down-
regulated BMP7-induced pβ-Catenin protein 
levels downstream of the canonical Wnt 
signalling pathway in differentiating OB 
progenitors. Data represent the Average 
Density of pβ-Catenin levels normalised to 
GAPDH.  The western blot image is 
representative of one out of three experiments. 
250ng/ml rhSOSTDC1 reduced BMP2-induced 
pβ-Catenin protein levels in OB progenitors on 
day 8 and 11 of differentiation (A, B). N=3 
independent experiments, Students unpaired t-
test. Data are displayed with mean ± 
SEM.*P=0.05. 
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5.4.2 SOSTDC1 inhibited BMP-induced CTNNB1 gene expression in differentiating 
OB progenitors 
 
To determine whether BMP could upregulate the expression of CTNNB1 downstream of 
the Wnt signalling pathway, the effect of Wnt ligand on CTNNB1 expression was initially 
assessed. The levels of CTNNB1 and B2M expression were quantified by qRT-PCR in OB 
progenitor cells obtained on day 8 and 11 of differentiation. The effects of Dkk1 on 
Wnt3a-induced and the effect of noggin on BMP-induced CTNNB1 expression were also 
assessed. Differences in CTNNB1 gene expression were normalised to B2M expression 
and overall fold changes in gene expression were calculated using the ΔΔ-CT method. 
Data were normalised to the PBS control. The data obtained from qRT-PCR analysis 
showed 50ng/ml rmWnt3a upregulated CTNNB1 expression in differentiating OB 
progenitors on day 8 of differentiation (Figure 5.4.2.1, A, *P=0.022).  
 
In the same experiments, 250ng/ml rhSOSTDC1 and 100ng/ml rmDkk1 reduced Wnt3a-
induced CTNNB1 levels (*P<0.05). The CTNNB1 expression of OB progenitors was not 
affected in the presence of rhSOSTDC1 or rmDkk1 alone. Further qRT-PCR analysis of 
CTNNB1 expression in BMP-stimulated OB progenitors showed that 30ng/ml rhBMP2 
and rhBMP7 induced CTNNB1 gene expression on day 8 of OB progenitor differentiation 
on a similar level observed in Wnt3a-induced CTNNB1 expression (Figure 5.4.2.2 A, 
**P=0.0057 and Figure 5.4.2.3 A *P=0.025). In the presence of rhBMP2, 250ng/ml 
rhSOSTDC1 reduced CTNNB1 levels in OB progenitors on day 8 of differentiation 
(Figure 5.4.2.2 A, ***P=0.0001). The 100ng/ml rhnoggin also had a suppressive effect 
on rhBMP2-induced CTNNB1 levels in OB progenitors on the same occasion (Figure 
5.4.2.2 A, **P=0.0057). The qRT-PCR analysis further showed that rhBMP7-induced 
CTNNB1 expression was reduced in the presence of 250ng/ml rhSOSTDC1 on day 8 of 
OB progenitor differentiation (Figure 5.4.2.2 A, *P=0.01). 100ng/ml rhnoggin also 
reduced rhBMP7-induced CTNNB1 levels in OB progenitors on day 8 of differentiation 
(Figure 5.4.2.3 A, **P=0.0081).  
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Figure 5.4.2.1 - SOSTDC1 inhibited Wnt-induced CTNNB1 expression in 
differentiating OB progenitors: OB progenitor cells were cultured with 50ng/ml 
rmWnt3a in the presence or absence of 250ng/ml rhSOSTDC1 or 100ng/ml rmDkk1 and the 
CTNNB1 expression quantified using qRT-PCR. Data represent the relative expression of 
CTNNB1 normalised to B2M. (A) The rmWnt3a upregulated CTNNB1 expression in OB 
progenitors on day 8 of differentiation. On this occasion rhSOSTDC1 and rmDkk1 reduced 
the Wnt3a-induced CTNNB1 levels. N=4 independent experiments, One way ANOVA and 
Holm-Sidak multiple comparisons test.  Data are displayed with mean ± SEM.*P=0.05. 
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Figure 5.4.2.2 - SOSTDC1 inhibited BMP2-induced CTNNB1 expression in 
differentiating OB progenitors: OB progenitor cells were cultured with 30ng/ml 
rhBMP2 in the presence or absence of 250ng/ml rhSOSTDC1 or 100ng/ml rhnoggin and the 
CTNNB1 expression quantified using qRT-PCR. Data represent the relative expression of 
CTNNB1 normalised to B2M. (A) The rhBMP2 upregulated CTNNB1 expression in OB 
progenitors on day 8 of differentiation. On this occasion rhSOSTDC1 and rhnoggin reduced 
the rhBMP2-induced CTNNB1 levels. N=4 independent experiments, Holm-Sidak multiple 
comparisons test. Data are displayed with mean ± SEM. **P=0.01, ***P=0.001. 
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Figure 5.4.2.3 - SOSTDC1 inhibited BMP7-induced CTNNB1 expression in 
differentiating OB progenitors: OB progenitor cells were cultured with 30ng/ml 
rhBMP7 in the presence or absence of 250ng/ml rhSOSTDC1 or 250ng/ml rhnoggin and the 
CTNNB1 expression quantified using qRT-PCR. Data represent the relative expression of 
CTNNB1 to B2M. (A) The rhBMP7 upregulated CTNNB1 expression in OB progenitors on 
day 8 of differentiation. On this occasion rhSOSTDC1 and rhnoggin reduced the rhBMP7-
induced CTNNB1 levels. N=4 independent experiments, Holm-Sidak multiple comparisons 
test. Data are displayed with mean ± SEM. *P=0.05, **P=0.01. 
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5.4.3 Recombinant SOSTDC1 protein bound with high affinity to recombinant LRP-
6, BMP2 and BMP7 determined by Bio-layer interferometry  
 
The affinity of 100µg/ml rhSOSTDC1 protein for purified carrier-free rmLRP-6, rhBMP2 
and rhBMP7 were determined using the Blitz Analysis system as outlined in section 
2.15.1. The measured affinity of the interaction KD (M) between the rhSOSTDC1 protein 
and rmLRP-6, rhBMP2 or rhBMP7 was reported by the BLItz Pro™ software. 
Interferometry data were globally fit to a 1:1 Langmuir model calculating the affinities 
and rate constants. The interaction of rhSOSTDC1 for multiple concentrations (µg/ml) of 
rmLRP-6, rhBMP2 or rhBMP7 was used for the Langmuir model fitting. The association 
and dissociation responses were baseline corrected and processed using the Octet 
Software to rise to the affinity constant KD.  
 
In addition, the interactions between 100µg/ml rhGST protein and 100µg/ml rmLRP-6, 
rhBMP2 and rhBMP7 were also assessed. The rhGST-analyte binding assays were carried 
out to ensure that the KD values obtained for interaction between rhSOSTDC1 and 
rmLRP-6, rhBMP2 and rhBMP7 were not affected by the presence of the GST-tag. The 
sensogram data collected in real time showed that rhSOSTDC1 bound with high affinity 
to rmLRP-6, rhBMP2 and rhBMP7 (Figure 5.4.3).  
 
The binding affinity of rhSOSTDC1 for the Wnt receptor rmLRP-6 was determined as 
8.502e-10M KD (Figure 5.4.3 A). The affinity of rhSOSTDC1 for rhBMP2 was 
determined as 9.569e-9M KD (Figure 5.4.3 B) and the affinity of rhSOSTDC1 for 
rhBMP7 was calculated at <1.0e-12M KD (Figure 5.4.3 C). The affinity of rhSOSTDC1 
for the rmLPR-6 receptor protein was one-fold higher compared to the affinity of 
rhSOSTDC1 rhBMP2 ligand protein. Subsequently, I showed that rhSOSTDC1 had the 
highest binding affinity for the ligand BMP7 protein out of all three rhSOSTDC1-protein 
interactions. The rhSOSTDC1 protein had a three-fold higher binding affinity for 
rhBMP7 compared to rmLRP-6. The 100µg/ml of rhGST did not bind at detectable levels 
to rmLRP-6 or rhBMP7 protein and the KD value of 1.096e-4M calculated for rhGST-
rhBMP2 interaction was negligible, indicating little or no binding (Appendix 3).  
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100µg/ml SOSTDC1 interaction with 
LRP-6 
 
Sample Concentration 
(µg/ml) 
kD (M) 
LRP-6 100 8.502e-10 
 
 
LRP-6 50 
LRP-6 25 
LRP-6 10 
LRP-6 1 
LRP-6 0 (buffer only) - 
100µg/ml SOSTDC1 interaction with 
BMP2 
 
Sample Concentration 
(µg/ml) 
kD (M) 
BMP2 100 9.569e-9 
 BMP2 50 
BMP2 25 
BMP2 10 
BMP2 1 
BMP2 0 (buffer only) - 
100µg/ml SOSTDC1 interaction with 
BMP7 
 
Sample Concentration 
(µg/ml) 
kD (M) 
BMP7 100 <1e-12 
 BMP7 50 
BMP7 25 
BMP7 10 
BMP7 1 
BMP7 0 (buffer only) - 
Figure 5.4.3 - Recombinant SOSTDC1 protein bound with high affinity to 
recombinant LRP, BMP2 and BMP7 proteins: The affinity KD (M) of rhSOSTDC1 
for purified carrier-free rmLRP-6, rhBMP2 and rhBMP7 proteins were determined using 
the Blitz Analysis system.  (A) Binding (nm) association showed 100ug/ml of 
rhSOSTDC1bound to; rmLRP-6 with a kD of 8.502e-10M (B) rhBMP2 with a kD of 9.569e-
9M and (C) rhBMP7 with a kD of <1.0e-12M. 
 
A 
B 
C 
LRP-6 Concentration 
(µg/ml) 
BMP2 Concentration 
(µg/ml) 
BMP7 Concentration 
(µg/ml) 
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5.5 Discussion 
 
This chapter focused on the role of SOSTSDC1 in Wnt-BMP crosstalk in OB progenitor 
differentiation, in which the main aim of the study was to determine whether SOSTDC1 
had an antagonistic effect on Wnt-BMP dependent signalling within OB progenitor cells. 
The hypothesis of SOSTDC1 suppresses Wnt-BMP crosstalk in signalling OB progenitor 
cells was supported by my finding. Previously my data provided evidence for the 
antagonistic actions of SOSTDC1 on Wnt and BMP signalling in differentiating OB 
progenitors. Evidence of regulation between canonical Wnt signalling and BMP 
signalling has previously been demonstrated in embryonic development and 
tumourgenesis (Zhang, Yan et al. 2009). In studies by Bill et al, Wnt signalling was found 
to induce expression of BMP2, BMP4, BMP7 and BMP target genes including Msx2 and 
gremlin in the mesenchyme (Bill et al, 2006). In gastrointestinal cancer cells, β-catenin 
induced BMP2 expression (Kim, Crooks et al. 2002). The downstream target genes of 
BMP signalling and cross-interaction between BMP ligands and Wnt signalling in OB are 
poorly understood. Recent studies demonstrate that BMP2 has a synergic effect with β-
catenin on OB differentiation in-vitro (Rawadi, Vayssiere et al. 2003, Mbalaviele, Sheikh 
et al. 2005). However, the effects of Wnt signalling on BMP expression in OB and the 
associated molecular mechanisms remain unclear. 
 
Specific secreted molecules have an effect on Wnt and BMP signalling by binding to the 
extracellular components of both pathways. For example, Cerberus which is known to 
induce head formation in Xenopus inhibits Wnt and BMP signalling by binding directly to 
Wnt and BMP ligands, regulating head formation (Silva, Filipe et al. 2003). Another 
secreted molecule includes connective tissue growth factor (CTGF) which can bind 
BMP4, TGFβ1 and LRP6 (Silva, Filipe et al. 2003). As mentioned previously Sclerostin 
is another molecule that can inhibit bone formation by binding to BMP ligands (Kusu, 
Laurikkala et al. 2003) and the LRP5/6 receptors (Ellies, Viviano et al. 2006). 
Interestingly the interaction of Sclerostin, which has a very similar homology to 
SOSTDC1, with BMP ligands and LRP5/6 has been shown to interfere with Wnt 
signalling (ten Dijke, Krause et al. 2008). It would therefore seem that extracellular 
mechanisms modulating both Wnt and BMP signalling regulate simultaneous suppression 
of both signalling pathways providing a rational for investigating the role of SOSTDC1 in 
Wnt-BMP crosstalk.  
185  
 
A limited number of studies have investigated the role of SOSTDC1 in Wnt-BMP 
crosstalk and these studies have been specific to tooth development and kidney disease. In 
a study by Liu et al SOSTDC1 mouse mutants exhibited supernumerary teeth, which were 
thought to be a result of increased BMP and Wnt/β-catenin activity (Liu, Chu et al. 2008). 
I investigated the effect of Wnt3a ligand on phosphorylated levels of Regulatory Smad 
protein complex downstream of the BMP pathway and subsequently assessed this effect 
in the presence of recombinant SOSTDC1 in differentiating OB progenitors.  In my 
study, Wnt3a induced phosphorylation of Smad1,5&8 protein in OB progenitors and 
SOSTDC1 reversed this effect during the early stage of differentiation. In similar studies 
by Rawadi et al investigating the crosstalk between Wnt-BMP signalling, blocking 
Wnt/LRP5 signalling resulted in the inhibition of BMP2-induced ALP activity in MSC. 
Moreover, MC3T3-E1 cells overexpression of Dkk1 reduced BMP2-induced extracellular 
matrix mineralization (Rawadi et al, 2003).  
 
In the same experiments, I showed that SOSTDC1 suppressed Wnt3-induced 
phosphorylated Smad 1,5&8 levels in in differentiating OB progenitor cells on a similar 
level to Dkk1. Based on the literature it can be deduced that SOSTSDC1 antagonises Wnt 
signalling in a similar mechanism to that of antagonist Dkk1. SOSTDC1 and Dkk1 both 
bind to the LRP/Frz Wnt receptor and in doing so block Wnt ligand interaction with the 
LRP/Fz receptor. In the same study by Liu et al, overexpression of Dkk1 blocked tooth 
formation and this was accompanied by down-regulation of BMP and Msx1/2 expression 
domains. The BMP4 induction of Msx1/2 expression was not affected in Dkk1-
overexpression suggesting that Wnt/β-catenin signals are required upstream of BMP4 
function (Liu, Chu et al. 2008).  Based on the similarities between the antagonistic role of 
SOSTSDC1 and Dkk1 in Wnt-BMP crosstalk in differentiating OB progenitors, it may be 
assumed that both molecules have a similar detrimental effect in osteolytic bone disease. 
One possibility for this similarity may be that in osteolytic bone disease, if one molecule 
is not in abundance, then the other is produced at high levels to compensate.  
 
In my studies investigating BMP stimulation of downstream intracellular Wnt signalling, 
I found that both BMP2 and BMP7 increased phosphorylated levels of β-catenin protein 
and active CTNNB1 gene expression. SOSTSDC1 reduced BMP-induced β-catenin levels 
in the early stages of OB progenitor differentiation. This data is similar to that found by 
Papathanasiou et al showing treatment of chondrocyte cultures with BMP2 resulted in an 
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up-regulation of β-catenin nuclear translocation and LRP-5 expression. Papathanasiou 
showed that BMP2-induced LRP-5 expression was mediated through Smad1/5/8 binding 
on the LRP-5 promoter. In these studies, LRP-5 silencing resulted in reduction of nuclear 
β-catenin protein, MMPs and collagen X expression, whereas phosphorylated β-catenin 
protein levels in BMP-2-treated chondrocyte increased (Papathanasiou, Malizos et al. 
2012).   
 
Fukuda et al showed that in the presence of BMP-4, canonical Wnt1 and Wnt3a but not 
non-canonical Wnt5a and Wnt11 stimulated ALP activity of OB-like C2C12 cells. This 
group also showed that Type I collagen and osteonectin expression increased in response 
to Wnt3a and BMP4 stimulation and both noggin and Dkk1 suppressed the synergistic 
effect of BMP-4 and Wnt3a (Fukuda, Kokabu et al. 2010). Stimulation of GSK3β activity 
in the presence of BMP-4 caused induction of ALP activity. The Fukuda et al showed that 
Wnt3a did not stimulate BMP receptor/Smad1-induced ALP level and overexpression of 
β-catenin did not affect BMP4-induced ALP levels in C2C12 cells. Fukuda et al 
concluded that Wnt-BMP regulation of OB differentiation, especially at the early stages, 
through a GSK3β-dependent but β-catenin-independent mechanism (Fukuda, Kokabu et 
al. 2010). In comparison the Zhang et al data was contradictory as in these studies BMP2 
stimulated Lrp5 expression and enhanced protein levels of the active form of β-catenin in 
OB. The in-vitro deletion of the CTNNB1 gene supressed OB proliferation and 
differentiation and reduced BMP2-induced OB differentiation. BMP2 also increased 
nuclear β-catenin protein levels suggesting the interaction between Wnt and BMP2 
signalling during OB differentiation is (Zhang et al, 2009). Recently Zhang et al also 
showed that similar to BMP2, Wnt3a increased transcriptional activity of BMP/Smad 
reporter and noggin blocked this Wnt3a-induced effect, concluding that Wnt signalling 
acts as an upstream regulator of BMP signalling (Zhang, Oyajobi et al. 2013). There data 
is complimentary to mine in that in my studies, noggin significantly suppressed BMP-
induced nuclear β-catenin levels.  
 
It is of particular interest that the Wnt-BMP crosstalk relationship that Fukada et al 
demonstrated was especially specific to the early stages of OB differentiation (Fukuda, 
Kokabu et al. 2010). The increase in BMP-induced β-catenin levels was also observed in 
preosteblastic cells in Zhang et al study (Zhang et al, 2009). The data from these studies 
187  
 
are in line with my results in showing that the Wnt-BMP crosstalk may be occur on when 
OB cells have a more immature phenotype.  
 
Having established that SOSTDC1 may potentially have an important role Wnt-BMP 
crosstalk in osteoprogenitors cells, I wanted to determine the relative binding 
characteristics of this molecule for BMPs and Wnt receptors. To produce informative 
results, the binding affinity of SOSTDC1 for each potential partner ligand/receptor was 
determined using the same recombinant proteins used for all functional and signalling 
assays. I showed that recombinant SOSTDC1 had a higher binding affinity for the LRP6 
(8.502e-10M) receptor protein compared to the recombinant BMP2 protein (9.569e-9M). 
Interestingly, SOSTDC1 had the highest affinity for BMP7 (<1.0e-12M) out of the three 
SOSTDC1-protein partner interactions assessed. To my knowledge there are no studies 
that have investigated the binding affinity of rhSOSTDC1 for LPR6, BMP2 and BMP7. 
However Laurikkala et al did examine the binding of Ectodin (recombinant mouse 
SOSTDC1) to BMP2, BMP4, BMP6, and BMP7 ligands using the BIAcore system with a 
recombinant Ectodin protein-fixed sensor tip. This group found that Ectodin bound to 
BMP2, BMP4, BMP6, and BMP7 with high affinity (Laurikkala, Kassai et al. 2003) 
similar to my data. Lintern et al did attempt to quantify binding affinity of Wise to LRP6 
and to compare it with that to BMPs, however they were unsuccessful in express pure 
Wise protein in bacteria (Lintern et al, 2009). Krause et al also investigated the binding of 
the SOSTDC1 homolog Sclerostin for LRP5 using the Biacore system. They revealed a 
relatively low binding affinity with KD values ranging from 2 to 8.6 μm for full-length 
murine and human sclerostin, respectively (Krause, Korchynskyi et al. 2010). This data is 
interesting in the sense that if SOSTDC1 has a higher binding affinity for LRP5/6 
receptor compared to sclerostin, SOSTDC1 may potentially have a more important role in 
OB dysfunction in osteolytic bone disease.  
 
In summary, my findings provide compelling evidence for the molecular mechanisms by 
which SOSTDC1 antagonises both the canonical Wnt pathway and BMP signalling 
pathways in OB differentiation through Wnt-BMP dependency. The data in my studies 
suggests that the functional communication between Wnt-BMP involves β-catenin and 
SOSTDC1 may play an important role in integrating the anabolic functions of both 
pathways in bone.  
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Chapter 6 – The Role of SOSTDC1 in 
Myeloma Bone Disease 
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6.1 Introduction 
 
The formation of lytic lesions in the skeleton is an established hallmark of MM growth in 
bone. However, our understanding of the processes involved in MM bone disease is 
limited. Recently, animal models have been used to identify the pathways and molecules 
involved in the mechanisms responsible for the suppression of bone formation and 
although a number of molecules have been implicated, there is a lack of functional data 
defining the roles of the latter in MM bone disease.  
 
Preliminary gene array data (unpublished) produced by the Myeloma group in Sheffield 
has identified SOSTDC1 as a molecule upregulated in the bone of syngeneic mice 
bearing the 5T2MM mouse myeloma model compared to naive non-tumour bearing 
animals. Initially described by Radl et al, the 5TMM series of MM were aging immune-
competent C57BL/KalwRij mice that displayed numerous clinical characteristics of 
human MM disease. These characteristics included spontaneous age-related origin, 
plasma cell proliferation within the BM, elevated paraprotein levels, reduced levels of 
normal immunoglobulin, and development of osteolytic bone lesions (Radl, Croese et al. 
1988). The 5TMM models have since been maintained via the injection of tumour cells 
isolated from tumour-infiltrated C57BL/KaLwRij mice into 6-8 week old mice of the 
same strain. The 5TGM1MM model similar to 5T33MM is an aggressive form of the 
disease that develops over a 4 week period. The two models do vary in that the 
5TGM1MM cells appear to be independent of their environment and growth of myeloma 
tumours develop in numerous locations including the bone, spleen and liver. Another 
important variable between the two models is that osteolytic bone disease occurs in the 
5TGM1MM model and not in the 5T33MM model (Croese, Vas Nunes et al. 1987, 
Vanderkerken, De Raeve et al. 1997).  
 
In previous chapters, my functional and signalling data identified SOSTDC1 as a Wnt and 
BMP signalling antagonist in OB cells. It is not clear which cells in the BM express 
SOSTDC1 and whether the interaction between OB and myeloma cells, induce 
production of SOSTDC1. Although data is limited, there is evidence that SOSTDC1 can 
regulate cell activity through BMP and Wnt signalling pathways within other cancers. 
Studies by Clausen et al into SOSTDC1 secretion and BMP/Wnt signalling in breast 
cancer cells, link decreased SOSTDC1 expression to increased tumour size, highlighting 
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the role of SOSTDC1 as a potential clinical target (Clausen, Blish et al. 2010). However, 
the function of SOSTDC1 in relation to bone disease secondary to cancer growth in bone 
has not been studied to date within any type of cancer.  
 
In myeloma patients, abnormalities in osteoprogenitor cells and the production of OB 
inhibitors by both myeloma cells and myelomatous bone microenvironment cells result in 
a reduction in osteoblastogenesis (Yaccoby 2010). In MM the osteolytic lesions arise in 
close proximity to the tumour indicating that in addition to the soluble factors that 
regulate osteoblastogenesis suppression, the close or direct contact between myeloma 
cells and MSC may also influence bone remodelling. As an example myeloma cells 
partially suppress osteocalcin levels in osteogenic cells through direct cell contact 
(Roodman 2004). This data supports the rational that direct myeloma and OB interaction 
may induce SOSTDC1 production in either myeloma, OB or indeed both cell types. 
Determining the conditions under which SOSTDC1 is expressed in myeloma is key in 
understanding the role of this protein in MM osteolytic bone disease. 
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6.2 Hypothesis and Objectives  
 
6.2.1 Aims 
The aim of this study was to determine the conditions under which myeloma and OB 
progenitor cells produce SOSTDC1. 
To achieve this, the following hypothesis was tested. 
 
6.2.1 Hypothesis 
 
The 5T Series of MM produce SOSTDC1 
 
OB progenitors produce SOSTDC1 
 
Direct myeloma and OB progenitor interaction upregulates the production of SOSTDC1 
in myeloma and OB progenitor cells 
 
 
6.2.2 Specific Objectives 
 
To test this hypothesis the following were determined: 
 
Whether  SOSTDC1 is produced by 5T33MM/5TGM1MM myeloma cells or OB 
progenitors 
 
Whether co-culture of myeloma and OB cells upregulates SOSTDC1 levels 
 
The distribution of SOSTDC1 in 5T33MM and 5TGM1MM tibia  
 
Whether SOSTDC1 is expressed at higher levels in myeloma cells that produce lytic 
versus non-lytic lesions in-vivo  
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6.3 Chapter specific methods 
 
 
Table 6.1 - Recombinant proteins required for the detection of SOSTDC1 in OB 
progenitors and myeloma cells cultures and co-cultures.  
 
 
6.3.1 Detection of SOSTDC1 in OB progenitors and myeloma cells cultured on their 
own and co-cultured together by immunofluorescent microscopy  
 
There are currently no publications that show SOSTDC1 is expressed in OB or myeloma 
cells. The aim of the first part of this study was to qualitatively establish whether OB or 
myeloma cells produced SOSTDC1. Human kidney cells were used as a positive control 
in this study as they are known to secrete SOSTDC1 (Blish, Clausen et al. 2010). To 
 Primary and Secondary Antibodies  
Antibody Concentration 
of stock 
CATALOGUE  
NUMBER 
SUPPLIER 
Anti-SOSTDC1 antibody 
Rabbit polyclonal  
0.5mg/ml Ab56079 Abcam 
Normal Rabbit IgG (Isotype 
Control) 
Rabbit polyclonal  
1.0mg/ml AB-105-C R&D 
PE Rat IgG2a Isotype 
Control  
0.2 mg/ml 400508 BioLegend 
Anti-GAPDH (6C5) antibody  
Mouse monoclonal 
1.0mg/ml Ab-37168 Abcam 
PE Rat Anti-Mouse CD138  
Mouse monoclonal 
0.2mg/ml 581070 BD 
Pharmingen™ 
Donkey Anti-Rabbit IgG 
NL637  NorthernLights 637 
Rabbit polyclonal 
1.0mg/ml NL005 R&D 
 
HRP-Rabbit Anti-Mouse 
IgG   Mouse  polyclonal 
2.0mg/ml 613420 Cell Signalling 
HRP-Goat Anti-Rabbit IgG 
Rabbit polyclonal 
2.0mg/ml HAF008 R&D 
Biotinylated Goat Anti 
Rabbit IgG (H+L) 
1.0mg/ml ab64256 Abcam 
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validate immunological methods of SOSTDC1 detection, protocols were optimised with 
Human Kidney-2 (HK-2) cells derived from the cortex/proximal tubules of the human 
kidney. Immunofluorescent microscopy was initially used to determine whether there was 
any production of SOSTDC1 protein in OB progenitors, 5T33MM and 5TGM1MM cells 
cultured on their own. HK-2, OB progenitors, 5T33MM and 5TGM1MM were plated in 
48 well culture plates at a cell density of 5700 cells per well
 
(6000 cell/cm
2
) and allowed 
to adhere to the plate surface for 48 hours. OB progenitors were differentiated in standard 
osteogenic media for up to 8 days.  HK-2 cells were maintained in standard keratinocyte 
media and 5T33MM and 5TGM1MM were maintained in standard RPMI for the duration 
of the 8 days.  Media was removed and 500μl of fresh media replaced every three days. 
To determine whether SOSTDC1 production was affected by contact between myeloma 
and OB, 5T33MM or 5TGM1MM myeloma cells were counted and co-cultured on the 
differentiating OB progenitors on day 8 of differentiation. Myeloma cells were co-
cultured at a cell density of approximately 12000 cell/cm
2
 or 11400 cells per well in a 48-
well plate that was similar to the estimated OB progenitor cell number on day of 8 of 
differentiation. This cell density was based on the OB progenitor growth curves 
performed in Chapter 3, suggesting that OB cultures approximately doubled in DNA 
contents/cell number by day 8 of differentiation. Myeloma cells were co-cultured with the 
OB progenitors for 24 hours in 1ml of RPMI. The immunostaining method for 
microscopy was carried out according to section 2.11.  
 
Cells were stained with 1µg/ml (1:500 dilution) anti-SOSTDC1 antibody or isotype 
control at the same concentration overnight at 4ºC and then stained with a secondary 
3.3µg/ml (1:300) dilution of Donkey anti-Rabbit IgG NL637 antibody for 1 hour at room 
temperature. Cells were co-stained with 6.6 µg/ml (1:300 dilution) PE Rat Anti-Mouse 
CD138 for 1 hour. Images of phase contrast, DAPI, CD138 and SOSTDC1 staining were 
visualised simultaneously and represented as a single stain on their own or merged as one 
image.  Blue staining represented positive nuclear staining for DAPI and the green 
staining represented positive nuclear staining for CD138. Any SOSTDC1 staining, both 
intra and extra-cellular, were represented by the red colour within images (Figure 6.3.1). 
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Figure 6.3.1 – Diagrammatic representation of 5T33MM/ 5TGM1MM and 
osteoblast co-culture: OB progenitors were seeded at 5700 cells per well in 48 well 
plates and then differentiated in osteogenic media for 8 days. Differentiating OB 
progenitor cells were co-cultured with myeloma cells at a cell density of 11400 cell per 
well for 24 hours. Co-cultures were stained with anti-CD138 and anti-SOSTDC1 
antibodies.  
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6.3.2 Flow Cytometric analysis of SOSTDC1 production in myeloma-OB progenitor 
co-cultures  
 
Flow cytometry was used as a quantitative method for SOSTDC1 detection in myeloma-
OB progenitor co-cultures. Using HK-2 cells as a positive control, HK-2, OB progenitors, 
5T33MM-GFP and 5TGM1MM-GFP were seeded in 25cm
2 
culture flasks at a density of 
150,000 per flask (6000 cell/cm
2
). Cells were allowed to adhere to the plate surface for 48 
hours in 7ml of media. OB progenitors were differentiated in standard osteogenic media 
for up to 8 days. On day 8 of OB progenitor cell differentiation, 5T33MM-GFP or 
5TGM1MM-GFP myeloma cells were counted and seeded onto the differentiating OB 
progenitors at a cell density of 300,000 cells per flask (12000 cell/cm
2
). Myeloma cells 
were co-cultured with the OB progenitor cells for 24 hours in 14ml of RPMI. After 24 
hours HK-2 cells, OB progenitor and myeloma-OB progenitor co-cultures were detached 
by trypsinisation as outlined in section 2.1.3. Media containing 300,000 
5T33MM/5TGM1MM cells cultured on their own were transferred to 15ml Falcon™ 
tubes and myeloma cells centrifuged at 1000 RPM for 5 minutes.  
 
1ml of ice cold PBS was added to the cell pellets and cell/PBS solution transferred to 
1.5ml eppendorfs in preparation for flow cytometric analysis. The method for flow 
cytometry analysis was carried out according to the protocol outlined in section 2.9.  
Cells were stained with 1µg/ml (1:500 dilution) anti-SOSTDC1 antibody for 30 minutes 
and then stained with a secondary 2µg/ml (1:500 dilution) of Donkey anti-Rabbit IgG 
NL637 antibody for 30 minutes at room temperature in the dark. The percentage of 
SOSTDC1 positive (%SOSTDC1+) cells within separate OB progenitors, 5T33MM-GFP 
and 5TGM1MM-GFP cell population were determined first and following this the co-
cultures samples containing both myeloma and OB progenitor populations were analysed. 
Gating was set so that separate GFP-positive and negative cell populations could be 
distinguished. The GFP-positive myeloma cells appeared at the top half of the scatter plot 
gate and GFP-negative OB progenitor at the bottom half of the scatter plot. A right shift 
in the population of either myeloma or OB progenitor cells indicated positive for 
SOSTDC1 staining.  
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6.3.3 Detecting SOSTDC1 levels in sorted myeloma and OB progenitor populations 
in-vitro by western blotting and end-point PCR 
 
FACS Aria flow cytometry technology was used to sort myeloma and OB progenitor cells 
from myeloma-OB progenitor co-cultures to determine the level of SOSTDC1 in 
individual cell populations. OB progenitor cells were seeded into T175 culture flasks at 
cell density of 1,050,000 cells (6000 cells/cm2) containing 24ml of standard Alpha-MEM 
media. Following 48 hours in culture, the Alpha-MEM was removed from the OB 
progenitor cells and replaced with standard osteogenic media and OB progenitors were 
differentiated for 8 days. At the same time HK-2 cells, 5T33MM-GFP and 5TGM1MM-
GFP were cultured separately in 175ml culture flasks at a cell density of 1,050,000 cells 
(6000 cell/cm
2
).  
 
On day 8 of OB progenitor differentiation, 5T33MM-GFP or 5TGM1MM-GFP myeloma 
cells were counted and co-cultured with the OB progenitors at a cell density of 
approximately 2,000,000 cells (12000 cell/cm
2
).
 
Myeloma cells were co-cultured with the 
differentiating OB progenitor cells for 24 hours in 50ml of RPMI. Following the 24 hour 
culture period, the OB progenitor cultures and co-cultures were detached from culture 
surfaces by trypsinisation as outlined in section 2.1.3. The 5T33MM/5TGM1MM cells 
cultured on their own were transferred to 50ml Falcon™ tubes and myeloma cells 
pelleted by centrifugation at 1000 RPM for 5 minutes. 1ml of PBS was added to the cell 
pellets and cell/PBS solution transferred to flow 1.5ml BD flow cytometry tubes.  
 
Whole 5T33MM/5TGM1MM and OB progenitor co-cultures were sorted into separate 
OB and myeloma cell populations using the FACS Aria flow cytometer according to 
section 2.10.  Myeloma-GFP and OB progenitor cells cultured alone were sorted first so 
that the correct gating could be applied for each individual population (Figure 6.3.2). 
Cells from OB-myeloma co-cultures were sorted into 1ml of RPMI for approximately 30 
minutes. 1ml sorted cell populations were then split into two tubes containing 500μl each; 
from which protein or RNA was extracted according to section  2.6 and section 2.12, 
respectively (Figure 6.3.3).  
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Figure 6.3.2 - Sort gating for OB progenitor-5TMM-GFP co-cultures using the 
FACS Aria flow cytometer: Cells were sorted on the basis of fluorescence and scatter 
characteristics i.e. GFP fluorescence vs non-GF cells. Nonviable cells that fell outside of the 
gates were excluded from the counts. OB progenitor cultures and 5T33MM-GFP and 
5TGM1MM-GFP were sorted separately and the appropriate gating applied. This gating 
was used as a sorting template for separating the OB progenitor and myeloma-GFP 
population.  
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Western blotting was used to detect SOSTDC1 protein levels in 5T33MM-GFP and 
5TGM1MM-GFP myeloma cells co-cultured with differentiating OB as outlined in 
section 2.8. Briefly, 12% polyacrylamide gels were loaded with 10μg of protein and 10µl 
of a 10-250kD protein molecular marker at the first lane. Proteins lysates were run 
through the stacking gel for 40 minutes at 60 Volts and then separated out for 1 hour at 
100 Volts. Proteins were transferred onto PVDF membranes for 70 minutes at 70 Volts in 
4ᴼC. Membranes were washed once in 0.05% PBS-Tween and probed with 1μg/ml (1:500 
dilution) primary anti-SOSTDC1 antibody overnight at 4ᴼC. Blots were incubated for 1 
hour at RT with 0.2μg/ml (1:10,000 dilution) of secondary HRP-conjugated anti-rabbit 
IgG antibody to detect SOSTDC1 protein. HK-2 cell lysates were used as a positive 
control for SOSTDC1 protein production. SOSTDC1 protein bands were visualised at 
~47kD using the molecular marker as a reference point and the average density quantified 
using the GS-710 Calibrated Imaging Densitometer.  
 
The same membranes were ‘stripped’ using Mild Stripping Buffer as described in section 
2.8.5. The newly exposed proteins on the blots were re-probed with 0.07μg/ml (1:15,000 
dilution) of anti-GAPDH mouse antibody overnight at 4ᴼC. Blots were incubated with 
0.1μg/ml (1:20,000 dilution) of secondary HRP-conjugated anti-mouse IgG antibody. 
GAPDH bands were visualised at ~35kD and the average density of SOSTDC1 protein 
was normalised to the average density of GAPDH to account for any loading variability.  
End-point PCR was used to qualitatively determine SOSTDC1 expression in OB 
progenitors, myeloma cells and sorted myeloma-OB progenitor co-culture cell 
populations.  Following cDNA synthesis end-point PCR reaction was performed to detect 
SOSTDC1 expression using the forward and reverse primers set for SOSTDC1 sequences 
as described in section 2.14.3.1. PCR products were run on a 1.5% agarose gels stained 
with ethidium bromide and bands detected using the Gel Doc XR System and Quantity 
One Software as described in section 2.14.3.2. SOSTDC1 expression was indicated by a 
product size of 198bp. PCR products were sequenced verify SOSTDC1 expression by the 
DNA sequencing Core Facility housed within the University of Sheffield, Medical School 
as described in section 2.14.3.3.  
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Figure 6.3.3 - Myeloma-OB progenitor co-cultures sorted into separate 
populations by FACS Aria and SOSTDC1 level detection using end-point PCR 
and western blotting: 5T33MM/5TGM1MM and differentiating OB progenitors were 
cultured in T175 culture flasks on their own for 8 days after which the RNA and protein was 
extracted. In separate flasks, differentiating day 7 OB progenitors were co-cultured with 
5T33MM/5TGM1MM cells for 24 hours. Co-cultures were then sorted for approximately 30 
minutes by FACS Aria into separate myeloma and OB progenitor populations. RNA and 
protein were extracted from sorted cells. SOSTDC1 levels were determined by western blot 
and end-point RT-PCR. 
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6.3.4 Assessing the dependency of SOSTDC1 production on direct myeloma-OB 
progenitor interaction 
 
To test the concept that SOSTDC1 is upregulated in myeloma cells as a result of direct 
interaction between OB progenitors and myeloma cells, co-culture experiments were set 
up as previously described in section 6.2. In these experiments, co-culture of 5T33MM-
GFP or 5TGM1MM-GFP with differentiating OB progenitor cells for 24 hours resulted in 
some myeloma cells adhering to the OB progenitor cells. From these co-cultures, the 
media that contained the non-adhering myeloma population was removed and transferred 
to 50ml Falcon™ tubes and cells pelleted by centrifugation. 1ml of PBS was added to the 
cell non adherent myeloma cell pellets and cell/PBS solution was transferred to 1.5ml 
eppendorfs tubes. Flow cytometry was used to determine the percentage of SOSTDC1+ 
myeloma cells that had physically attached to the OB progenitors compared to the 
percentage of SOSTDC1+ myeloma cells that had not adhered to the OB progenitors but 
were present in co-culture.  
 
In separate experiments, myeloma-OB progenitor co-cultures were set up and sorted by 
FACS Aria into separate populations as previously described in section 6.3.3. Again the 
media from the myeloma-OB progenitor co-culture that contained the non-adhering 
myeloma cells was transferred to 50ml Falcon™ tubes and cells pelleted by 
centrifugation. 1ml of PBS was added to the non-adherent myeloma cell pellets and 
cell/PBS solutions were transferred to 1.5ml eppendorfs tubes in preparation for the 
protein lysing, BCA and western blotting procedure outlined in sections 2.6, -2.7 and -
2.8, respectively. Western blotting was used to compare SOSTDC1 protein levels in non- 
adherent 5T33MM-GFP/5TGM1MM-GFP myeloma cells taken from the media of 
myeloma-OB progenitor co-cultures and compared to adherent 5T33MM-
GFP/5TGM1MM-GFP cells sorted from co-cultures. Briefly, 12% polyacrylamide gels 
were loaded with 10μg of protein and blots were probed with 5μg/ml (1:100 dilution) 
primary anti-SOSTDC1 antibody overnight at 4ᴼC. Blots were incubated with 0.13μg/ml 
(1:15,000 dilution) of secondary HRP-conjugated anti-rabbit IgG antibody to detect 
SOSTDC1 protein. Membranes were stripped using mild stripping buffer as described in 
section 2.8.5 and proteins re-probed with 0.1μg/ml (1:20,000 dilution) dilution of mouse 
anti-GAPDH overnight at 4ᴼC. The average density of SOSTDC1 protein was normalised 
to the average density of GAPDH using the GS-710 Calibrated Imaging Densitometer.  
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6.3.5 Detection of SOSTDC1 in tibiae bearing myeloma tumour in-vivo 
 
Leading groups have characterised the 5TMM series myeloma cell lines which include 
the 5T33MM and 5TGM1MM and have reported protocols for the production and 
maintenance of the 5T model in C57BL/KaLwRijHsd mice (Asosingh, Radl et al. 2000, 
Oyajobi, Munoz et al. 2007). Our Myeloma group in Sheffield has used these protocols to 
reproduce the 5T33MM-GFP and 5TGM1MM-GFP myeloma model in our laboratory. In 
brief, bone marrow isolated from the long bones of 5TMM bearing mice were injected 
into the lateral tail of young naïve syngeneic mice. The growth of myeloma tumour was 
monitored by ELISA quantification of serum paraprotein. The long bones were then 
dissected from the terminally diseased mice and the bone marrow contents flushed out of 
the bones. Isolated bone marrow contents were purified by Lymphocyte M gradient 
centrifugation and the mononuclear layer of cells retained. 1,000,000 mononuclear cells 
were re-injected back into other naïve syngeneic mice. At the same time naïve mice were 
injected with PBS and used as tumour-negative controls. 5T33 and 5TGM1MM mice 
developed myeloma within 6-12 weeks of inoculation. The 5TGM1MM animals 
developed osteolytic bone disease associated with myeloma tumour burden and the 5T33 
animals did not.  Naïve animals were sacrificed at the same time as terminally ill 
5T33MM and 5TGM1MM animals.  
 
Tibiae from all animals were dissected and fixed in 4% paraformaldehyde ready for tissue 
processing and sectioning. Immunohistochemical analysis of mouse tibiae sections 
infiltrated with 5T33MM and 5TGM1MM myeloma in-vivo were used to detect 
SOSTDC1 staining in tumour bearing mice compared to naïve animals. Details of 
immunohistochemical staining are outlined in section 2.12. 5T33MM and 5TGM1MM 
tibiae sections were de-waxed and antigen removal was performed using 1/4 dilution of 
trypsin reagent. Non-specific binding was blocked using 10% normal goats serum and 
sections were stained with the manufactured 1μg/ml (1:500 dilution) primary anti-
SOSTDC1 rabbit antibody or rabbit IgG isotype control overnight at 4ºC. Sections were 
further stained with a 2.5μg/ml (1:400 dilution) dilution of goat anti-rabbit biotinylated 
secondary antibody. SOSTDC1 staining was developed using DAB and counter-stained 
with Gills haematoxylin.  
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6.3.6 Comparing SOSTDC1 expression in lytic 5TGM1MM versus non-lytic 
5T33MM myeloma cells in-vitro 
 
As mentioned previously, mice injected with 5TGM1MM cells developed lytic bone 
disease similar to that observed in MM patients. However, 5T33MM mice did not 
develop bone disease associated with tumour burden. To test the hypothesis that 
SOSTDC1 expression was upregulated in lytic 5TGM1MM myeloma cells compared to 
non-lytic 5T33MM cells, the data obtained from the SOSTDC1 western blot and cDNA 
samples obtained from the experiment outlined in section 6.3.3 and 6.3.4 were re-
analysed.  
 
6.3.7 Blocking SOSTDC1 production in myeloma-OB progenitor co-cultures 
 
In previous chapters I had shown that recombinant SOSTDC1 suppressed Runx2 and 
CTNNB1 expression via Wnt and BMP signalling in differentiation OB progenitor cells. 
To relate this mechanism to MM bone disease, I investigated the effect of the SOSTDC1 
produced by lytic 5TGM1 cells on Runx2 and CTNNB1 gene expression. If the 
5TGM1MM cells were indeed producing SOSTDC1 and this SOSTDC1 was suppressing 
markers of OB differentiation, then blocking the effect of SOSTDC1 would reverse this 
suppressive effect.    
 
Quantitative RT-PCR was used to determine whether blocking SOSTDC1 in 
5TGM1MM-OB progenitor co-cultures had an effect on Runx2 and CTNNB1 gene 
expression. OB progenitor cells were harvested from a near confluent flask by 
trypsinisation and cell pellets were counted using a haemocytometer as described in 
section 2.1.3. OB progenitor cells were resuspended in MEM-Alpha medium at 57,000 
cells per well in 6 well culture plates containing 1.5ml of media within each well. 
Following 72 hours in culture, the media was removed from the adhered OB progenitor 
culture and cells were washed with PBS. Cells were differentiated in 1500µl/well of 
standard osteogenic media for up to 8 days. On day 8 of differentiation, 5TGM1MM 
myeloma cells were counted and co-cultured on the differentiating OB progenitors at a 
cell density of approximately 100,000 cells per well. Myeloma cells were co-cultured 
with the OB progenitors for 24 hours in 1ml of RPMI. In the same experiments, OB 
progenitors cultured alone, 5TGM1MM cultured alone and 5TGM1MM-OB progenitor 
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co-cultures were also incubated with 1.5µg/ml anti-SOSTDC1 polyclonal antibody from 
Abcam for the 24 hour duration.  
 
RNA was isolated from the OB progenitor cultures using the RNA mini Prep kit and 
quantified with a Nanodrop as described in section 2.13. The expression of Runx2, 
CNTTB1 and housekeeper B2M gene were quantified using TaqMan® Assays for qRT-
PCR analysis. Relative quantification of gene expression were performed by normalising 
to the house keeping B2M gene using the formula ΔCT = CT target – CT housekeeping as 
described in section 2.13.3.  
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6.4 Results  
 
6.4.1 The level of immunofluorescent SOSTDC1 staining in myeloma and OB 
progenitor co-cultures increased in both cell types 
 
Using HK-2 cells as a SOSTDC1-producing positive control, immunofluorescent 
microscopy was used to determine the presence of SOSTDC1 protein in OB progenitor 
cells, 5T33MM and 5TGM1MM cells cultured on their own. Images obtained from 
immunofluorescent microscopy of permeabilised HK-2 stained with anti-SOSTDC1 
antibody showed that HK-2 cells were positive for SOSTDC1 throughout the culture 
period (Figure 6.4.1.1 A). The red staining representing SOSTDC1 protein was apparent 
in both the nucleus and membrane of cells. HK-2 cells stained with isotype control 
antibody were negative for SOSTDC1 staining (Figure 6.4.1.1 B). 
In the same experiments, immunofluorescent microscopy of permeabilised OB 
progenitors stained with either anti-SOSTDC1 antibody or isotype control showed that 
OB progenitor cells were negative for SOSTDC1, indicated by the lack of red staining 
(Figure 6.4.1.2 A and B). Permeabilised 5T33MM and 5TGM1MM cells stained with 
anti-SOSTDC1 antibody showed variable SOSTDC1 staining (Figure 6.4.1.3 and 
6.4.1.4) in that in some experiments, some of the cells were positive for SOSTDC1 and in 
others no staining was visible. In summary, immunofluorescent microscopy data 
indicated that 5T33MM and 5TGM1MM cells produced low levels of SOSTDC1.  
 
Co-culture of 5T33MM or 5TGM1MM myeloma cells with OB progenitor cells for the 
duration of 24 hours resulted in some myeloma cells adhering to the OB progenitors, 
whilst other myeloma cells that were not bound were washed off during the 
immunocytochemistry procedure. In contrast to the variable staining associated with the 
5T33MM and 5TGM1MM cells cultured on their own, the immunofluorescent images 
taken from the co-culture cells showed clear and strong SOSTDC1 staining compared to 
the isotype controls (Figure 6.4.1.5 and Figure 6.4.1.6).  The SOSTDC1 staining 
appeared to be both intracellular and membrane bound. Furthermore, the red staining 
representing the SOSTDC1 protein was highly distinct and intense where there was direct 
contact between a myeloma cell and a OB within both 5T33MM and 5TGM1MM 
experiments. Both the OB progenitors and myeloma cells appeared to be positive for 
SOSTDC1 red fluorescence when in contact.  
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Figure 6.4.1.1 - SOSTDC1 was detected in HK-2 cells by immunofluorescent 
microscopy: (A) The red colour in the images indicated SOSTDC1 could be detected 
throughout permeabilised HK-2 cells using 1ug/ml of anti-SOSTDC1 antibody. (B) No 
staining was detected in HK-2 cells incubated with 1ug/ml isotype control antibody. Images 
of phase contrast, DAPI, CD138 and SOSTDC1 staining were visualised simultaneously. 
Images are representative of at least two replicates across three independent experiments 
(N=3). 
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Figure 6.4.1.2 - SOSTDC1 could not be detected in OB progenitors cultured on 
their own using immunofluorescent microscopy: (A) Red staining for SOSTDC1 
could not be detected in permeabilised OB progenitors stained with anti-SOSTDC1. (B) No 
staining was detected in OB progenitor cells incubated with isotype control antibody. 
Images of phase contrast, DAPI, CD138 and SOSTDC1 staining were visualised 
simultaneously. Images are representative of at least at least two replicates across three 
independent experiments (N=3) 
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Figure 6.4.1.3 - SOSTDC1 could be detected in low levels in 5T33MM cells 
cultured on their own using immunofluorescent microscopy: (A) 5T33MM cells 
were CD138+ and red staining representing SOSTDC1 was detected in some permeabilised 
5T33MM cells. (B) No SOSTDC1 staining was detected in 5T33MM cells incubated with 
isotype control antibody. Images of phase contrast, DAPI, CD138 and SOSTDC1 staining 
were visualised simultaneously. Images are representative of at least two replicates within 
three independent experiments (N=3). 
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Figure 6.4.1.4 – SOSTDC1 could be detected in 5TGM1MM cells cultured on 
their own using immunofluorescent microscopy:.(A) 5TGM1MM cells were CD138+ 
and red staining representing SOSTDC1 was detected in permeabilised 5TGM1MM cells. 
(B) No SOSTDC1 staining was detected in 5TGM1MM cells incubated with isotype control 
antibody. Images of phase contrast, DAPI, CD138 and SOSTDC1 staining were visualised 
simultaneously. Images are representative of at least two replicates within three independent 
experiments (N=3). 
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Merged 
Figure 6.4.1.5 – The levels of SOSTDC1 immunofluorescent staining in 
5T33MM and OB co-cultures increased in both cell types: (A) SOSTDC1 staining 
was detected in permeabilised 5T33MM and OB progenitor co-cultures (B) The SOSTDC1 
staining detected in 5T33MM-OB progenitor co-cultures appeared intense where there was 
direct contact between 5T33MM and the OB progenitor.  Images of phase contrast, DAPI, 
CD138 and SOSTDC1 staining were visualised simultaneously. Images are representative of 
at least two replicates within three independent experiments (N=3).   
 
 
DAPI 
CD138 
SOSTDC1 SOSTDC1 
Merged 
CD138 
DAPI 
SOSTDC1 
CD138 
DAPI 
SOSTDC1 
Merged 
A 
B 
212  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DAPI 
CD138 
DAPI CD138 SOSTDC1 
Merged 
Figure 6.4.1.6 - The levels of SOSTDC1 immunofluorescent staining in 
5TGM1MM and OB progenitor co-cultures increased in both cell types: (A) 
SOSTDC1 staining was detected in permeabilised 5TGM1MM and OB progenitor co-
cultures. (B) The SOSTDC1 staining detected in 5TGM1MM-OB progenitor co-cultures 
appeared to be more intense within both OB progenitor and 5TGM1MM cells that were in 
direct contact compared to cells that were not in contact. Images are representative of at 
least two replicates within three independent experiments (N=3). 
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6.4.2 The population of SOSTDC1-positive cells detected by Flow cytomtery 
increased in co-cultured myeloma and OB cell populations compared to either 
population cultured alone 
 
Data obtained from immunofluorescent microscopy showed that SOSTDC1 was not 
produced by OB progenitors but was produced at low levels in 5T33MM and 
5TGM1MM myeloma cells when cultured on their own. There was evidence that co-
culture of OB progenitors and myeloma cells stimulated SOSTDC1 production. The 
immunocytochemistry results were qualitative and therefore flow cytometric analysis was 
used to quantify SOSTDC1 production in individual OB progenitors and myeloma cells 
cultured on their own compared to cells co-cultured together.  
 
Scatter plots obtained from flow cytometric analysis of permeabilised HK-2 stained with 
anti-SOSTDC1 antibody showed that on average approximately 40% of HK-2 cells were 
positive for SOSTDC1. Less than 1% of the HK-2 cell population were positive for 
SOSTDC1 when stained with isotype control antibody (Figure 6.4.2.1 C). A population 
of the permeabilised 5T33MM-GFP and 5TGM1MM-GFP cells that were cultured on 
their own and stained with anti-SOSTDC1 antibody were SOSTDC1+ (Figure 6.4.2.1). 
This data confirms that myeloma cells do produce SOSTDC1 and this production can be 
seen using a more sensitive assay such as flow cytometry. Data also showed that in the 
population of OB progenitor cultured alone and stained with either anti-SOSTDC1 
antibody or isotype control, there was no significant right shift (<1%) on the scatter plots 
suggesting no specific staining. This flow cytometry data was confirmatory of the 
immunofluorescent microscopy data, suggesting that OB progenitor cells cultured on 
their own do not produce SOSTDC1 (Figure 6.4.2.2).  
 
Flow cytometry scatter plots obtained from myeloma-OB progenitor co-cultures showed 
that some cells within the 5T33MM/5TGM1MM myeloma population as well as within 
the OB progenitor population were SOSTDC1+ compared to their respective isotype 
controls (Figure 6.4.2.3 and Figure 6.4.2.4). Findings showed that 5T33MM-OB 
progenitor co-culture resulted in the ‘switch on’ of SOTSDC1 in the OB progenitor 
population. However, the percentage of SOSTDC1+ 5T33MM cells from the co-culture 
did not increase compared to percentage of SOSTDC1+ 5T33MM cells cultured on their 
own (Figure 6.4.2.2). Flow cytometry data from the 5TGM1MM co-culture experiments 
also showed that that 5TGM1MM-OB progenitor co-culture resulted in the ‘switch’ on of 
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SOTSDC1 in the OB progenitor population (Figure 6.4.2.3 A, B). Interestingly, the 
proportion of SOSTDC1+ 5TGM1MM cells from the co-culture increased in comparison 
to the proportion SOSTDC1+ 5TGM1MM cells cultured on their own. This data provides 
evidence for the rational that if SOSTDC1 has a key role in OB progenitor suppression, 
then its upregulation by myeloma cells is dependent on contact between tumour and the 
bone microenvironment. This data suggested that interaction between myeloma-OB 
progenitors stimulated the OB progenitor cells to produce SOSTDC1, illustrated by the 
right shift in the OB progenitor population in the scatter plots. 
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Figure 6.4.2.1 – SOSTDC1 was detected in 5T33MM and 5TGM1MM myeloma 
cells by Flow cytometry: HK-2 cells were used as a positive control. The percentage of 
SOSTDC1 positive cells was determined by setting gating threshold at <1% for the isotype 
control. (A) A population of 5T33MM-GFP cells were positive for SOSTDC1 protein in 
comparison to the isotype control (B) A comparably sized population of 5TGM1MM-GFP 
cells were also positive for SOSTDC1 protein in comparison to the isotype control. (C) 
SOSTDC1+ cells are represented by a right shift in Hk-2 and myeloma cell populations. 
N=8, Man-Whitney, ***P<0.001, ****P<0.0001) 
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Figure 6.4.2.2 - SOSTDC1 was upregulated in OB progenitor cells that were co-
cultured with 5T33MM cells as detected by flow cytometry: (A) OB progenitors 
cultured on their own were not SOSTDC1+ (<1%). OB progenitors co-cultured with 
5T33MM-GFP cells were positive for SOSTDC1 protein. Some 5T33MM-GFP cells cultured 
alone produced SOSTDC1. (B) SOSTDC1+ cells are represented by a right shift in OB 
progenitors and 5T33MM -GFP populations in the scatter plots. N=4 independent 
experiments, Man-Whitney, **P<0.01. 
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Figure 6.4.2.3 - SOSTDC1 was upregulated in both OB progenitor and 5TGM1 
populations co-cultured together as detected by flow cytometry: (A) OB 
progenitors cultured on their own were not SOSTDC1 positive (<1%). SOSTDC1 was 
switched on in OB progenitors that were co-cultured with 5TGM1-GFP cells. Some 
5TGM1MM-GFP cells cultured alone were positive for SOSTDC1. Compared to 
5TGM1MM-GFP cells cultured alone, a larger proportion of 5TGM1MM-GFP cells that 
were co-cultured with OB progenitors produced SOSTDC1. (B) SOSTDC1+ cells are 
represented by a right shift in OB progenitor and 5TGM1MM populations on the scatter 
plots. N=3 independent experiments, Man-Whitney, *P=<0.05, **P<0.001. 
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6.4.3 SOSTDC1 protein and RNA levels increased in myeloma/OB progenitor cells 
sorted from co-cultures 
 
To confirm that SOSTDC1 levels were upregulated in both individual myeloma and OB 
progenitor cell populations from co-cultures, whole co-cultures were sorted into separate 
OB and myeloma cell populations using FACS Aria technology. Western blotting was 
used to detect SOSTDC1 protein levels in sorted 5T33MM-GFP and 5TGM1MM-GFP 
myeloma cells co-cultured with differentiating OB progenitors. Similar to results obtained 
from flow cytometric analysis, western blot analysis confirmed SOSTDC1 detection in 
the OB progenitor population sorted from both 5T33MM-OB progenitor and 
5TGM1MM-OB progenitor co-cultures in comparison to an absence of SOSTDC1 in OB 
progenitors cultured alone. Furthermore, there was no difference between the SOSTDC1 
levels in 5T33MM cells co-cultured with OB progenitors compared to 5T33MM cultured 
on their own (Figure 6.4.3.1 A). However, there was an increase in SOSTDC1 protein in 
the 5TGM1MM cells sorted from the co-cultures compared to 5TGM1MM cultured on 
their own (Figure 6.4.3.1 B).  
 
End-point RT-PCR was performed to assess the expression of SOSTDC1 as an RNA 
gene transcript.  End-point PCR confirmed SOSTDC1 expression in the OB progenitor 
population sorted from both 5T33MM-OB progenitors and 5TGM1MM-OB progenitors 
co-cultures (band was visible) in comparison no SOSTDC1 expression in OB progenitors 
cultured alone (no band detected). In addition, the PCR product band representative of 
SOSTDC1 expression in myeloma cells sorted from myeloma-OB progenitor co-cultures 
appeared stronger suggesting a higher level of SOSTDC1 expression compared to 
myeloma cells cultured on their own (Figure 6.4.3.2 A, B). Sequencing of the end-point 
RT-PCR products were used to verify that the myeloma and co-cultured cells did express 
SOSTDC1. The sequence of bases obtained from the sequencing analysis of OB 
progenitors cultured alone showed that these cells did not have a similar homology to any 
form of SOSTDC-specific nucleotide collection using the BLAST software (Appendix 
4). However, data did show that the 5T33MM, 5TGM1MM, OB and 
5T33MM/5TGM1sorted from myeloma-OB progenitor co-cultures did have between 98-
100% homology to the Mus musculus Sostdc1, mRNA (NM_025312.3) sequence (Figure 
6.4.3.3).  
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Figure 6.4.3.1 – SOSTDC1 protein levels detected by western blotting were 
upregulated in osteoblast and myeloma cell populations sorted from osteoblast-
myeloma co-cultures: Protein was extracted from sorted samples and non-adherent 
5T33MM cells obtained from co-culture media. HK-2 cell lysates were used as a positive 
control for SOSTDC1 protein production. The western blot image is representative of three 
independent experimental repeats. (A and B) SOSTDC1 was detected in the OB population 
sorted from OB-5T33MM and OB-5TGM1MM co-culture in comparison to an absence of 
SOSTDC1 in OB cultured alone (*P<0.05). (B) SOSTDC1 protein levels obtained from 
adherent 5TGM1MM cells increased compared with no-adherent 5TGM1MM. N=3 
independent experiments, Man-Whitney, *P<0.05.  
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Figure 6.4.3.2 - SOSTDC1 expression was detected by end-point RT-PCR in 
sorted OB progenitor and 5T33MM/5TGM1MM cells that had been co-
cultured together: (A, B) SOSTDC1 was expressed in the OB progenitor population 
sorted from 5T33MM/5TGM1MM-OB progenitor co-cultures in comparison to no 
SOSTDC1 expression in OB progenitors cultured alone. SOSTDC1 expression was 
detectable in 5T33MM and 5TGM1MM cells cultured on their own. N=3 independent 
experiments. The HK-2 was used as a positive control for SOSTDC1 expression at 200pb. 
The gel image is representative of three independent experimental repeats. 
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Figure 6.4.3.3 - SOSTDC1 cDNA sequencing of 5T33MM and 5TGM1MM cells: End-
point RT-PCR products obtained from 5T33MM/5TGM1MM myeloma cells were sequenced 
for SOSTDC1 using SOSTDC1-specific primers. The (A)5T33MM and (B) 5TGM1MM had 
>98% homology with the SOSTDC1-specific sequence identified in BLAST (NCBI Reference 
Sequence: NM_025312.3). Images are representative of one sequencing assay with the 
reverse primer for SOSTDC1 (5’-TGTGGCTGGACTCGTTGTGC-3’). N=3 independent 
experiments. 
 
Score Expect Identities Gaps Strand 
241 bits(130) 1e-60 131/132(99%) 0/132(0%) Plus/Minus 
Query 1    TTTGTAGGTGCGCGTGCTGCCGTCCTGACACTGCAGCTGGNTCCTCTGGGTGCGCGTCTT  60 
           |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||| 
Sbjct 593  TTTGTAGGTGCGCGTGCTGCCGTCCTGACACTGCAGCTGGATCCTCTGGGTGCGCGTCTT  53 
 
Query 61  GTCGTTGACACACCGCCACTCCTGAGAGCTCCTCCGGCTCCAGTACTTTGTTCCATAGCC  120 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 533 GTCGTTGACACACCGCCACTCCTGAGAGCTCCTCCGGCTCCAGTACTTTGTTCCATAGCC  474 
 
Query 121 TCCTCCGATCCA  132 
          |||||||||||| 
Sbjct 473 TCCTCCGATCCA  462 
 
 
5T33MM 
Score Expect Identities Gaps Strand 
165 bits(89) 7e-38 106/118(90%) 0/118(0%) Plus/Plus 
Query  1    CGTACCCAGAGAATCCAGCTGCAGTGCCNTTANGGCAGCACACGCACCTACAAAATCACA  60 
            ||||||||||||||||||||||||||||   | ||||||||||||||||||||||||||| 
Sbjct  606  CGTACCCAGAGAATCCAGCTGCAGTGCCAAGATGGCAGCACACGCACCTACAAAATCACA  665 
 
Query  61   GTANTCCCTGCCTGCCAGTGCAAGANGTACACCCGGCAGCanaannaGTCCAGCCACA  118 
            ||| || |||||||| ||||||||| ||||||||||||||| ||  ||||||| |||| 
Sbjct  666  GTAGTCACTGCCTGCAAGTGCAAGAGGTACACCCGGCAGCACAACGAGTCCAGTCACA  723 
5TGM1MM 
A 
B 
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OB from 5TGM1MM Co-culture 
Score Expect Identities Gaps Strand 
130 bits(70) 2e-27 74/77(96%) 0/77(0%) Plus/Minus 
Query  2    TTTTGTCATTGACACACCGCCACTCCTGGNANCTCCTCCTGCTCCAGTACTTTGTTCCAT  61 
            ||||||||||||||||||||||||||||| | |||||||||||||||||||||||||||| 
Sbjct  603  TTTTGTCATTGACACACCGCCACTCCTGGGAGCTCCTCCTGCTCCAGTACTTTGTTCCAT  544 
 
Query  62   AGCCTCCTCCGATCCAG  78 
            |||||||||| |||||| 
Sbjct  543  AGCCTCCTCCAATCCAG  527 
Figure 6.4.3.4 - SOSTDC1 cDNA sequencing of 5T33MM/5TGM1MM sorted 
from myeloma-OB progenitor co-cultures: End-point RT-PCR products obtained 
from myeloma cells sorted from OB progenitor co-cultures were sequenced for SOSTDC1 
using SOSTDC1-specific primers. The co-cultured (A) 5T33MM and (B) 5TGM1MM cells 
had 100% homology with the SOSTDC1-specific sequence identified in BLAST 
(NM_025312.3).Images are representative of one sequencing assay with the reverse primer 
for SOSTDC1 (5’-TGTGGCTGGACTCGTTGTGC-3’). N=3 independent experiments. 
 N=3.  
 
Score Expect Identities Gaps Strand 
113 bits(61) 1e-22 66/70(94%) 0/70(0%) Plus/Minus 
Query  1    GTCATTGACACACCGCCACTCCTGGNANCTCCTCCTGCTCCAGTACTTTGTTCCATANCC  60 
            ||||||||||||||||||||||||| | ||||||||||||||||||||||||||||| || 
Sbjct  599  GTCATTGACACACCGCCACTCCTGGGAGCTCCTCCTGCTCCAGTACTTTGTTCCATAGCC  540 
 
Query  61   TCCTCCGATC  70 
            |||||| ||| 
Sbjct  539  TCCTCCAATC  530 
5T33MM from Co-culture 
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B 
223  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.4.3.5 - SOSTDC1 cDNA sequencing of OB progenitors sorted from 
myeloma-OB progenitor co-cultures: End-point RT-PCR products obtained from OB 
progenitors sorted from 5T33MM/5TGM1MM myeloma co-cultures were sequenced for 
SOSTDC1 using SOSTDC1-specific primers. The OB progenitor cells collected from (a) 
5T33MM and (B) 5TGM1MM co-cultures had 100% homology with the SOSTDC1-specific 
sequence identified in BLAST (NM_025312.3). Images are representative of one sequencing 
assay with the reverse primer for SOSTDC1 (5’-TGTGGCTGGACTCGTTGTGC-3’). N=3 
independent experiments. 
 
Score Expect Identities Gaps Strand 
241 bits(130) 1e-60 131/132(99%) 0/132(0%) Plus/Minus 
Query  1    TTTGTAGGTGCGCGTGCTGCCGTCCTGACACTGCAGCTGGATCCTCTGGGTGCGCGTCTT  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  593  TTTGTAGGTGCGCGTGCTGCCGTCCTGACACTGCAGCTGGATCCTCTGGGTGCGCGTCTT  534 
 
Query  61   GTCGTTGACACACCGCCACTCCTGANAGCTCCTCCGGCTCCAGTACTTTGTTCCATAGCC  120 
            ||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||| 
Sbjct  533  GTCGTTGACACACCGCCACTCCTGAGAGCTCCTCCGGCTCCAGTACTTTGTTCCATAGCC  474 
 
Query  121  TCCTCCGATCCA  132 
            |||||||||||| 
Sbjct  473  TCCTCCGATCCA  462 
OB from 5T33MM Co-culture 
Score Expect Identities Gaps Strand 
148 bits(80) 4e-33 80/80(100%) 0/80(0%) Plus/Minus 
Query  1    GCGCGTCTTGTCGTTGACACACCGCCACTCCTGAGAGCTCCTCCGGCTCCAGTACTTTGT  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  542  GCGCGTCTTGTCGTTGACACACCGCCACTCCTGAGAGCTCCTCCGGCTCCAGTACTTTGT  483 
 
Query  61   TCCATAGCCTCCTCCGATCC  80 
            |||||||||||||||||||| 
Sbjct  482  TCCATAGCCTCCTCCGATCC  463 
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6.4.4 Assessing the dependency of SOSTDC1 production on direct OB-myeloma 
interaction 
 
In section 6.4.3 I observed an increase in the proportion of SOSTDC1+ 5TGM1MM cells 
that were co-cultured with OB progenitors. To test the concept that SOSTDC1 is 
upregulated in myeloma cells as a result of direct interaction between the myeloma and 
OB progenitor cell, co-culture experiments were set up as previously described in section 
6.2. In these experiments, co-culture of 5T33MM-GFP/5TGM1MM-GFP with OB 
progenitor resulted in some myeloma cells adhering to the OB progenitors. From these 
co-cultures, the media that contained the non-adhering myeloma population was removed 
and maintained as a separate sample ready for flow cytomtery analysis. Flow cytomteric 
analysis was used to compare the proportion of SOSTDC1+ myeloma cells from adherent 
and non-adherent populations, I showed that there was no difference between the 
proportions of SOSTDC1+ non-adherent 5T33MM cells compared to adherent 5T33MM 
cells sorted from 5T33MM-OB progenitor co-cultures. Flow cytometric analysis of 
adherent and no-adherent 5TGM1MM showed a significantly higher number of adherent 
5TGM1MM cells sorted from the myeloma-OB progenitor co-cultures were SOSTDC1+ 
compared to the non-adherent 5TGM1MM population (Figure 6.4.4.1 A, B). 
 
In other experiments, co-cultures were set up and sorted by FACS Aria into separate 
populations prior to protein extraction as previously described in section 6.3. Western blot 
analysis was performed to assess SOSTDC1 protein level in adherent and non-adherent 
myeloma cells. Densitometry, normalised to GAPDH protein levels  showed that the 
average density of bands representing SOSTDC1 protein did not differ between the non-
adherent population and adherent 5T33MM cells sorted from 5T33MM-OB progenitor 
co-cultures (Figure 6.4.4.2 A).  Similar to the flow cytomtery data, western blotting 
showed adherent 5TGM1MM cells sorted from the myeloma-OB progenitor co-cultures 
had higher SOSTDC1 protein levels compared to the non-adherent 5TGM1MM cells that 
were floating the media of co-cultures (Figure 6.4.4.2 B).  
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Figure 6.4.4.1 – The proportion of SOSTDC1+ 5TGM1MM cells increased as a 
result of direct myeloma-OB progenitor interaction: (A) There was no difference in 
the proportion of SOSTDC1+ cells from non-adherent 5T33MM-GFP cells compared to the 
5T33MM-GFP adherent population. (B) The proportion of SOSTDC1+ 5TGM1MM-GFP 
cells was higher in adherent myeloma cells compared to non-adherent cells floating in the 
co-culture media. N=3 independent experiments, Man-Whitney, *P<0.05. 
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Figure 6.4.4.2 - Direct 5TGM1MM-OB progenitor interaction upregulated 
SOSTDC1 protein levels: Following co-culture, 5T33MM-GFP/5TGM1MM-GFP cells that 
had adhered to the OB progenitors were sorted by FACS Aria into separate populations. Western blot 
images are representative of three independent experimental repeats. (A) There was no difference in 
SOSTDC1 levels in 5T33MM cells co-cultured compared to 5T3MM cells cultured alone (B) 
SOSTDC1 protein levels obtained from 5TGM1MM cells adherent to OB progenitors increased 
compared to non-adherent 5TGM1MM cells. N=3 independent experiments, Man-Whitney, *P<0.05. 
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6.4.5 SOSTDC1 was present in tibea bearing myeloma tumour and not naïve 
animals determined by immunohistochemical analysis  
 
Immunohistochemical analysis of mouse tibiae sections infiltrated with 5T33MM and 
5TGM1MM myeloma in-vivo was used to detect SOSTDC1 staining in diseased mice 
compared to naïve animals. 5T33MM and 5TGM1MM tibiae sections were stained with 
anti-SOSTDC1 rabbit or isotype control antibody to detect the presence of SOSTDC1 
protein. Immunohistochemical staining showed that SOSTDC1 protein was present in 
both 5T33MM and 5TGM1MM sections compared to their respective isotype controls. 
This staining appeared mainly focused in the myeloma cells/colony vicinity, strongest 
within the myeloma cells themselves. The staining appeared around the myeloma cells as 
well as within the cells themselves; correlating with the fact that SOSTDC1 is a secreted 
protein (Figure 6.4.5.1 A, B). Naïve tibiae sections that were did not have myeloma did 
not appear to have SOSTDC1 present. Some light brown staining did appear around the 
megakaryocytes but this staining was also present in some of the isotype controls (Figure 
6.4.5.1 C). 
 
In immunohistochemical analysis of mouse tibiae sections infiltrated with myeloma, it 
was difficult to identify many OB cells in close proximity of myeloma colonies. The OB 
cells that were identified appeared to be more morphologically similar to bone lining 
cells.  Immunohistochemical analysis showed a lack of OB cells in close proximity to 
5TGM1MM myeloma cells which were stained positive for SOSTDC1 (Figure 6.4.5.2 
A). In the same 5TGM1MM section where no myeloma colony was present OB/bone 
lining cells were present (Figure 6.4.5.2 B).  
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Figure 6.4.5.1 - SOSTDC1 was detected using immunohistochemistry in 
5T33MM and 5TGM1MM tibia in vivo: (A) SOSTDC1 staining was present in 
5T33MM sections compared to the isotype antibody and this staining was mainly confined to 
the myeloma cells/colony area. (B) SOSTDC1 staining was present in 5TGM1MM sections 
compared to the isotype CT and this staining was specific in regions the myeloma 
cells/colonies were present. (C) Naïve tibia sections did not appear to produce SOSTDC1. 
Images are representative of at 3 slides from N=6.   
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Figure 6.4.5.2 - There were few OB/bone-lining cells in proximity of SOSTDC1-
positive myeloma colonies: Images are representative of different areas within the same 
slide. (A) There were few OB cells or bone- lining in close proximity of myeloma colonies 
that were positive for SOSTDC1 staining. (B) In the same 5TGM1MM section , where no 
myeloma colony was present, more OB cells were present.  
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6.4.6 Lytic 5TGM1MM myeloma cells express more SOSTDC1 compared to non-
lytic 5T33MM myeloma cells   
 
As mentioned previously, mice injected with 5TGM1MM cells developed lytic bone 
disease similar to that observed in MM patients. However 5T33MM mice did not develop 
bone disease associated with tumour burden. To test the hypothesis that SOSTDC1 
expression was upregulated in lytic 5TGM1MM myeloma cells compared to non-lytic 
5T33MM cells, the data obtained from the SOSTDC1 western blot and end-point RT-
PCR experiment outlined in section 6.4 were re-analysed. 
 
Western blotting analysis of the average density calculated for SOSTDC1 protein levels 
(normalised to GAPDH), was upregulated in lytic 5TGM1MM cells produced compared 
to non-lytic 5T33MM myeloma cells (*P<0.05, Figure 6.4.6.1 A). End-point RT-PCR 
analysis was used to determine whether lytic 5TGM1MM myeloma cells had higher 
SOSTDC1 expression in comparison to non-lytic 5T33MM myeloma cells. The average 
density of SOSTDC1 PCR product bands were normalised to GAPDH. Lytic 5TGM1MM 
cells expressed more SOSTDC1 compared to non-lytic 5T33MM myeloma cells 
(*P<0.05, Figure 6.4.6.1 B).  
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Figure 6.4.6.1 - 5TGM1MM cells produced more SOSTDC1 than 5T33MM 
cells: (A) Western blot analysis showed that lytic 5TGM1MM cells produce more SOSTDC1 
protein compared to non-lytic 5T33MM myeloma cells (B) End-point RT-PCR analysis 
showed that lytic 5TGM1MM cells express higher level of SOSTDC1 compared to non-lytic 
5T33MM myeloma cells. N=3 independent experiments, Man-Whitney, *P<0.05.  
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Figure 6.4.6.2 – Anti-SOSTDC1 antibody reversed 5TGM1-induced 
suppression of Runx2 expression in OB progenitors: (A) 5TGM1MM cells cultured 
alone did not produce detectable levels of Runx2. Runx2 was detected in differentiating OB 
progenitors cultured alone. (B) Runx2 gene expression in OB progenitors was reduced in 
the presence of 5TGM1MM myeloma cells and treatment of 5TGM1MM-OB progenitor co-
cultures with anti-SOSTDC1 antibody reversed this effect restoring Runx2 levels.  N=3 
independent experiments, Students t-tes (A). One-Way Anova, with Holme-Sidak’s adhoc test 
(B) *P<0.05.  
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6.5 Discussion  
 
MM is associated with the suppression of OB activity leading to osteolytic bone disease. 
In recent years it has been suggested that myeloma and OB interaction may be involved 
in the regulation and promotion of osteolytic bone disease via suppression of 
osteoblastogensis. The molecular mechanisms by which myeloma cells inhibit OB 
activity and the consequences of myeloma-OB interaction on myeloma cell growth and 
OB suppression are unclear. In previous chapters I showed that SOSTDC1 had more of 
suppressive effect on OB progenitors when they were in the stages of differentiation (day 
8-11 in culture). This provided the rational for assessing SOSTDC1 expression during the 
early phase of OB progenitor differentiation. The aim of this study was to determine 
whether myeloma cells and OB progenitors express SOSTDC1 and to also establish the 
conditions under which SOSTDC1 is expressed with reference to the question; is 
SOSTDC1 expression dependent on myeloma-OB progenitor interaction? Thus the main 
aim of this study was to determine the conditions under which myeloma and OB 
progenitor cells produced SOSTDC1, testing the hypotheses that the 5TMM and OB 
progenitors produce SOSTDC1 and that the direct interaction between myeloma and OB 
progenitors upregulates the production of SOSTDC1 in both myeloma and OB progenitor 
cells. Interestingly my data support the hypothesis that myeloma cells produce SOSTDC1 
and refute the hypothesis that OB progenitors produce SOSTDC1. Additionally, my 
findings from this study also support the hypothesis that myeloma-OB progenitor 
interaction upregulates SOSTDC1 expression in both cell types.   
 
Due to the heterogeneity associated with myeloma disease, cell cultures originating from 
both 5T33MM and 5TGM1MM C57BL/KaLwRij mice were tested separately in this 
study. In preliminary experiments, the presence of SOSTDC1 was tested qualitatively by 
immunofluorescent microscopy. Originally, 5T33MM-GFP and 5TGM1MM-GFP 
myeloma cells were used to verify the presence of myeloma cells in 
immunocytochemistry experiments, particularly so that the myeloma cells could be 
distinguished from the OB progenitor cells when in co-culture. However, the GFP in 
myeloma cells was difficult to detect following fixation (live cells were tested to 
compare). One possible reason for this may have been the cell fixation process in 4% 
formalin (pH 6.8) in PBS resulted in some degradation of the GFP on the myeloma cells. 
Studies have shown that GFP is more stable in a hypotonic solution with a pH range of 
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7.5 - 8.5 and shifts in structure/stability outside this pH range (Tavare, Fletcher et al. 
2001). An alternative would have been to use Paraformaldyhye (PFA). However all 
aspects of the immunostaining protocol had been optimised using the anti-SOSTDC1 
antibody which only stained using 4% formalin as a fixative. As an alternative, CD138 
plasma cell protein was used to verify the presence of myeloma cells.  
 
In my studies, a known density of myeloma and differentiated OB progenitor cells 
cultured on their own were fixed with 4% formalin and stained with the commercial anti-
SOSTDC1 rabbit polyclonal antibody overnight. To further determine that the myeloma 
cells were positive for the plasma cell marker CD138, the cells were co-stained with an 
anti- CD138 rabbit antibody. These immunofluorescent experiments were consistent in 
showing that differentiating OB progenitor cells did not stain positive for SOSTDC1 
compared to the HK-2 cell positive controls, which were strongly positively stained for 
SOSTDC1.  
 
On the other hand, the immunofluorescent staining for SOSTDC1 in the 5T33MM-GFP 
and 5TGM1MM-GFP myeloma cells showed myeloma cells produced SOSTDC1 in low 
levels. The problem with using immunofluorescent microscopy as a method of SOSTDC1 
detection in myeloma cells was that non-adherent myeloma cells has to be artificially 
attached to the culture plate surface. The main issue was that although Poly-L-Lysine was 
used to facilitate the adherence of the myeloma cells to the culture plate wells, the 
washing steps throughout the immunoassay resulted in many of the myeloma cells 
detaching. In some experiments SOSTDC1 was detected in a few of remaining attached 
myeloma cells, whilst in others no SOSTDC1 was detected. Flow cytometry was used to 
verify the data obtained from the immunofluorescent microscopy analysis using the same 
experimental setup. This time when myeloma cells were screened for the presence of 
SOSTDC1 using flow cytometry, GFP could be detected using the same method as 
immunofluorescent microscopy. Although the reason for this is unclear, a possible 
explanation is that various studies looking at protein detection in cells using both flow 
cytometry and immunofluorescent microscopy have shown that flow cytometry is more 
sensitive of the two methods (Jenson, Grant et al. 1998, Muratori, Forti et al. 2008).  
 
Flow cytometric analysis showed that between 5-10% of the 5T33MM and 5TGM1MM 
myeloma cells were positive for SOSTDC1, suggesting that variability seen in the 
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immunofluorescent microscopy may have been due to technical issues. The low number 
of myeloma cells that were adherent to the plate surface by the end stage of the 
immunofluorescent assay and the small percentage of myeloma cells that were positive 
for SOSTDC1 as detected by flow cytometry, could mean that many SOSTDC1 positive 
cells were detached and washed off during the immunofluorescent assay. This may 
explain why in immunofluorescent microscopy experiments, some myeloma cells 
produced SOSTDC1 whilst in others SOSTDC1 could not be detected. 
 
Initially, co-culture conditions were tested to determine the minimum time required for 
SOSTDC1 to be produced and the optimal media conditions that both the OB progenitor 
and myeloma cells required for growth. This pilot data determined that in order to 
produce SOSTDC1, OB progenitors and 5T33MM cells required co-culturing overnight 
and SOSTDC1 was still present at 48 hours following co-culture. To maintain minimum 
variability between experiments, all co-cultures were carried out for 24 hours. In addition, 
it was determined that although OB progenitors could be maintained for up to 48 hours in 
RPMI myeloma media, the 5T33MM cells started to die and would not adhere to the OB 
progenitors at 24 hours in co-culture when in OGM. Therefore, differentiated OB 
progenitor cells were co-cultured with 5T33MM or 5TGM1MM cells for 24 hours in 
RPMI.  
 
Flow cytometry and immunofluorescent microscopy data were clear in showing that 
compared to cells cultured on their own, OB progenitors and myeloma co-cultured 
together produced SOSTDC1. The immunofluorescent analysis of co-cultures showed 
that SOSTDC1 appeared to be present within both the myeloma cells and also the OB 
progenitors. This staining was focused where the OB progenitor and myeloma cells were 
physically interacting.  Flow cytometric data was able to confirm this quantitatively 
where the myeloma-GFP-population could actually be distinguished from the OB 
progenitor population. The proportion of SOSTDC1 positive myeloma cells were 
compared to the proportion of SOSTC1 positive OB progenitor cells. I showed that where 
OB progenitors did not produce detectable levels of SOSTDC1 when cultured on their 
own, SOSTDC1 production was induced in the OB progenitor as a result of interaction 
with the myeloma cells. Interestingly, although SOSTDC1 levels did not vary in 
5T33MM that were co-cultured with OB progenitors compared to 5T33MM cells that 
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cultured on their own, a significant difference could be seen in the same experiments 
using 5TGM1MM cells.  
 
Although flow cytometry data indicated that SOSTDC1 production was induced as a 
result of OB progenitors and myeloma cell co-culture, there was a need for a more 
sophisticated method of separating the two cell populations for analysis of SOSTDC1 
expression.  Myeloma-GFP-OB progenitor co-cultures were sorted by FACS Aria in a 
similar method to the one outlined by C. Edwards et al (Edwards, Lwin et al. 2009). 
Western blot analysis and End-point PCR showed that the sorted GFP positive myeloma 
cells and GFP-negative OB progenitor, as individual populations, were positive for 
SOSTDC1 expression. Both western blot and End-point RT-PCR data correlated with the 
flow cytometry analysis, in that SOSTDC1 production was switched on in OB progenitor 
cells following co-culture with myeloma cells. Western blotting further determined that 
SOSTDC1 protein levels increased in 5TGM1MM cells that had been co-cultured with 
OB progenitor cells compared to 5TGM1MM cells cultured on their own. 
 
The hypothesis that SOSTDC1 expression is dependent on myeloma-OB physical 
interaction is important in understanding role of SOSTDC1 in osteolytic bone disease in 
MM. To test this hypothesis, I determined the levels of SOSTDC1 protein present in the 
myeloma cells that were co-cultured with OB progenitors but had not adhered to the OB 
progenitor cells. Western blot and flow cytometry analysis showed that co-cultured 
5TGM1MM cells that had adhered to OB progenitors contained higher SOSTDC1 protein 
levels compared to those myeloma cells that had not adhered to the OB progenitors. 
Identical experiments with 5T33MM showed that there was no difference between 
adherent and non-adherent 5T33MM cells co-cultured with OB progenitors.  
 
Immunohistochemical analysis of 5T33MM and 5TGM1MM tibiae sections stained with 
anti-SOSTDC1 antibody confirmed that SOSTDC1 was present in bone that was 
infiltrated with myeloma disease. There was a lack of SOSTDC1 staining in naïve bone 
sections, indicating that SOSTDC1 was only expressed in sites associated with myeloma 
bone disease. The presence of SOSTDC1 appeared most focused where the myeloma cell 
colonies were located. As the myeloma sections were obtained 10 days post-injection, 
some OB/bone-lining cells were still present within the myeloma-infiltrated bone. In parts 
of these 5T33MM/5TGM1MM sections, where myeloma colonies were stained for 
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SOSTDC1, no OB/bon-lining cells could be identified. However in parts of the same 
5T33MM/5TGM1MM sections where no myeloma colonies were present, there was a 
lack of SOSTDC1 staining and some OB/bone-lining cells were present.  
 
Western blotting and end-point RT-PCR data indicated that 5TGM1MM cells expressed a 
higher level of SOSTDC1 compared to 5T33MM cells. The 5T33MM myeloma model is 
an aggressive form of myeloma with evident signs of morbidity at 4 weeks. Reports vary 
on the development of osteolytic bone disease in 5T33MM models. Although some 
laboratories have reported diffuse osteolytic bone lesions in their 5T33MM mice, in our 
laboratory the C57BL/KaLwRij mice injected with 5T33MM cells did not develop bone 
disease. This variability could be explained as mice are injected with in-vitro growing 
variants rather than parental cells. In the literature the 5T33MM model is now used more 
for investigating myeloma cell homing and proliferation the more recently developed 
5TGM1MM model is preferred for the study of bone disease related to tumour burden 
(Croese, Vas Nunes et al. 1987, Vanderkerken, De Raeve et al. 1997). These data support 
the rational that SOSTDC1 is a molecule that may be involved in the induction of 
osteolytic bone disease in myeloma. Therefore would be predicted that SOSTDC1 would 
be more of a regulator role in the lytic 5TGM1MM model in comparison to the non-lytic 
5T33MM model. Furthermore, the Taqman gene expression assays showed that Runx2 
expression levels decreased in OB progenitors co-cultured with 5TGM1MM myeloma 
cells and treatment with anti-SOSTDC1 antibody reversed this effect. This data is 
compelling in that is suggests that SOSTDC1 in fact does module the suppression of OB 
differentiation induced by myeloma cells.  
 
Although the 5TMM series are reproducible and an excellent model for MM studies, 
there is a constant need for the development of these animal models to further enhance 
our understanding of MM as well as the limitations associated with them. In humans, MM 
is heterogeneous as a disease and this poses a problem in that no single animal model can 
constitute of all MM features. This study would benefit from looking into SOSTDC1 
expression in human myeloma cell lines and human BM samples so as to move into 
translational research for potential therapeutic purposes.  
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Chapter 7 – General Discussion  
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7.1 Discussion  
 
To better understand the molecular mechanism involved in osteolytic bone destruction 
associated with MM, the biochemical pathways and soluble factors involved need to be 
identified. Until recently, research has focused on identifying the mechanisms resulting in 
increased osteoclastogenesis and OC activation, with particular interest in the role of the 
RANK/OPG signalling axis (Pearse, Sordillo et al. 2001). The current therapies that are 
administered to MM patients suffering from bone disease target increased osteolysis 
mainly caused by osteoclasts-induced bone resorption . Bisphosphonates such as 
pamidronate, zoledronic acid and clodronate form the foundations of the management of 
myeloma-related bone disease on an international scale (Terpos, Roodman et al. 2013). 
However, in the past few years, it has become apparent that the impairment of bone 
formation is key to the uncoupling of bone remodelling in MM. As a result there is an 
essential need for therapeutic agents that also target the OB suppression observed in MM 
bone disease.  
 
Myeloma cells themselves have been implicated in the inhibition of bone formation by 
preventing OB differentiation (Oshima, Abe et al. 2005, Giuliani, Rizzoli et al. 2006). 
However, functional data is limited and little is known about the causal roles of the 
suppression of bone formation in MM bone disease. A number of extracellular molecules 
have been implicated in the reduced osteoblastogensis observed in patients with MM, 
including the Dkk and SFRP family of proteins (Tian, Zhan et al. 2003, Giuliani, Morandi 
et al. 2007). In the last decade studies have linked increased Dkk1 protein levels in MM 
with decreased OB activity in bone remodelling (Tian, Zhan et al. 2003). Further to this, 
our group has shown that blocking Dkk1 impedes suppression of bone formation and 
prevents osteolytic bone disease from developing in MM. Nevertheless, data also show 
that Dkk1 levels are not up-regulated in the serum of all MM patients (Heath, Chantry et 
al. 2009). Consequently, MM patients with normal Dkk1 levels cannot be treated with the 
current  
 
Based on these findings, we can assume that other molecules, either produced by the 
myeloma cells, or produced by other cells within the bone microenvironment, are 
involved in suppression of bone formation. In our search to identify other molecules that 
that could have a potential causal role in the suppression of osteoblastogenesis in MM, we 
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identified SOSTDC1 (data unpublished), as a gene that was highly upregulated in the 
murine 5T2MM myeloma model compared to naïve animals using Affymetrix 
GeneChip™, TaqMan™ gene expression assays and immunohistochemistry (Buckle et 
al, 2014). The identification of SOSTDC1 in the 5T2MM model was particularly 
interesting due the fact that mice which are injected with 5T2MM cells develop osteolytic 
bone disease that is similar to that observed in human MM patients. With the exception of 
the present study, SOSTDC1 has previously not been associated with myeloma-related 
bone disease.  
 
Within the literature there is evidence for the expression of SOSTDC1 and its orthologues 
in various tissues including embryos, teeth, hair follicles, breast and kidney, with 
particular focus on a  modulatory role for SOSTDC1 in Wnt and BMP signalling 
(Laurikkala, Kassai et al. 2003, Yanagita, Oka et al. 2004, Beaudoin, Sisk et al. 2005, 
Clausen, Blish et al. 2010).  There is less known in regards to the effect of SOSTDC1 on 
osteoblastogenesis with the exception of a few key studies that have shown the mouse 
orthologue (Wise) of SOSTDC1 to be an inhibitor of BMP2, -4, or -7 induced bone 
differentiation in MC3T3-E1. Similarly recombinant SOSTDC1 was found to bind 
directly to specific BMPs and suppress BMP2, -4 and -7 stimulated ALP activity in the 
mouse myoblast cell line, C2C12 (Yanagita, Oka et al. 2004). The antagonistic effect on 
BMP signalling is apparently through its ability to bind directly to the BMP ligands 
themselves (Laurikkala et al., 2003 and Yanagita et al., 2004). Other studies have also 
shown that SOSTDC1-Wnt signalling is regulated via interactions with Wnt co-receptors 
LRP5/6, with data suggesting SOSTDC1 consists of separating binding domains for the 
BMP ligands and Wnt receptors (Lintern, Guidato et al. 2009). This information provided 
some insight into the interactions of SOSTDC1 with its BMP ligands and LRP receptors 
on a molecular level.  
 
The compelling data from our group showing that SOSTDC1 was upregulated in the lytic 
5T2MM myeloma model compared to naïve mice, combined with other reports indicating 
SOSTDC1 may modulate BMP signalling in OB-like cells, encouraged the rational that 
SOSTDC1 could have a fundamental role in the suppression of OB differentiation in 
MM. In a clinical setting, SOSTDC1 could potentially be targeted as a therapeutic agent 
reversing the suppression in osteoblastogenesis, which ultimately leads to osteolytic bone 
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disease in MM. In particular, in cases where MM patients do not exhibit elevated levels 
of Dkk1, targeting SOSTDC1 could be the ideal Dkk1-substitute therapy in MM.  
 
In the first part of the present study I characterised an in-vitro culture system using OB 
progenitor cultures derived from the calvaria of naïve neonatal C57BLkawRij mice. This 
system reflected the different stages of osteogenic maturation during cell differentiation. 
These primary cells exhibit a wide range of OB phenotypic changes, making them the 
preferable murine OB model which is used widely in the literature (Wang, Christensen et 
al. 1999, Fernandes, Harkey et al. 2007). Characterisation of the OB progenitor model 
was fundamental to understanding experimental data obtained from studying the 
molecular mechanisms involved in OB differentiation. The primary OB progenitor 
cultures had a clear OB phenotype, including ALP enzymatic activity, extracellular 
matrix mineralisation, Runx2, Collagen and β-catenin expression, which were in line with 
the literature (Ecarot-Charrier, Glorieux et al. 1983, Prince, Banerjee et al. 2001, Komori 
2006).  
 
In this model, the exponential differentiation period of OB progenitor cultures started at 
approximately day 8 and cells become mature at around day 15. This data agreed with 
existing reports with the literature demonstrating that ALP of MC3T3-E1 and murine 
primary calvarial cells increased up to 14 and 15 days in culture, respectively (Yazid, 
Ariffin et al. 2010, Birmingham, Niebur et al. 2012).  Furthermore, the mineralisation 
assays showed by day 15 of culture, OB progenitors had produced matrix nodules visible 
to the eye and these results were similar to the studies carried out by other groups 
(Hasegawa, Shimada et al. 2008, Kawazoe, Katoh et al. 2008). From the data in chapter 1, 
I established that the primary OB progenitors had differentiation profiles that were 
specific to progenitor/pre-osteoblasts up to day 11 of differentiation and beyond this time 
point amplified into mature functional OB cells.  
 
Using the OB progenitor characterisation data from Chapter 1 as an experimental 
platform, I investigated the effect of rhSOSTDC1 on Wnt/BMP-induced differentiation 
and intracellular signalling in OB progenitor cells in-vitro. The hypothesis was; 
SOSTDC1 antagonises Wnt and BMP-induced differentiation and acute signalling in OB 
progenitors. Any regulatory effect of SOSTDC1 was assessed throughout the various 
stages of OB progenitor maturation established during the earlier characterisation of the 
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OB progenitor model. In these studies, the effect of SOSTDC1 on Wnt and BMP 
signalling in OB progenitors was compared simultaneously to that of well characterised 
Wnt antagonist Dkk1 and BMP antagonist noggin.  
 
The data from these studies showed that SOSTDC1 alone did not have any effect on OB 
progenitor differentiation markers ALP and Runx2 or OB mineralisation.  It is unclear 
whether the levels of BMP and Wnt proteins which are known to be present within the 
FCS (Sasse, Lengwinat et al. 2000) or produced by the OB progenitor cells (Zhang, 
Oyajobi et al. 2013), were impeding the physiological effect of SOSTDC1. Although in 
this study it was not possible to use serum-free media, it may be that elimination of the 
Wnt/BMP proteins from culture serum or from within the cells themselves could magnify 
the suppressive effect of SOSTDC1. Continuous exposure of OB progenitor cultures to 
recombinant Wnt3a, BMP2 and BMP7, induced ALP enzyme activity and an antagonistic 
effect of SOSTDC1 was evident in BMP2 and not BMP7 or Wnt-induced ALP activity. 
The inhibitory effect of SOSTDC1 was only significant on the first analysed day 8 time-
point of OB progenitor differentiation. These findings were partially similar to 
Laurikkala, Kassai et al study which found the mouse orthologue of SOSTDC1 inhibited 
both Wnt and BMP-induced ALP activity of MC3T3-E1 cells (Laurikkala, Kassai et al. 
2003; Rawadi et al. 2004). Although unclear, the differences between the present study 
and those of Laurikkala may be due to the phenotypic differences observed between cell-
lines and primary OB progenitor cultures as well as differences in methodology.  
 
Based on the literature, Runx2 seems to be a transcription factor that is mutually 
important in both the Wnt and BMP signalling in OB cells. In fact, studies showing that 
mice deficient in LRP5 express Runx2 normally, suggest that Runx2–regulated OB 
differentiation also occurs through the BMP pathway (Kato, Patel et al. 2002; Ducy 2000; 
Gong, Slee et al. 2001). As a result, Runx2 expression was used as the second marker of 
OB progenitor differentiation to assess any modulatory effect of SOSTDC1 on both Wnt 
and BMP signalling. Interestingly, in these experiments SOSTDC1 did exert a 
suppressive effect on OB progenitor differentiation when in the presence of Wnt3a, 
BMP2 or BMP7. The Runx2 Taqman gene expression assays suggest that SOSTDC1 
inhibits Runx2 expression when in the presence of recombinant Wnt3a, BMP2 or BMP7 
proteins. Similar to the ALP data, the suppressive effect of SOSTDC1 was again 
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observed on the earliest day 8 time point, when Runx2 expression is known to be high in 
immature differentiating OB progenitor cells (Prince, Banerjee et al. 2001).  
 
Measurement of mRNA is thought to be a more sensitive approach of detection compared 
to protein assays such as ALP analysis (Sperisen, Wang et al. 1992), however, any effects 
of SOSTDC1 on Wnt and BMP-induced mineral deposition would establish a clearer 
insight. Alizarin red staining showed that OB progenitors cultured continuously with 
recombinant SOSTDC1 protein suppressed Wnt3a, BMP2 and BMP7-induced OB 
progenitor mineralisation. The detrimental effect of SOSTDC1 when in the presence of 
Wnt and BMP ligands was again only evident during early OB progenitor differentiation. 
In all the latter experiments performed in which SOSTDC1 exerted inhibitory effects on 
Wnt3a-induced differentiation and mineralisation significantly, Dkk1 appeared less 
effective in general. This is interesting as Dkk1, similar to SOSTDC1, is known to block 
β-catenin/Wnt-signalling by forming a complex with Wnt- LRP receptors (Brott and 
Sokol 2002). One possibility that has not been tested is comparing the affinity of LRP5/6 
for SOSTDC1 in comparison to Dkk1. BMP antagonist noggin also had variable 
suppressive effect on the differentiation and mineralisation activity of OB progenitor 
cultures. Noggin inhibited BMP-induced ALP activity and Runx2 expression throughout 
early OB progenitor differentiation. This is consistent with other reports which have 
shown noggin to inhibit differentiation in BMC and pre-osteoblastic UAMS-33 cell 
cultures (Lecka-Czernik, Gubrij et al. 1999, Abe, Yamamoto et al. 2000). The negative 
effect of noggin on OB progenitor mineralisation was not significant at any time point 
throughout differentiation compared to SOSTDC1 in the same experiments. This may 
have been due to the dosage of noggin used in these studies; i.e. higher dosage of noggin 
may have suppressed BMP-induced OB progenitor mineralisation.  
 
To establish a  clearer understanding of the molecular mechanisms by which SOSTDC1 
interfered with Wnt and BMP signalling,  protein levels downstream of activated Wnt and 
BMP signalling pathways were quantified following acute treatments with recombinant 
SOSTDC1 protein. In Wnt signalling, the activation of the LRP5/6 receptors results in β-
catenin stabilisation, phosphorylation and its translocation into the nucleus inducing the 
transcription of target genes (Miller, Hocking et al. 1999). Wnt-induced stabilisation of β-
catenin is central to the effect of Wnt ligands on proliferation and differentiation in OB 
cells. Studies have shown that loss of function in LRP5 causes reduced bone formation in 
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postnatal humans and mice (Gong, Slee et al. 2001, Kato, Patel et al. 2002) and point 
mutations in the LRP5 receptor increase bone mass (Boyden, Mao et al. 2002), 
highlighting the crucial role of Wnt-LRP signal transduction in bone development. It is 
not known whether SOSTDC1 has any influence on β-catenin/Wnt signalling in 
differentiating OB cells. The western blot data in the present study showed that 
SOSTDC1 in the presence of Wnt3a, reduced protein level of β-catenin phosphorylation. 
Similarly, western blotting was also used to quantify phosphorylated levels of regulatory 
Smad complexes downstream of the BMP signalling pathway following treatment with 
recombinant SOSTDC1 protein in the presence of BMP2 or BMP7. The Addition of 
SOSTDC1 in the presence of BMP ligands reversed BMP-induced Smad phosphorylation 
in OB progenitor cells of an early lineage. Consistently throughout the present studies it 
was apparent that SOSTDC1 antagonised Wnt/BMP signalling in OB progenitors that 
were still in the early phase of differentiation. This is interesting as data from in-vitro 
studies have suggested that Dkk1 mainly affects the function of mature OB cells and 
drives pluripotent cells to an OB linage (Morvan, Boulukos et al. 2006). It may be that 
Dkk1 targets mature OB cells and SOSTDC1 targets immature osteoprogenitors in an 
MM setting.   
 
It is interesting to note that the suppressive SOSTDC1 effects within the present study 
were only observed when OB progenitors were in the presence of excess Wnt or BMP 
ligand. Immunohistochemical and in situ hybridization analyses carried out as early as the 
1970’s demonstrated that OB express BMPs and their receptors at high fracture repair 
(Helder, Ozkaynak et al. 1995, Lyons, Hogan et al. 1995, Yamaguchi, Komori et al. 
2000). The canonical Wnt proteins are also known to be upregulated at the sites of bone 
fractures, inducing osteoblastogensis. Hadjiargyrou et al reported increased mRNAs for 
Wnt ligands, LRP5 receptors and β-catenin at bone fracture sites. There data suggests that 
Wnts have an essential role in the early stages of bone healing which involve the 
upregulation of OB activity (Hadjiargyrou, Lombardo et al. 2002). On the basis of the 
above data, it could be hypothesised that SOSTDC1 antagonises Wnt and BMP-induced 
signalling when the OB is under stress and producing high levels of Wnt and BMP 
molecules. In osteolytic bone disease in MM, where fractures are common, there may be 
high levels of Wnt and BMP ligands providing the optimal molecular environment for 
SOSTDC1 activity. This hypothesis can be supported by reports that Dkk1 also prevents 
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the activation of the Wnt/β-catenin/Tcf reporter during early fracture healing and 
supresses bone regeneration (Kim, Leucht et al. 2007).  
 
Studies by Lintern and Guidato et al addressed the notion that SOSTDC1 may have 
separate domains for Wnt and BMP interaction. Immunoprecipitation analysis revealed 
the independent binding capabilities of SOSTDC1 to LRP6 and BMP4, as SOSTDC1-
LRP6 binding was not disrupted by the addition of BMP4. Conversely, addition of LRP6 
impeded the effect of BMP4 suppression by SOSTDC1, implicating that SOSTDC1 
bound to LRP6 loses its full potential as a BMP antagonist (Lintern, Guidato et al. 2009). 
It is not known whether BMP2 and Wnt3a interactions occur independently, 
synergistically or competitively. Crosstalk between the β-Catenin/Wnt signalling and 
BMP signalling is poorly understood. There is a lack of functional for identifying 
downstream target genes of Wnt-BMP signalling intracellular molecules involved in Wnt-
BMP dependency. A few recent in-vitro studies have demonstrated a synergic 
relationship between BMP2 and β-catenin during OB differentiation (Rawadi, Vayssiere 
et al. 2003, Mbalaviele, Sheikh et al. 2005). Although BMP and WNT signalling have 
been shown to have opposing effects in osteoprogenitors, it seems that they primarily 
function cooperatively in OB cells (Baron and Kneissel 2013). As an example, Bain and 
colleagues showed that BMP2 may regulate OB function via modulation of β-
catenin/Wnt signalling (Bain, Muller et al. 2003).  
 
The crosstalk between Wnt and BMP is thought to be context dependent, where 
exogenous BMP ligands have been shown to induce bone regeneration and ectopic bone 
formation, suggesting differences in the effects of BMP signalling. Exogenous BMPs are 
thought to be inducers in bone induction and repressors of β-catenin/Wnt signalling in 
bone homeostasis (Baron and Kneissel 2013). This could provide an explanation for why 
Baud'huin et al found that in a preclinical rodent model, 
 
inhibition of BMPRIA-
dependent BMP signalling by the soluble BMPRIA receptor–Fc fusion protein was bone 
anabolic (Baud'huin, Solban et al. 2012). In the same study, deletion of noggin resulted in 
a reduction in BMD and bone formation in mice (Baud'huin, Solban et al. 2012). 
Therefore, BMP activation in the mature skeleton reduces bone formation/mass and this 
could be regulated through inhibition of Wnt signalling.  
 
248  
 
Extracellular secreted molecules such as Cerberus and Sclerostin that have a OB-
inhibiting function as SOSTDC1, can bind to both BMP/Wnt ligands (Silva, Filipe et al. 
2003) and receptors (Ellies, Viviano et al. 2006). There are currently no studies that have 
investigated the regulatory role of SOSTDC1 on Wnt-BMP crosstalk on differentiating 
OB progenitors.  In the present study I investigated the effect of Wnt3a ligand on Smad 
phosphorylation downstream of the BMP pathway. This effect was assessed in the 
presence and absence of SOSTDC1. Western blotting analysis showed Wnt3a induced 
phosphorylation of Smad1,5&8 protein in OB progenitors and SOSTDC1 reversed this 
effect during the early stage of differentiation. Furthermore, I found that both BMP2 and 
BMP7 upregulated phosphorylation β-catenin protein and gene (CTNNB1) expression and 
again SOSTSDC1 supressed this effect in the early stages of OB progenitor 
differentiation. 
 
Rawadi et al previously studied the crosstalk between Wnt-BMP signalling. This group 
demonstrated that blocking Wnt/LRP5 signalling with Dkk1 in MSC inhibited of BMP2-
induced ALP activity (Rawadi et al, 2003). In the present crosstalk studies, I also 
demonstrated that SOSTDC1 reduced Wnt3-induced Smad phosphorylation 
differentiating OB progenitor cells on a similar level to Dkk1. Dkk1 has been shown to 
targets the BMPRIA BMP receptor in OB and mediate suppression of BMP signalling in 
mature bone (Kamiya 2012). Furthermore, the data by Liu et al suggested that 
overexpression of Dkk1 in tooth blocked tissue development and this was associated with 
the down-regulation of BMP and Msx1/2 expression domains. The BMP-induced Msx1/2 
expression was unaffected in Dkk1-overexpression suggesting that Wnt/β-catenin signals 
are required upstream of BMP to function (Liu, Chu et al. 2008). SOSTDC1 and Dkk1 
both target the LRP/Frz Wnt receptors, blocking Wnt ligand interaction with the receptor 
complex. Based on these similarities between the antagonistic role of SOSTSDC1 and 
Dkk1 in Wnt-BMP crosstalk in differentiating OB progenitors, it may be assumed that 
both molecules have a similar detrimental effect in osteolytic bone disease. One 
possibility for this similarity may be that in osteolytic bone disease, if one molecule is not 
in abundance, then the other is produced at high levels to compensate.  
 
Papathanasiou et al in showed that BMP2-induced LRP-5 expression was mediated 
through Smad1/5/8 binding on the LRP-5 promoter (Papathanasiou, Malizos et al. 2012). 
Fukuda et al study a elaborated on the Wnt-BMP regulation of OB differentiation at the 
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early stages of differentiation in preosteblastic cells, suggesting that crosstalk occurred 
through a GSK3β-dependent but β-catenin-independent mechanism (Fukuda, Kokabu et 
al. 2010). This data contradicted Zhang et al, who showed Lrp5 expression was BMP-
induced and BMP2 also upregulated nuclear β-catenin protein levels (Zhang et al, 2009). 
This data suggested that the interaction between Wnt and BMP signalling during OB 
differentiation is β-catenin-dependent. Similar to the data that I have presented, Zhang e t 
al also reported that Wnt3a increased transcriptional activity of BMP/Smad reporter and 
noggin inhibited this effect (Zhang, Oyajobi et al. 2013). In light of the data in the present 
study and reports within the literature, it can be deduced that the corporative action 
between Wnt-BMP is mediated by β-catenin-and the regulatory Smad complex within OB 
progenitors and SOSTDC1 antagonises this interaction. This data also supports findings 
within the literature showing SOSTDC1 having the molecular ability to bind to both BMP 
ligands and Wnt LRP receptors. However, it is unknown whether SOSTDC1 binds to 
LRP6 with a higher affinity than with to BMP2, -4 or -7.  
 
Determining the potency of this molecule for its ligands and receptors allows for a better 
understanding of the mechanisms involved between SOSTDC1 and Wnt-BMP signalling 
in OB progenitors. Although no studies have investigated the binding affinity of human 
recombinant SOSTDC1 protein for LPR6, BMP2 and BMP7,  Laurikkala et al did 
examine the binding of recombinant mouse SOSTDC1 (Ectodin) to BMP2, BMP4, 
BMP6, and BMP7 ligands using the BIAcore system. Although they showed Ectodin 
bound to BMP2, BMP4, BMP6, and BMP7 with high affinity (Laurikkala, Kassai et al. 
2003), they have not quantified the binding affinity to LRP6. In my study, the affinity of 
rhSOSTDC1 for BMP2, BMP7 and LRP6 were determined using BLItz technology, 
which works on a similar principle to Biacore technology. The recombinant SOSTDC1 
had a highest binding affinity for BMP7, followed by LRP6 and lastly BMP2. These 
findings are compelling in that in osteolytic bone disease, SOSTDC1 has a preference for 
BMP signalling and yet antagonises both the canonical Wnt pathway and BMP signalling 
pathways in OB differentiation through the Wnt-BMP dependency.  
 
With the exception of breast and renal cancers, the role of SOSTDC1 as a BMP and Wnt 
antagonist in cancer is not well established. In breast cancer, SOSTDC1 is under-
expressed, yet increases Wnt3a and decreases BMP7 signalling (Clausen, Blish et al. 
2010). Similarly, in kidney tumours, SOTSDC1 is down-regulated and restoration of 
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SOSTDC1 expression impairs carcinoma cell proliferation. Both Wnt3a signalling and 
BMP7 induced phosphorylation of Smads are found to be suppressed by SOSTDC1 
(Blish, Wang et al. 2008). There is very little data on the effect of either BMP or Wnt 
signalling, in myeloma. Nevertheless, Yamaguchi et al did show that BMP2 and -4 induce 
apoptosis and suppress proliferation of human myeloma cells Yamaguchi, Komori et al. 
2000). This data is of interest in the context of the present study findigs: perhaps 
SOSTDC1 binds to BMP7 competitevely and therefore prevents the BMP from exerting 
its supressive effects on the myeloma cell. The effect of Wnt3a on MM associated bone 
disease is variable. Qiang et al investigated in-vitro and in-vivo effects of Wnt3a on bone 
disease and MM cell growth. Their data show that Wnt3a had no effect on MM cell 
growth in-vitro. However, bones engrafted with Wnt3a-expressing NCIH-929 MM cells 
and mice carrying primary disease, treated with recombinant Wnt3a, exhibited increased 
OB number and reduced tumour burden (Qiang et al, 2008). Along with the findings from 
this report, these data suggest that both the Wnt and BMP are necessary for bone 
formation, and that they can potentially interact with each other to induce OB 
differentiation, in line with the findings from my study.  
 
With this concept in mind, I wanted to further explore the role of SOSTDC1 in the well-
characterised mouse 5TMM myeloma models and determine whether this molecule had 
the potential to contribute to the suppression in osteoblastic activity observed in 
myeloma. The aim of the final part of the study was to determine whether myeloma and 
OB progenitor cells expressed SOSTDC1 and to then reveal the conditions under which 
SOSTDC1 was expressed. Previously, the ‘seed and soil’ theory has been the 
predominant concept in myeloma bone disease, in that the myeloma cells use the bone’s 
fertile microenvironment to flourish and exert their detrimental effect on the bone (Guise 
and Mundy 1998). In this study I considered a new dimension to the ‘seed and soil’ 
theory in respect to SOSTDC1 in that myeloma cells may require a direct interaction with 
the OB cells in order to supress OB differentiation optimally.  
 
Unpublished gene array data from our group had previously shown that SOSTDC1 was 
upregulated in the 5T2MM myeloma model. This model was no longer available, and as a 
substitute the 5TGM1MM and 5T33MM models were used. The C57BL/KaLwRij mice 
injected with 5T33MM myeloma cells did not develop bone disease, so were used to 
compare any variance in SOSTDC1 with the osteolytic 5TGM1MM model. The data 
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obtained from immunofluorescent microscopy, flow cytometry, western blotting, end-
point PCR and sequencing all showed that 5T33MM and 5TGM1MM cells produced 
SOSTDC1, in line with the gene array analysis previously performed on 5T2MM cells. 
However, SOSTDC1 was not detectable in OB progenitor cells under the same 
experimental conditions used for SOSTDC1 detection in myeloma cells and HK-2 cell 
positive control.  
 
To determine whether interaction between the myeloma cells and OB progenitors had any 
effect on SOSTDC1 expression, the myeloma cells were co-cultured with the 
differentiating OB progenitors. Using cells cultured on their own, the level of SOSTDC1 
was also determined. The data from this study showed that SOSTDC1 was upregulated in 
the co-cultured 5TGM1MM cells but not 5T33MM cells. Interestingly, OB progenitors 
that had been co-cultured with myeloma cells and then sorted now expressed SOSTDC1 
detectable on a protein and gene level. This ‘switch on’ in SOSTDC1 expression was 
further confirmed by sequencing the end-point PCR reaction products obtained from 
sorted OB progenitor cells. The SOSTDC1 levels in myeloma cells that were co-cultured 
with OB progenitors but had not adhered to the OB progenitor cells were semi-
quantitatively measured to compare with SOSTDC1 levels in adherent myeloma cells. 
This experiment addressed the question of whether SOSTDC1 production in myeloma 
cells was dependent on the cells physically adhering to OB progenitors. The 5TGM1MM 
cells that had adhered to OB progenitors expressed a higher level of SOSTDC1 compared 
to cells that had not adhered to the OB progenitors. Interestingly, in experiments with 
5T33MM cells there were no differences SOSTDC1 levels of adherent and non-adherent 
5T33MM cells. The fact that SOSTDC1 seemed to have more of a role in the lytic 
5TGM1MM-OB progenitor interactions compared to the non-lytic 5T33MM model in 
general was important. Direct comparison of the SOSTDC1 levels in 5T33MM versus 
5TGM1MM showed that 5TGM1MM cells expressed a higher level of SOSTDC1. This 
is perhaps not surprising as in the literature the 5T33MM model is commonly used for 
investigating myeloma cell homing and proliferation whereas the 5TGM1MM model is 
preferred for the study of bone disease (Croese, Vas Nunes et al. 1987, Vanderkerken, De 
Raeve et al. 1997). If SOSTDC1 is indeed upregulated in myeloma-OB interaction and 
exerts its antagonistic effects on osteoblastogensis, then it would be expected that 
SOSTDC1 would have more of a regulatory role in the lytic 5TGM1MM cells.  
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Immunohistochemical analysis of 10 days post-injection 5T33MM and 5TGM1MM 
tibiae sections stained confirmed that SOSTDC1 was present in bone that was infiltrated 
with myeloma disease compared to an absence of SOSTDC1 in naïve bone sections. This 
data complemented the in-vitro results in that SOSTDC1 staining was mainly observed in 
sites were myeloma cells formed colonies. In areas of the 5T33MM/5TGM1MM sections 
were myeloma colonies were stained for SOSTDC1, OB/bon-lining cells could be 
identified. However, in the same 5T33MM/5TGM1MM sections, in areas were no 
myeloma colonies were present, there was little SOSTDC1 staining and some OB/bone-
lining cells could be identified.   
 
Finally, my studies have linked  concept that SOSTDC1 is upregulated as a result of 
myeloma-OB progenitor interaction to the proposed hypothesis that excess SOSTDC1 
available in the bone microenvironment then has a detrimental effect on the OB-
progenitor differentiation. The myeloma-OB progenitor co-cultures were treated with 
1.5µg/ml of commercial anti-SOSTDC1 antibody, previously determined to be specific 
for SOSTDC1 by western blotting.  
 
Detection of Runx2 gene expression, known to have a pivotal role in OB differentiation 
(Philip, Bulbule et al. 2001), was detected in OB progenitor cultures and 5TGM1MM 
cells cultures alone and together in the presence and absence of the anti-SOSTDC1 
antibody. Runx2 was detectable in OB progenitor cultures but not in 5TGM1MM cells in 
context with the literature, with the exception of a study by Colla et al, demonstrating for 
the first time the expression and of Runx2/Cbfa1 in human myeloma cells (Colla, 
Morandi et al. 2005). The co-culture of 5TGM1MM and OB progenitors resulted in 
reduced levels of Runx2. Furthermore, treatment of myeloma-OB progenitor co-cultures 
with the anti-SOSTDC1 antibody resulted in reversal of this myeloma-induced Runx2 
suppression. Taken together this compelling data provides a clearer insight into the role of 
SOSTDC1 in myeloma-bone disease, which is best summarised diagrammatically as 
illustrated in Figure 7.  
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Figure 7 - Schematic diagram of the potential antagonistic effect of myeloma 
induced SOSTDC1 expression on Wnt and BMP signalling pathways. 
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7.2 Future Studies 
 
Despite the high incidence of bone related complications secondary to MM, there is an 
obvious need for improved preventative regimes and drug treatments (Roodman 2011). 
Although we now have a relatively clear insight into the mechanism by which myeloma-
induced bone resorption is up-regulated, our understanding of the mechanism responsible 
for OB suppression is not so clear. SOSTDC1 expression and its role within both Wnt and 
BMP signalling, has been implicated as a mechanism in various tissues (Lintern, Guidato 
et al. 2009). However, to date no data has been published on the role of SOSTDC1 in the 
suppression of bone formation in MM. Determination of SOSTDC1 effect if any, on OB 
differentiation and proliferation in-vitro is key to understanding the role of this novel 
protein in myeloma-induced suppression of bone formation and perhaps bone resorption. 
 
We have raised monoclonal antibodies against SOSTDC1 in rats. Western blot analysis 
will be used to characterise the specificity of these anti-SOSTDC1 antibodies. The 
monoclonal anti-SOSTDC1 antibody will be a more useful tool due to its specificity, 
particularly when used in in-vivo investigations. Currently there are no available 
manufactured monoclonal antibodies against SOSTDC1. Therefore, characterisation of 
in-house antibodies is potentially a very important tool in both the detection and blockade 
of SOSTDC1 expression MM experimental models. The next step is to determine the 
effect of administrating rhSOSTDC1 as well as blocking SOSTDC1 on of bone formation 
in experimental models of myeloma in-vivo. We have already carried out a pilot study in 
investigation the ability of SOSTDC1 to inhibit bone formation in-vivo. C57BLkawRij 
mice were injected locally with rhSOSTDC1 on one side of the calvaria and vehicle (rh-
GST) on the condralateral side. MicroCT analysis revealed significantly reduced OB 
number. The next pilot study will involve administration of systemic injection to mouse 
tibia and vertebrae and then in the presence or absence of the BMP and Wnt ligands. The 
effect on bone structure will be determined by microCT analysis as well as static and 
dynamic bone histomorphometry.  To look at blocking SOSTDC1 in MM models, 
C57BLkawRij mice will be injected with 5T2MM murine myeloma cells and treated with 
antibodies to SOSTDC1. The effect of treatment on the development of myeloma bone 
disease will be determined by microCT analysis, as well as static and dynamic bone 
histomorphometry. Although the 5TMM series are reproducible and an excellent model 
for MM studies, there is a constant need for the development of these animal models to 
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further enhance our understanding of MM as well as the limitations associated with them. 
In humans, MM is heterogeneous as a disease and this poses a problem in that no single 
animal model can constitute of all MM features. This study would benefit from looking 
into SOSTDC1 expression in human myeloma cell lines and human BM samples so as to 
move into translational research for potential therapeutic purposes.  
 
From the data in this study, it has become apparent that interaction between myeloma and 
the OB cell is a requirement in stimulating the production of SOSTDC1 in both myeloma 
and OB cells. Previously, the ‘seed and soil’ theory has been the predominant concept in 
myeloma bone disease, in that the myeloma cells use the bone’s fertile microenvironment 
to flourish and exert their detrimental effect on the bone (Guise and Mundy 1998). The 
data presented in this study could add a dimension to this concept, in that not only do the 
myeloma cells select the environment that best suits their requirements to thrive, but they 
may also switch on OB-signalling antagonists by interacting with the OB cells directly. It 
would be interesting to determine whether myeloma interact with any other cells within 
the bone marrow as there no data within the literature. The role of SOSTDC1 has not 
been investigated in myeloma-OC interaction. It would be valuable to determine whether 
SOSTDC1 role is specific to OB-mediated osteolytic bone disease or also regulates the 
increased OC activity observed in MM. This theory is based on Pederson et al data 
showing that stimulation of human MSC nodule formation by OC conditioned media was 
diminished by Dkk1 and a BMP6-neutralizing antibody (Pederson, Ruan et al. 2008).  
 
Therapeutic neutralising antibodies against Sclerostin and Dkk1 are currently in late 
preclinical/early clinical development for the treatment of osteolytic lesions in MM. 
Although these therapeutic antibodies are a good starting point for the modulation of Wnt 
signalling pharmacologically, the ultimate objective would be to develop orally active 
compounds that target both OC and OB activity (Ke, Richards et al. 2012). Future 
projects could focus on combining Dkk1 and SOSTDC1 as one treatment to determine 
whether the two together could be a more effective form of therapy.  
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Appendix 1 - GST had no effect on Wnt or BMP-induced ALP activity and 
rhSOSTDC1 suppressed BMP2-induced ALP activity in differentiating OB 
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GST had no effect on Wnt or BMP-induced ALP activity in OB: To determine 
whether the GST protein tag attached to the SOSTDC1 protein had any effect on OB 
differentiation, OB cells were treated with Wnt3a, BMP2 or BMP7 in the absence or 
presence of 250ng/ml GST. ALP activity of OB were determined and normalised to total 
DNA contents. (A, B amd C) The 250ng/ml GST, at the same concentration as SOSTDC1 
used in experiments, had no effect on ALP activity of OB when in the presence of Wnt3a, 
BMP2 or BMP7.Unpaired t-test. Data are displayed with mean ± SEM. P=ns. 
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Appendix 2 – SOSTDC1 had no effect SAOS2 cell differentiation in the presence of 
BMP and Wnt 
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Figure 4.4.3.1 - SOSTDC1 had no effect on Wnt-induced or BMP-induced ALP 
activity in SAOS2 cells: Differentiating SAOS2 cells were treated with vehicle or 250 ng/ml 
rhSOSTDC1 and also separately with 50ng/ml rmWnt3a, 30ng/ml rhBMP2 or 30ng/ml 
rhBMP7 in the presence or absence of rhSOSTDC1. (A) Wnt3a and SOSTDC1 had no effect 
on SAOS2 ALP activity. (B, C) BMP 2, BMP7 and SOSTDC1 had no effect on SAOS2 ALP 
activity. N=3 independent experiments, One way ANOVA and Holme-Sidak’s post-test. Data 
are displayed with mean ± SEM.  
 
 
 
A 
C 
B 
281  
 
Appendix 3 - Recombinant GST protein did not bind to recombinant LRP, BMP2 
and BMP7 proteins with high affinity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
100µg/ml GST interaction with LRP-6, BMP2 
and BMP7 
Sample Concentration 
(µg/ml) 
kD (M) 
Buffer n/a - 
LRP-6 100 - 
BMP2 100 1.096e-4 
BMP7 100 - 
Recombinant GST protein did not bind to recombinant LRP, BMP2 and BMP7 
proteins: The affinity kD (M) of rhGST for purified carrier-free rmLRP-6, rhBMP2 and 
rhBMP7 proteins were determined using the Blitz Analysis system as control for the GST-
tagged SOSTDC1 binding assays. Binding (nm) association showed 100ug/ml of rhGST did 
not bind at detectable levels to rmLRP-6 or rhBMP7 proteins. The high kD value calculated 
for rhGST and rhBMP2 interaction suggest any interaction would be of low affinity and not 
biologically relevant.  
. 
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Appendix 4 - SOSTDC1 was not upregulated in myeloma-endothelial cell co-culture  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Upregulation of SOSTDC1 levels was specific to myeloma-OB progenitor co-
culture and not myeloma-endothelial co-culture: Immunofluorescent microscopy was 
performed to detect production of SOSTDC1 in 5T33MM/5TGM1MM-STR10 and 
5T33MM/5TGM1MM-OB progenitor co-cultures. Permeabilised myeloma cells were co-cultured with 
endothelial cells or OB progenitors for 24 hours and stained with 1μg/ml primary anti-SOSTDC1 
antibody or isotype control antibody. Co-cultures were also co-stained with anti-CD138 antibody and 
mounted with DAPI reagent. Images of phase contrast, DAPI, CD138 and SOSTDC1 staining were 
visualised simultaneously. Images are representative of at two replicates within 2 independent 
experiments. (A) STR10 cells did not produce detectable levels of SOSTDC1 compared to HK-2 
control.(B)SOSTDC1 was upregulated in myeloma-OB progenitor co-cultures compared to myeloma-
STR10 co-cultures. SOSTDC1 that was present in myeloma-STR10 co-cultures appeared to be 
specific to myeloma cells and not STR10 cells. 
 
A 
B 
HK-2 
STR-10 
STR-10+5T33MM 
OB + 5T33MM 
STR-10 + 
5TGM1MM 
OB + 5TGM1MM 
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Appendix 5 - OB progenitors did not have a SOSTDC1-specific nucleotide sequence 
compared to HK-2 positive control determined by sequencing  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
OB Progenitors 
SOSTDC1 cDNA sequencing of OB progenitor cells cultured alone compared to 
HK-2 positive control: End-point RT-PCR products obtained from OB progenitor cells and HK-
2 cells cultures were sequenced for SOSTDC1 using SOSTDC1-specific primers. (A) The OB 
progenitor did not have detectable SOSTDC1-specific nucleotide sequences identified by BLAST 
software. (B) The HK-2 cells had 97% homology with the SOSTDC1-specific sequence identified in 
BLAST (NCBI Reference Sequence: NM_025312.3).  
 
A 
B 
Score Expect Identities Gaps Strand 
124 bits(67) 6e-26 71/74(96%) 0/74(0%) Plus/Minus 
Query  1    TGTCATTGACACACCGCCACTCCTGGNANCTCCTCCTGCTCCAGTACTTTGTTCCATAGC  60 
            |||||||||||||||||||||||||| | ||||||||||||||||||||||||||||||| 
Sbjct  600  TGTCATTGACACACCGCCACTCCTGGGAGCTCCTCCTGCTCCAGTACTTTGTTCCATAGC  541 
 
Query  61   CTCCTCCGATCCAG  74 
            ||||||| |||||| 
Sbjct  540  CTCCTCCAATCCAG  527 
HK-2 
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List of Abbreviations 
 
1,25(OH)2D3  1,25-Dihydroxyvitamin D3  
ALP Alkaline phosphatise 
APC adenomatous polyposis coli protein 
BCA Bicinchoninic  
Bcl-2 B-cell lymphoma-2   
BLC bone lining cell 
BM bone marrow  
BMP bone morphogenetic protein  
BMSC  Bone Marrow Stromal Cells   
BSA Bovine serum albumin  
BSP bone sialoprotein  
c-fms colony stimulating factor  
C-Smad common mediator Smad  
CBFA1 core-binding factor-1  
CD138 Syndecan 1 
CK1γ serine/threonine kinase  
 CuSO
4
  Copper II sulphate   
Dkk1 Dickkopf-1  
DMSO Dimethyl Sulfoxide  
dsDNA PicoGreen® double-stranded DNA  
Dsh Dishevelled  
EDTA  trypsin-ethylene-diaminetetraacetic acid  
FCS Fetal Calf Serum  
FGF fibroblast growth factors  
Fz frizzled  
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GSK-3β glycogen synthase kinase-3β  
GST Glutathione-S-transferase 
HGFs  hepatocyte growth factors  
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HK-2 Proximal tubule epithelial cell line  
HRP Horse Radish peroxidase   
HMCL Human myeloma cell lines 
I-Smads inhibitory Smads  
IFN-γ interferon-gamma  
IGF-I insulin-like growth factor –I   
IGFs insulin-like growth factors  
Ihh Indian hedgehog   
IL-11 interleukin-11   
IL-1β interleukin-1β   
IL-4 interleukin-4   
JNK c-Jun N-terminal kinase  
KSFM Keratinocyte serum free medium 
LEF/TCF lymphoid enhancer-binding factor 1/T cell–specific 
transcription factor 
LIF leukaemia inhibiting factor  
lLRP5/6 lipoprotein receptor–related protein 5/6   
m-1α  macrophage inflammatory protein-1α  
M-CSF Macrophage colony-stimulating factor 
MAPK mitogen-activated protein kinase   
MEM Minimum Essential Medium   
MGUS Monoclonal Gammopathy of Undetermined Significance  
MIP-β macrophage inflammatory protein-1β 
MMTV mouse mammary tumour virus  
MSC mesenchymal stem cells  
OAF OC activating function   
OB osteoblasts   
OC  osteoclasts   
OPG  osteoprotegerin  
PAGE polyacrylamide gel electrophoresis  
PBS Phosphate Buffered Saline  
PDGF Platelet-derived growth factor   
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PenStrep Penicillin: Streptomycin  
PgE2 TNF-α or prostaglandin E2   
PI3K phosphatidylinositol-3 kinase   
PIC protease inhibitor cocktail  
PMSF Phenylmethylsulfonyl Fluoride  
pNPP p-Nitrophenyl phosphate  
PVDF Polyvinylidene fluoride  
R-Smads Regulatory Smads  
RANK Receptor Activator of Nuclear Factor κ B   
RANKL receptor activator of nuclear factor-κB ligand  
RUNX2 Runt-related transcription factor 2   
SDF-α stromal derived factor-1α 
SDS sodium dodecyl sulfate  
sFRPs   secreted Frizzled-related proteins 
SMM  Smouldering Multiple Myeloma  
SOSTDC1 Sclerostin Domain Containing 1  
Src  tyrosine kinase  
TGF-β  Transforming growth factor β   
TNF Tumour Necrosis Factor  
TRAFs TNFR-associated factors  
TRAIL Tumour necrosis factor-related apoptosis inducing ligand  
USAG-1 uterine sensitisation-associated gene-1 
VCAM-1 vascular cell adhesion molecule-1   
VEGF  vascular endothelial growth factor  
Wg Wingless  
Wnt Wingless-type  
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